WO2000039156A1 - Glycopeptide derivatives and pharmaceutical compositions containing the same - Google Patents

Glycopeptide derivatives and pharmaceutical compositions containing the same Download PDF

Info

Publication number
WO2000039156A1
WO2000039156A1 PCT/US1999/030543 US9930543W WO0039156A1 WO 2000039156 A1 WO2000039156 A1 WO 2000039156A1 US 9930543 W US9930543 W US 9930543W WO 0039156 A1 WO0039156 A1 WO 0039156A1
Authority
WO
WIPO (PCT)
Prior art keywords
substimted
hydrogen
alkyl
group
cycloalkyl
Prior art date
Application number
PCT/US1999/030543
Other languages
French (fr)
Inventor
J. Kevin Judice
Paul Ross Fatheree
Bernice M. T. Lam
Michael Leadbetter
Martin Sheringham Linsell
Yongqi Mu
Sean Gary Trapp
Guang Yang
Yan Zhu
Original Assignee
Advanced Medicine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK99965331T priority Critical patent/DK1140993T3/en
Priority to HU0400887A priority patent/HU230190B1/en
Priority to AT99965331T priority patent/ATE242783T1/en
Priority to IL14009399A priority patent/IL140093A0/en
Priority to PL348451A priority patent/PL198311B1/en
Priority to EP99965331A priority patent/EP1140993B1/en
Priority to AU31273/00A priority patent/AU768204B2/en
Application filed by Advanced Medicine, Inc. filed Critical Advanced Medicine, Inc.
Priority to CA2336445A priority patent/CA2336445C/en
Priority to BRPI9914221A priority patent/BRPI9914221B8/en
Priority to NZ508594A priority patent/NZ508594A/en
Priority to SI9930389T priority patent/SI1140993T1/en
Priority to DE69908819T priority patent/DE69908819T2/en
Priority to JP2000591067A priority patent/JP4362017B2/en
Publication of WO2000039156A1 publication Critical patent/WO2000039156A1/en
Priority to US09/674,456 priority patent/US6455669B1/en
Priority to IL140093A priority patent/IL140093A/en
Priority to ZA200007222A priority patent/ZA200007222B/en
Priority to NO20006323A priority patent/NO326066B1/en
Priority to HK02102171.5A priority patent/HK1040721B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to novel derivatives of glycopeptide antibiotics.
  • This invention also relates to pharmaceutical compositions containing such glycopeptide derivatives, to methods of using such glycopeptide derivatives as antibacterial agents, and to processes for preparing such glycopeptide derivatives.
  • Glycopeptides are a well-known class of antibiotics produced by various microorganisms. These complex multi-ring peptide compounds are effective antibacterial agents against a majority of Gram-positive bacteria.
  • the use of glycopeptides as antibiotics has been overshadowed by the semi- synthetic penicillins, cephalosporins and lincomycin due to the higher levels of mammalian toxicity observed with the glycopeptides.
  • bacteria resistant to the penicillins, cephalosporins and the like have emerged resulting in, for example, multiple-resistant and methicillin-resistant staphylococcal (MRS) infections.
  • MRS methicillin-resistant staphylococcal
  • Glycopeptides such as vancomycin
  • vancomycin are typically effective against such microorganisms and vancomycin has become the drug of last resort for MRS and other infections.
  • the glycopeptides are believed to be effective against such resistant microorganism because they have a different mode of action than other antibiotics.
  • the glycopeptides are believed to selectively inhibit a different step in bacterial cell wall synthesis than the penicillin-type antibiotics.
  • the cell wall of bacteria consists of linear polysaccharide chains cross-linked by short peptides.
  • This arrangement of cross-linked polysaccharides confers mechanical support to the cell wall, thus preventing the bacteria from bursting due to its high internal osmotic pressure.
  • cross-linking of the polysaccharides takes place after lipid-linked disaccharide-pentapeptide constructs are incorporated into linear polysaccharide chains by a transglycolase enzyme.
  • the subsequent cross-linking reaction is the last step in the synthesis of the cell wall and is catalyzed by an enzyme known as peptidoglycan transpeptidase.
  • glycopeptide antibiotics such as vancomycin
  • N-terminal sequences i.e., L-lysyl-D-alanyl- D-alanine in vancomycin-sensitive organisms
  • vancomycin By binding to and sequestering these precursors, vancomycin prevents their utilization in cell wall biosynthesis. Thus, vancomycin inhibits the bacterial transglycosylase that is responsible for adding lipid intermediate II subunits to growing peptidoglycan chains. This step of bacterial cell wall synthesis preceeds the cross-linking transpeptidation step which is known to be inhibited by beta-lactams antibiotics. It is also believed that vancomycin inhibits transpeptidation which involves the D-alanyl-D-alanine termini. However, since this step occurs subsequent to transglycosylation, inhibition of transpeptidation is not directly observed.
  • glycopeptide derivatives having improved activity, selectivity and reduced mammalian toxicity are beginning to develop resistance to vancomycin, such as vancomycin-resistant enterococci (VRE). Accordingly, it would be highly desirable to provide novel glycopeptide derivatives which are effective against a broad spectrum of bacteria, including resistant strains such as VRE. Moreover, it would be highly advantageous to provide glycopeptide derivatives having improved antibacterial activity and selectivity, and low mammalian toxicity.
  • VRE vancomycin-resistant enterococci
  • the present invention provides novel derivatives of glycopeptide antibiotics having improved properties compared to the unsubstituted glycopeptide, including enhanced activity, selectivity and reduced mammalian toxicity.
  • certain vancomycin derivatives of this invention demonstrate greatly enhanced antibacterial activity compared to vancomycin itself.
  • Such vancomycin derivatives are also highly effective against vancomycin-resistant enterococci strains while exhibiting reduced mammalian toxicity.
  • this invention provides a glycopeptide compound having at least one substituent of the formula:
  • each R a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene; each R b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substimted alkynylene, provided R b is not a covalent bond when Z is hydrogen; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- , -NR C - , -S(O)- , -SO 2 - , -NR c C(O)- , -OC(O)- , -NR c SO 2 - , -OSO 2 - , -C(O)NR c - , -C(O)O- , -SO 2 NR c - , -SO 2 O-
  • the glycopeptide compound is substimted with from 1 to 3 substituents of the formula -R a -Y-R b -(Z) X .
  • Each R a is preferably independently selected from alkylene having from 1 to 10 carbon atoms, more preferably, from 1 to 6 carbon atoms.
  • R a is ethylene (-CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -) or butylene (-CH 2 CH 2 CH 2 CH 2 -). Still more preferably, R a is ethylene or propylene.
  • R b is preferably alkylene of from 8 to 12 carbon atoms. Accordingly, in this embodiment, R b and Z preferably form an «-octyl, n- nonyl, /i-decyl, tz-undecyl or /z-dodecyl group.
  • R b is preferably a covalent bond or alkylene of from 1 to 10 carbon atoms.
  • R b is preferably, a covalent bond, methylene, -(CH 2 ) 6 -, -(CH 2 ) 7 -, -(CH 2 ) 8 -, -(CH 2 ) 9 - or -(CH 2 ) 10 -.
  • Each Y is preferably independently selected from the group consisting of oxygen, sulfur, -S-S-, -NR C - , -S(O)- , -SO 2 - , -NR c C(O)- , -OC(O)- , -NR c SO 2 - , -C(O)NR c - , -C(O)O- and -SO 2 NR c - . More preferably, Y is oxygen, sulfur, -NR C - or -NR c SO 2 - .
  • each Z is independently selected from hydrogen, aryl, cycloalkyl, heteroaryl and heterocyclic. More preferably, Z is hydrogen or aryl.
  • preferred Z group include phenyl, substimted phenyl, biphenyl, substimted biphenyl and terphenyl groups.
  • Z groups are phenyl, 4-isobutylphenyl, 4'-chlorobiphenyl-4-yl, 4'-trifluoromethylbiphenyl-4-yl, 4-(naphth-2-yl)phenyl, 4-(2-phenylethynyl)phenyl, 4-(3,4-dichlorobenzyloxy)- phenyl, and -terphenyl.
  • x is 1.
  • Particularly preferred -R a -Y-R b -(Z) X groups of this invention are selected from the group consisting of:
  • this invention provides a compound of formula I:
  • R 1 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -R a -Y-R b -(Z) X ; or a saccharide group optionally substimted with -R a -Y-R b -(Z) X ;
  • R 2 is hydrogen or a saccharide group optionally substimted with -R a -Y-R b -(Z) X ;
  • R 3 is -OR c , -NR C R C , -O-R a Y-R b -(Z) x , -NR C -R a -Y-R b -(Z) X , -NR c R e , or -O-R e ;
  • R 4 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -R a -Y-R b -(Z) X , -C(O)R d and a saccharide group optionally substimted with -R a -Y-R b -(Z) X ;
  • R 5 is selected from the group consisting of hydrogen, halo, -CH(R C )-NR C R C , -CH(R c )-NR c R e and -CH(R C )-NR C -R a -Y-R b -(Z) X ;
  • R 6 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -R a -Y-R b -(Z) X , -C(O)R d and a saccharide group optionally substimted with -NR C -R a -Y-R b -(Z) X , or R 5 and R° can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substimted with -NR C -R a -Y-R b -(Z) X ;
  • R 7 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -R a -Y-R b -(Z) X , and -C(O)R d ;
  • R 8 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
  • R 9 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
  • R 10 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic; or R 8 and R 10 are joined to form -Ar'-O-Ar 2 - , where Ar 1 and Ar 2 are independently arylene or heteroarylene;
  • R 11 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R 10 and R 11 are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;
  • R 12 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic, -C(O)R d
  • R 13 is selected from the group consisting of hydrogen or -OR 14 ;
  • R 14 is selected from hydrogen, -C(O)R d and a saccharide group; each R a is independently selected from the group consisting of alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene; each R b is independently selected from the group consisting of a covalent bond, alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene, provided R b is not a covalent bond when Z is hydrogen; each R c is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl
  • R e is a saccharide group; X 1 , X 2 and X 3 are independently selected from hydrogen or chloro; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- , -NR C - , -S(O)- , -SO 2 - , -NR c C(O)- , -OSO 2 - , -OC(O)- , -NR c SO 2 - , -C(O)NR c - , -C(O)O- , -SO 2 NR c - , -SO 2 O- , -P(O)(OR c )O- , - P(O)(OR c )NR c - , - OP(O)(OR c )O- , - OP(O)(OR c )NR c - , - OC(O)O- , -NR c C
  • R 1 is a saccharide group optionally substimted with -R a -Y-R b -(Z) X . More preferably, R 1 is a saccharide group of the formula:
  • R 15 is -R a - Y-R b -(Z) X , where R a , R ⁇ Y, Z and x are as defined herein;
  • R 16 is hydrogen or methyl.
  • R 2 is hydrogen
  • R 3 is preferably -OR c or -NR C R C ; more preferably R 3 is -OH. Particularly preferred R 3 groups are those shown in Tables I-IV as R 22 .
  • R 4 , R° and R 7 are each independently selected from hydrogen or -C(O)R d . More preferably, R 4 , R 6 and R 7 are each hydrogen.
  • R 5 is preferably hydrogen, -CH 2 -NHR C , -CH 2 -NR c R e and -CH 2 -NH-R a - Y-R b -(Z) X , where R a , R b , R c , R e , Y, Z and x are as defined herein.
  • R 5 groups include hydrogen, -CH 2 -N-(N-CH 3 -D- glucamine); -CH 2 - ⁇ H-CH 2 CH 2 - ⁇ H-(CH 2 ) 9 CH 3 ; -CH 2 -NH-CH 2 CH 2 -NH- (CH 2 ) ⁇ CH 3 ; -CH 2 -NH-(CH 2 ) 5 -COOH; and -CH 2 -N-(2-amino-2-deoxygluconic acid).
  • Other preferred R 5 groups are those shown in Table III as R 23 .
  • R 8 is -CH 2 C(O) ⁇ H 2 , -CH 2 COOH, benzyl, 4-hydroxyphenyl or
  • R 8 is -CH 2 C(O)NH 2 .
  • R 9 is preferably hydrogen or alkyl. More preferably, R 9 is hydrogen.
  • R 10 is preferably alkyl or substimted alkyl. More preferably, R 10 is the side-chain of a naturally occurring amino acid. Still more preferably, R 10 is isobutyl. R u is preferably hydrogen or alkyl. More preferably, R 11 is hydrogen or methyl.
  • R 12 is preferably hydrogen, alkyl, substimted alkyl or -C(O)R d . More preferably, R 12 is hydrogen or -CH 2 COOH. Other preferred R 12 groups are those shown in Table II as R 27 .
  • X 1 and X 2 are preferably chloro.
  • X 3 is preferably hydrogen.
  • n is 0 or 1. More preferably, n is 1.
  • this invention provides a compound of formula II:
  • R 21 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -R a -Y-R b -(Z) X ; or a saccharide group optionally substimted with -R a -Y-R b -(Z) X ;
  • R 22 is -OR c , -NR C R C , -O-R a -Y-R b -(Z) x or -NR C -R a -Y-R b -(Z) X ;
  • R 23 is selected from the group consisting of hydrogen, halo, -CH(R C )-NR C R C , -CH(R C )-R e and -CH(R C )-NR C -R a -Y-R b -(Z) X ;
  • R 24 is selected from the group consisting of hydrogen and lower alkyl
  • R 25 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
  • R 26 is selected from the group consisting of hydrogen and lower alkyl; or R 25 and R 26 are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;
  • R 27 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic, -C(O)R d , -C(NH)R d , -C(O)NR c R c , -C(O)OR d , -C(NH)NR C R C and -R a - Y-R b -(Z) X , or R 26 and R 27 are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring; each R a is independently selected from the group consisting of alkylene, substimted alkylene, alkenylene, substimted alkenylene,
  • each R c is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)R d ; each R d is independently selected from the group consisting of alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl
  • R e is an aminosaccharide group; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- ,-NR c - , -S(O)- , -SO 2 - , -NR c C(O)- , -OSO 2 - , -OC(O)- , - NR c SO 2 - , - C(O)NR c - , - C(O)O- , - SO 2 NR c - , - SO 2 O- , - P(O)(OR c )O- , -P(O)(OR c )NR c - , -OP(O)(OR c )O- ,-OP(O)(OR c )NR c - , -OC(O)O- , -NR c C(O)O- , -NR c C(O)NR c - ,
  • R 21 is a saccharide group of the formula:
  • R 15 is -R a -Y-R b -(Z) X , wherein R a , R b , Y, Z and x are as defined herein;
  • R 16 is hydrogen or methyl.
  • R 22 is preferably -OR c or -NR C R C ; more preferably R 22 is -OH. Particularly preferred R 22 groups are those shown in Tables I-IV.
  • R 23 is preferably hydrogen, -CH 2 -R e , -CH 2 -NHR C and -CH 2 -NH-R a -Y-R b -(Z) X , where R a , R b , R c , R e , Y, Z and x are as defined herein.
  • R 23 groups include hydrogen, -CH 2 -N-(N-CH 3 -D- glucamine); -CH 2 - ⁇ H-CH 2 CH 2 - ⁇ H-(CH 2 ) 9 CH 3 ; -CH 2 -NH-CH 2 CH 2 -NH- (CH 2 ) U CH 3 ; -CH 2 -NH-(CH 2 ) 5 -COOH; and -CH 2 -N-(2-amino-2-deoxygluconic acid).
  • Other preferred R 23 groups are shown in Table III.
  • R 24 is preferably hydrogen or alkyl. More preferably, R 24 is hydrogen.
  • R 25 is preferably alkyl or substimted alkyl. More preferably, R 25 is the side-chain of a naturally occurring amino acid. Still more preferably, R 25 is isobutyl.
  • R 26 is preferably hydrogen or alkyl. More preferably, R 26 is hydrogen or methyl.
  • R 27 is preferably hydrogen, alkyl, substimted alkyl or -C(O)R d . More preferably, R 27 is hydrogen or -CH 2 COOH. Other preferred R 27 groups are those shown in Table II.
  • this invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a glycopeptide compound having at least one substituent of the formula:
  • R a , R b , Y, Z and x are as defined herein.
  • this invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound of formula I or II.
  • this invention provides a method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a glycopeptide compound having at least one substituent of the formula: -R a -Y-R b -(Z) X
  • R a , R b , Y, Z and x are as defined herein.
  • this invention provides a method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula I or II.
  • This invention also provides processes for preparing glycopeptide derivatives, which processes are described further herein below.
  • this invention is directed to the use of a glycopeptide derivative of formula I or formula II in the manufacture of a formulation or medicament for a medicinal treatment.
  • the formulation or medicament is used as an antibacterial agent.
  • Preferred compounds of this invention are those set forth in the following tables as formulas III, IV, V, VI, VII and VIII, and pharmaceutically-acceptable salts thereof:
  • Ph phenyl
  • Ph phenyl
  • Ph phenyl
  • This invention relates to novel derivatives of glycopeptide antibiotics and to pharmaceutical compositions and methods employing such glycopeptide derivatives.
  • the following terms have the following meanings, unless otherwise indicated.
  • alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain preferably having from 1 to 40 carbon atoms, more preferably 1 to 10 carbon atoms, and even more preferably 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, rc-propyl, iso-p ⁇ opyl, n-butyl, isobutyl, /z-hexyl, /z-decyl, tetradecyl, and the like.
  • substituted alkyl refers to an alkyl group as defined above, having from 1 to 8 substituents, preferably 1 to 5 substitutents, and more preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocycl
  • alkylene refers to a diradical of a branched or unbranched saturated hydrocarbon chain, preferably having from 1 to 40 carbon atoms, preferably 1-10 carbon atoms, more preferably 1-6 carbon atoms. This term is exemplified by groups such as methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), the propylene isomers (e.g., -CH 2 CH 2 CH 2 - and -CH(CH 3 )CH 2 -) and the like.
  • substimted alkylene refers to an alkylene group, as defined above, having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamin
  • substimted alkylene groups include those where 2 substiments on the alkylene group are fused to form one or more cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heterocyclic or heteroaryl groups fused to the alkylene group.
  • fused groups Preferably contain from 1 to 3 fused ring strucmres.
  • substimted alkylene includes alkylene groups in which from 1 to 5 of the alkylene carbon atoms are replaced with oxygen, sulfur or -NR- where R is hydrogen or alkyl.
  • substituted alkylenes are chloromethylene (-CH(Cl)-), aminoethylene (-CH(NH 2 )CH2-), 2- carboxypropylene isomers (-CH 2 CH(CO 2 H)CH 2 -), ethoxyethyl (-CH 2 CH 2 O-CH 2 CH 2 -) and the like.
  • alkaryl refers to the groups -alkylene-aryl and -substimted alkylene-aryl where alkylene, substimted alkylene and aryl are defined herein. Such alkaryl groups are exemplified by benzyl, phenethyl and the like.
  • alkoxy refers to the groups alkyl-O-, alkenyl-O-, cycloalkyl-O- , cycloalkenyl-O-, and alkynyl-O-, where alkyl, alkenyl, cycloalkyl, cycloalkenyl, and alkynyl are as defined herein.
  • Preferred alkoxy groups are alkyl-O- and include, by way of example, methoxy, ethoxy, /j-propoxy, iso- propoxy, n-butoxy, tert-butoxy, sec-butoxy, /z-pentoxy, n-hexoxy, 1,2- dimethylbutoxy, and the like.
  • substimted alkoxy refers to the groups substimted alkyl-O-, substimted alkenyl-O-, substimted cycloalkyl-O-, substimted cycloalkenyl-O-, and substimted alkynyl-O- where substimted alkyl, substimted alkenyl, substimted cycloalkyl, substimted cycloalkenyl and substimted alkynyl are as defined herein.
  • alkylalkoxy refers to the groups -alkylene-O-alkyl, alkylene-O-substimted alkyl, substimted alkylene-O-alkyl and substimted alkylene- O-substimted alkyl wherein alkyl, substimted alkyl, alkylene and substimted alkylene are as defined herein.
  • Preferred alkylalkoxy groups are alkylene-O-alkyl and include, by way of example, methylenemethoxy
  • alkylthioalkoxy refers to the group -alkylene-S-alkyl, alkylene-S-substimted alkyl, substimted alkylene-S-alkyl and substimted alkylene- S-substimted alkyl wherein alkyl, substimted alkyl, alkylene and substimted alkylene are as defined herein.
  • Preferred alkylthioalkoxy groups are alkylene-S- alkyl and include, by way of example, methylenethiomethoxy (-CH 2 SCH 3 ), ethylenethiomethoxy (-CH 2 CH 2 SCH 3 ), n-propylene-ts ⁇ -thiopropoxy (-CH 2 CH 2 CH 2 SCH(CH 3 ) 2 ), methylene-t-thiobutoxy (-CH 2 SC(CH 3 ) 3 ) and the like.
  • alkenyl refers to a monoradical of a branched or unbranched unsamrated hydrocarbon group preferably having from 2 to 40 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of vinyl unsaturation.
  • substimted alkenyl refers to an alkenyl group as defined above having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxya
  • alkenylene refers to a diradical of a branched or unbranched unsamrated hydrocarbon group preferably having from 2 to 40 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of vinyl unsaturation.
  • substimted alkenylene refers to an alkenylene group as defined above having from 1 to 5 substiments, and preferably from 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxya
  • substimted alkenylene groups include those where 2 substiments on the alkenylene group are fused to form one or more cycloalkyl, substimted cycloalkyl.
  • alkynyl refers to a monoradical of an unsamrated hydrocarbon preferably having from 2 to 40 carbon atoms, more preferably 2 to 20 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of acetylene (triple bond) unsamration.
  • Preferred alkynyl groups include ethynyl (-C ⁇ CH), propargyl (-CH 2 C ⁇ CH) and the like.
  • substimted alkynyl refers to an alkynyl group as defined above having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxy
  • alkynylene refers to a diradical of an unsamrated hydrocarbon preferably having from 2 to 40 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of acetylene (triple bond) unsamration.
  • Preferred alkynylene groups include ethynylene (-C ⁇ C-), propargylene (-CH 2 C ⁇ C-) and the like.
  • substimted alkynylene refers to an alkynylene group as defined above having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy,
  • acyl refers to the groups HC(O)-, alkyl-C(O)-, substimted alkyl-C(O)-, cycloalkyl-C(O)-, substimted cycloalkyl-C(O)-, cycloalkenyl-C(O)-, substimted cycloalkenyl-C(O)-, aryl-C(O)-, heteroaryl-C(O)- and heterocyclic- C(O)- where alkyl, substimted alkyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • acylamino or “aminocarbonyl” refers to the group -C(O)NRR where each R is independently hydrogen, alkyl, substimted alkyl, aryl, heteroaryl, heterocyclic or where both R groups are joined to form a heterocyclic group (e.g., morpholino) wherein alkyl, substimted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • aminoacyl refers to the group -NRC(O)R where each R is independently hydrogen, alkyl, substimted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substimted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • aminoacyloxy or " alkoxy carbonylamino” refers to the group -NRC(O)OR where each R is independently hydrogen, alkyl, substimted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substimted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • acyloxy refers to the groups alkyl-C(O)O-, substimted alkyl- C(O)O-, cycloalkyl-C(O)O-, substimted cycloalkyl-C(O)O-, aryl-C(O)O-, heteroaryl-C(O)O-, and heterocyclic-C(O)O- wherein alkyl, substimted alkyl, cycloalkyl, substimted cycloalkyl, aryl, heteroaryl, and heterocyclic are as defined herein.
  • aryl refers to an unsamrated aromatic carbocyclic group of from 6 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple condensed (fused) rings (e.g., naphthyl or anthryl). Preferred aryls include phenyl, naphthyl and the like.
  • such aryl groups can optionally be substimted with from 1 to 5 substiments, preferably 1 to 3 substiments, selected from the group consisting of acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substimted alkyl, substimted alkoxy, substimted alkenyl, substimted alkynyl, substimted cycloalkyl, substimted cycloalkenyl, amino, substimted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, aminoacyloxy, oxyacylamino, sulfon
  • aryloxy refers to the group aryl-O- wherein the aryl group is as defined above including optionally substimted aryl groups as also defined above.
  • arylene refers to the diradical derived from aryl (including substimted aryl) as defined above and is exemplified by 1,2-phenylene, 1,3- phenylene, 1,4-phenylene, 1,2-naphthylene and the like.
  • amino refers to the group -NH 2 .
  • substrate amino refers to the group -NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, cycloalkyl, substimted cycloalkyl, alkenyl, substimted alkenyl, cycloalkenyl, substimted cycloalkenyl, alkynyl, substimted alkynyl, aryl, heteroaryl and heterocyclic provided that both R's are not hydrogen.
  • amino acid refers to any of the naturally occurring amino acids, as well as synthetic analogs and derivatives thereof.
  • ⁇ -Amino acids comprise a carbon atom to which is bonded an amino group, a carboxy group, a hydrogen atom, and a distinctive group referred to as a "side chain".
  • side chains of naturally occurring amino acids include, for example, hydrogen (e.g., as in glycine), alkyl (e.g., as in alanine, valine, leucine, isoleucine, proline), substimted alkyl (e.g., as in threonine, serine, methionine, cysteine, aspartic acid, asparagine, glutamic acid, glutamine, arginine, and lysine), alkaryl (e.g., as in phenylalanine and tryptophan), substimted arylalkyl (e.g., as in tyrosine), and heteroarylalkyl (e.g., as in histidine).
  • hydrogen e.g., as in glycine
  • alkyl e.g., as in alanine, valine, leucine, isoleucine, proline
  • substimted alkyl e.g., as in thre
  • carboxyalkyl or “alkoxycarbonyl” refers to the groups "-C(O)O-alkyl", “-C(O)O-substituted alkyl", * '-C(O)O-cycloalkyl", “-C(O)O- substimted cycloalkyl", “-C(O)O-alkenyl”, “-C(O)O-substituted alkenyl", “-C(O)O-alkynyl” and “-C(O)O-substituted alkynyl” where alkyl, substimted alkyl, cycloalkyl, substimted cycloalkyl, alkenyl, substimted alkenyl, alkynyl and substimted alkynyl alkynyl are as defined herein.
  • cycloalkyl refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings.
  • Such cycloalkyl groups include, by way of example, single ring strucmres such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring strucmres such as adamantanyl, and the like.
  • cycloalkyl refers to cycloalkyl groups having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxya
  • cycloalkenyl refers to cyclic alkenyl groups of from 4 to 20 carbon atoms having a single cyclic ring and at least one point of internal unsamration.
  • suitable cycloalkenyl groups include, for instance, cyclobut-2-enyl, cyclopent-3-enyl, cyclooct-3-enyl and the like.
  • cycloalkenyl refers to cycloalkenyl groups having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy,
  • halo or halogen refers to fluoro, chloro, bromo and iodo.
  • Haloalkyl refers to alkyl as defined herein substituted by 1 -4 halo groups as defined herein, which may be the same or different.
  • Representative haloalkyl groups include, by way of example, trifluoromethyl, 3-fluorododecyl, 12,12,12- trifluorododecyl, 2-bromooctyl, 3-bromo-6-chloroheptyl, and the like.
  • heteroaryl refers to an aromatic group of from 1 to 15 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within at least one ring (if there is more than one ring).
  • such heteroaryl groups can be optionally substimted with 1 to 5 substiments, preferably 1 to 3 substiments, selected from the group consisting of acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substimted alkyl, substimted alkoxy, substimted alkenyl, substimted alkynyl, substimted cycloalkyl, substimted cycloalkenyl, amino, substimted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl,
  • Preferred aryl substiments include alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy.
  • Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl).
  • Preferred heteroaryls include pyridyl, pyrrolyl and furyl.
  • Heteroarylalkyl refers to (heteroaryl)alkyl- where heteroaryl and alkyl are as defined herein. Representative examples include 2-pyridylmethyl and the like.
  • heteroaryloxy refers to the group heteroaryl-O-.
  • heteroarylene refers to the diradical group derived from heteroaryl (including substimted heteroaryl), as defined above, and is exemplified by the groups 2,6-pyridylene, 2,4-pyridiylene, 1 ,2-quinolinylene, 1,8- quinolinylene, 1,4-benzofuranylene, 2,5-pyridnylene, 2,5-indolenyl and the like.
  • heterocycle or “heterocyclic” refers to a monoradical saturated unsamrated group having a single ring or multiple condensed rings, from 1 to 40 carbon atoms and from 1 to 10 hetero atoms, preferably 1 to 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within the ring.
  • heterocyclic groups can be optionally substimted with 1 to 5, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxy
  • nitrogen heterocycles and heteroaryls include, but are not limited to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, morpholino, piperidinyl, tetrahydrofuranyl, and the like as well as N-alkoxy-nitrogen containing
  • crown compounds refers to a specific class of heterocyclic compounds having one or more repeating units of the formula [-(CH 2 -) a A-] where a is equal to or greater than 2, and A at each separate occurrence can be O, N, S or P.
  • Examples of crown compounds include, by way of example only, [-(CH 2 ) 3 -NH-] 3 , [-((CH 2 ) 2 -O) 4 -((CH 2 ) 2 -NH) 2 ] and the like.
  • crown compounds can have from 4 to 10 heteroatoms and 8 to 40 carbon atoms.
  • heterocyclooxy refers to the group heterocyclic-O-.
  • thioheterocyclooxy refers to the group heterocyclic-S-.
  • heterocyclene refers to the diradical group formed from a heterocycle, as defined herein, and is exemplified by the groups 2,6-morpholino, 2,5-morpholino and the like.
  • oxyacylamino or “aminocarbonyloxy” refers to the group -OC(O)NRR where each R is independently hydrogen, alkyl, substimted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substimted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • saccharide group refers to an oxidized, reduced or substimted saccharide monoradical covalently attached to the glycopeptide or other compound via any atom of the saccharide moiety, preferably via the aglycone carbon atom.
  • Respresentative saccharides include, by way of illustration, hexoses such as D- glucose, D-mannose, D-xylose, D-galactose, vancosamine, 3-desmethyl- vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine, N-methyl-D-glucamine, D- glucuronic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, sialyic acid, iduronic acid, L-mcose, and the like; pentoses such as D-ribose or D-arabinose; ketoses such as D-ribulose or D-fructose; disaccharides such as 2-O-( -L- vancosaminyl)- ⁇ -D-glucopyranose, 2-O-(3-desmethyl
  • amino-containing saccharide group refers to a saccharide group having an amino substiment.
  • Representative amino-containing saccharides include L-vancosamine, 3-desmethyl-vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine, N- methyl-D-glucamine and the like.
  • spiro-attached cycloalkyl group refers to a cycloalkyl group attached to another ring via one carbon atom common to both rings.
  • sulfonamide refers to a group of the formula -SO 2 ⁇ RR, where each R is independently hydrogen, alkyl, substimted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substimted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • thiol refers to the group -SH.
  • thioalkoxy refers to the group -S-alkyl.
  • substituted thioalkoxy refers to the group -S-substituted alkyl.
  • thioaryloxy refers to the group aryl-S- wherein the aryl group is as defined above including optionally substimted aryl groups also defined above.
  • thioheteroaryloxy refers to the group heteroaryl-S- wherein the heteroaryl group is as defined above including optionally substimted aryl groups as also defined above.
  • any of the above groups which contain one or more substiments it is understood, of course, that such groups do not contain any substitution or substimtion patterns which are sterically impractical and/or synthetically non- feasible.
  • the compounds of this invention include all stereochemical isomers arising from the substimtion of these compounds.
  • glycopeptide refers to heptapeptide antibiotics, characterized by a multi- ring peptide core optionally substimted with saccharide groups, such as vancomycin. Examples of glycopeptides included in this definition may be found in "Glycopeptides Classification, Occurrence, and Discovery", by Raymond C. Rao and Louise W. Crandall, ("Drugs and the Pharmaceutical Sciences'Nolume 63, edited by Ramakrishnan Nagarajan, published by Marcal Dekker, Inc.), which is hereby incorporated by reference in its entirety.
  • glycopeptides include those identified as A477, A35512, A40926, A41030, A42867, A47934, A80407, A82846, A83850 ,A84575, AB-65, Actaplanin, Actinoidin, Ardacin, Avoparcin, Azureomycin, Balhimycin, Chloroorientiein, Chloropolysporin, Decaplanin, N-demethylvancomycin, Eremomycin, Galacardin, Helvecardin, Izupeptin, Kibdelin, LL-AM374, Mannopeptin, MM45289, MM47756, MM47761, MM49721, MM47766, MM55260, MM55266, MM55270, MM56597, MM56598, OA-7653, Orenticin, Parvodicin, Ristocetin, Ristomycin, Synmonicin, Teicoplanin, UK-68597, UK-69542, UK-720
  • glycopeptide as used herein is also intended to include the general class of peptides disclosed above on which the sugar moiety is absent, i.e. the aglycone series of glycopeptides. For example, removal of the disaccharide moiety appended to the phenol on vancomycin by mild hydrolysis gives vancomycin aglycone. Also within the scope of the invention are glycopeptides that have been further appended with additional saccharide residues, especially aminoglycosides, in a manner similar to vancosamine.
  • Vancomycin refers to a glycopeptide antibiotic having the formula:
  • NTM When describing vancomycin derivatives, the term "NTM"-" indicates that a substiment is covalently attached to the amino group of the vacosamine moiety of vacomycin. Similarly, the term “N leu -” indicates that a substiment is covalently attached to the amino group of the leucine moiety of vancomycin.
  • Transglycosylase enzyme substrate denotes the molecular target of the transglycosylase enzyme.
  • the substrate binds to the enzyme and evenmally results in synthesis of the bacterial cell wall.
  • the action of this enzyme is inhibited by a ligand domain that binds to the enzyme substrate.
  • a ligand such as vancomycin binds to this substrate and in effect “sequesters” the substrate to prevent its recognition by the enzyme and subsequent use in the construction of the bacterial cell wall.
  • Potency refers to the minimum concentration at which a compound or ligand is able to achieve a desirable biological or therapeutic effect.
  • the potency of a compound or ligand is typically proportional to its affinity for its binding site. In some cases, the potency may be non-linearly correlated with its affinity
  • inorganic solvent or inorganic solvent
  • inert diluent mean a solvent or diluent which is essentially inert under the conditions of the reaction in which it is employed as a solvent or diluent.
  • materials which may be used as inert solvents or diluents include, by way of illlustration, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform (“CHC1 3 "), methylene chloride (or dichloromethane or "CH 2 C1 2 ), diethyl ether, ethyl acetate, acetone, methylethyl ketone, methanol, ethanol, propanol, isopropanol, tert- butanol, dioxane, pyridine, and the like.
  • the solvents used in the reactions of the present invention are inert solvents.
  • “Pharmaceutically acceptable salt” means those salts which retain the biological effectiveness and properties of the parent compounds and which are not biologically or otherwise harmful as the dosage administered.
  • the compounds of this invention are capable of forming both acid and base salts by virtue of the presence of amino and carboxyl groups respectively.
  • Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substimted amines including naturally-occurring substimted amines, and cyclic amines, including isopropylamine, trimethyl amine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, and N- ethylpiperidine.
  • carboxylic acid derivatives would be useful in the practice of this invention, for example carboxylic acid amides, including carboxamides, lower alkyl carboxamides, di ⁇ ower alkyl) carboxamides, and the like.
  • Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like.
  • Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • the compounds of this invention typically contain one or more chiral centers. Accordingly, this invention is intended to include racemic mixtures, diasteromers, enantiomers and mixture enriched in one or more steroisomer.
  • the scope of the invention as described and claimed encompasses the racemic forms of the compounds as well as the individual enantiomers and non-racemic mixtures thereof.
  • treatment includes any treatment of a condition or disease in an animal, particularly a mammal, more particularly a human, and includes: (i) preventing the disease or condition from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;
  • disease state which is alleviated by treatment with a broad spectrum antibacterial is intended to cover all disease states which are generally acknowledged in the art to be usefully treated with a broad spectrum antibacterial in general, and those disease states which have been found to be usefully treated by the specific antibacterials of this invention.
  • disease states include, but are not limited to, treatment of a mammal afflicted with pathogenic bacteria, in particular staphylococci (methicillin sensitive and resistant), streptococci (penicillin sensitive and resistant), enterococci (vancomycin sensitive and resistant), and Clostridium difficile
  • therapeutically effective amount refers to that amount which is sufficient to effect treatment, as defined herein, when administered to a mammal in need of such treatment.
  • the therapeutically effective amount will vary depending on the subject and disease state being treated, the severity of the affliction and the manner of administration, and may be determined routinely by one of ordinary skill in the art.
  • protecting group or “blocking group” refers to any group which, when bound to one or more hydroxyl, thiol, amino, carboxyl or other groups of the compounds, prevents undesired reactions from occurring at these groups and which protecting group can be removed by conventional chemical or enzymatic steps to reestablish the hydroxyl, thio, amino, carboxyl or other group.
  • removable blocking group employed is not critical and preferred removable hydroxyl blocking groups include conventional substiments such as allyl, benzyl, acetyl, chloroacetyl, thiobenzyl, benzylidine, phenacyl, t-butyl- diphenylsilyl and any other group that can be introduced chemically onto a hydroxyl functionality and later selectively removed either by chemical or enzymatic methods in mild conditions compatible with the nature of the product.
  • Protecting groups are disclosed in more detail in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis” 2 nd Ed., 1991, John Wiley and Sons, N.Y.
  • Preferred removable amino blocking groups include conventional substiments such as t-butyoxycarbonyl (t-BOC), benzyloxycarbonyl (CBZ), fluorenylmethoxycarbonyl (FMOC), allyloxycarbonyl (ALOC) and the like, which can be removed by conventional conditions compatible with the nature of the product.
  • t-BOC t-butyoxycarbonyl
  • CBZ benzyloxycarbonyl
  • FMOC fluorenylmethoxycarbonyl
  • ALOC allyloxycarbonyl
  • Preferred carboxyl protecting groups include esters such as methyl, ethyl, propyl, t-butyl etc. which can be removed by mild conditions compatible with the nature of the product.
  • Bio effect includes, but is not limited to, increased affinity, increased selectivity, increased potency, increased efficacy, increased duration of action, decreased toxicity, and the like.
  • glycopeptide compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
  • the choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and references cited therein.
  • glycopeptide compounds are depicted in a simplified form as a box "G” that shows the carboxy terminus labeled [C], the vancosamine amino terminus labeled [V], the "non-saccharide” amino terminus (leucine amine moiety) labeled [N], and optionally, the resorcinol moiety labeled [R] as follows:
  • glycopeptide compounds of the present invention are prepared by reductive alkylation of a glycopeptide as shown in the following reaction:
  • A represents R a minus one carbon atom and R a , R ⁇ Y, Z and x are as defined herein.
  • This reaction is typically conducted by first contacting one equivalent of a glycopeptide, such as vancomycin, with an excess, preferably from 1.1 to 1.3 equivalents, of the desired aldehyde in the presence of an excess, preferably about 2.0 equivalents, of a tertiary amine, such as diisopropylethylamine (DIPEA) and the like.
  • DIPEA diisopropylethylamine
  • the resulting imine and/or hemiaminal is typically not isolated, but is reacted in situ with a metal hydride reducing agent, such as sodium cyanoborohydride and the like, to afford the corresponding amine.
  • a metal hydride reducing agent such as sodium cyanoborohydride and the like
  • This reaction is typically conducted by contacting the imine and/or hemiaminal with about 1 to 1.2 equivalents of the reducing agent at ambient temperature in methanol in the presence of an excess, preferably about 3 equivalents, of trifluoroacetic acid.
  • the resulting alkylated product is readily purified by conventional procedures, such as reverse-phase HPLC.
  • the selectivity for the reductive alkylation reaction is greatly improved, i.e., reductive alkylation at the amino group of the saccharide (e.g. , vancosamine) is favored over reductive alkylation at the N-terminus (e.g., the leucinyl group) by at least 10: 1, more preferably 20:1.
  • the glycopeptide compounds of this invention can also be prepared in a step-wise manner in which a precursor to the -R a -Y-R b -(Z) X group is first attached the glycopeptide by reductive alkylation, followed by subsequent elaboration of the attached precursor using conventional reagent and procedures to form the -R a -Y-R b -(Z) X group as illustrated below.
  • ketones may also be employed in the above-described reductive alkylation reactions to afford ⁇ - substimted amines.
  • glycopeptide having an amino group may be employed in these reductive alkylation reactions.
  • Such glycopeptides are well-known in the art and are either commercially available or may be isolated using conventional procedures. Suitable glycopeptides are disclosed, by way of example, in U.S.
  • aldehydes and ketones employed in the reactive alkylation reaction are also well-known in the art and are either commercially available or can be prepared by conventional procedures using commercially available starting materials and conventional reagents. Typically, such materials are prepared by conventional coupling of, for example, functionalized acetals having an amino, thiol, hydroxyl, halo or other substimtent, with an suitable intermediate having a complementary functional group to form sulfides, ethers, amines, sulfonamides and the like. Subsequent hydrolysis of the acetal affords the corresponding aldehyde.
  • R represents -R b -(Z) X or -(R b minus one carbon atom)-(Z). (where R b , Z and x are as defined herein).
  • Scheme A illustrates a method for preparing an Fmoc-aminoaldehyde 5 from the corresponding aminoalcohol 3, where A is as defined herein.
  • the aminoalcohol is protected by conventional techniques, for example, by treatment with 9-fluorenylmethyl chloroformate in the presence of base, to yield the Fmoc-protected aminoalcohol 4.
  • Oxidation by known techniques then provides the aldehyde 5.
  • Scheme B illustrates an alternate route to F-moc- protected aminoaldehyde 5. This route is described in further detail in Sasake, Y., Abe, J. Chem. Pharm. Bull. (1997), 45(1), 13-17.
  • the Fmoc-protected aminoaldehyde of formula 5 can then be reacted with a glycopeptide, for example vancomycin, as shown in Scheme C.
  • B represents -(R b minus one carbon atom)-(Z) x , where R b , Z and x are as defined herein.
  • glycopeptide intermediate 11 This reaction is conducted under reductive alkylation conditions to yield a glycopeptide intermediate 11.
  • Deprotection of 11 with piperidine yields the corresponding the glycopeptide 12 having a primary amino group.
  • Reaction of 12 with aldehyde 13 under standard reductive alkylation conditions gives glycopeptide derivative 14 and the corresponding bis-adduct 15, which are separated by conventional techniques, such as HPLC.
  • Scheme D illustrates a method for preparing an Fmoc protected aminoaldehyde 24.
  • reaction of acid chloride 19 with aminoester 20 under conventional amide coupling conditions gives amidoester 21.
  • Reduction of the both the ester and amide moieties using a metal hydride reducing agent, such as lithium aluminum hydride (LAH) gives aminoalcohol 22.
  • aldehyde 24 can be prepared as shown in Scheme D' .
  • direct alkylation of amino alcohol 3 under conventional amine alkylation conditions gives amino alcohol 22, which can then be used as described above in Scheme D.
  • Scheme E illustrates an alternative method for preparing aldehyde 24.
  • amino acetal 6 is reductively alkylated to provide 25.
  • Subsequent protection of the amino group and hydrolysis of the acetal under conventional conditions then provides aldehyde 24.
  • Scheme F illustrates another method for reductive alkylation of a glycopeptide.
  • Fmoc-protected aldehyde 24 prepared as descrubed above, is reacted with a glycopeptide 10, such as vancomycin, under reductive alkylation conditions to afford glycopeptide derivative 27.
  • a glycopeptide 10 such as vancomycin
  • Scheme G illustrates the conversion of the carboxyl group of a glycopeptide derivative, such as vancomycin, into an amide.
  • amine 28 is reacted with a glycopeptide derivative, such as 27, under standard peptide coupling conditions, for example, PyBOP and HOBT in DMF, to provide amide 29, after deprotection.
  • Scheme G illustrates the conversion of the carboxyl group of a glycopeptide derivative, such as vancomycin, into an amide.
  • amine 28 is reacted with a glycopeptide derivative, such as 27, under standard peptide coupling conditions, for example, PyBOP and HOBT in DMF, to provide amide 29, after deprotection.
  • Scheme H illustrates the introduction of an aminoalkyl sidechain at the resorcinol moiety of a glycopeptide, such as vancomycin, via a Mannich reaction.
  • amine 30 and an aldehyde, such as formalin are reacted with the glycopeptide under basic conditions to give the glycopeptide derivative 31.
  • Scheme I illustrates a introduction of a substiment of the formula -R a - Y-R b -(Z) X at the resorcinol moiety of a glycopeptide using the Mannich reaction.
  • excess aldehyde such as formaldehyde, can react to afford the cyclized compounds of formula Vila and/or Vllb.
  • Scheme J illustrates a synthesis of a glycopeptide derivative using several of the reactions described above.
  • glycopeptide derivative 27 is derivatized at the resorcinol moiety using the Mannich reaction described in Scheme H to provide glycopeptide derivative 40.
  • Scheme L illustrates multiple reductive alkylation reaction of a glycopeptide derivative 27 to afford glycopeptide derivative 44a.
  • This invention also includes pharmaceutical composition containing the novel glycopeptide compounds of this invention.
  • the glycopeptide compound preferably in the form of a pharmaceutically acceptable salt, can be formulated for oral or parenteral administration for the therapeutic or prophylactic treatment of bacterial infections.
  • the glycopeptide compound can be admixed with conventional pharmaceutical carriers and excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such pharmaceutical compositions will contain from about 0.1 to about 90% by weight of the active compound, and more generally from about 10 to about 30%.
  • the pharmaceutical compositions may contain common carriers and excipients, such as corn starch or gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid.
  • Disintegrators commonly used in the formulations of this invention include croscarmellose, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
  • a liquid composition will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example ethanol, glycerine, sorbitol, non-aqueous solvent such as polyethylene glycol, oils or water, with a suspending agent, preservative, surfactant, wetting agent, flavoring or coloring agent.
  • a liquid formulation can be prepared from a reconstitutable powder.
  • a powder containing active compound, suspending agent, sucrose and a sweetener can be reconstimted with water to form a suspension; and a syrup can be prepared from a powder containing active ingredient, sucrose and a sweetener.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid compositions.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose, microcrystalline cellulose and binders, for example polyvinylpyrrolidone.
  • the tablet can also be provided with a color film coating, or color included as part of the carrier(s).
  • active compound can be formulated in a controlled release dosage form as a tablet comprising a hydrophilic or hydrophobic matrix.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures, for example by incorporation of active compound and excipients into a hard gelatin capsule.
  • a semi-solid matrix of active compound and high molecular weight polyethylene glycol can be prepared and filled into a hard gelatin capsule; or a solution of active compound in polyethylene glycol or a suspension in edible oil, for example liquid paraffin or fractionated coconut oil can be prepared and filled into a soft gelatin capsule.
  • Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, poly-vinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.
  • Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicone fluid, talc, waxes, oils and colloidal silica.
  • Flavoring agents such as peppermint, oil of wintergreen, cherry flavoring or the like can also be used. Additionally, it may be desirable to add a coloring agent to make the dosage form more attractive in appearance or to help identify the product.
  • the compounds of the invention and their pharmaceutically acceptable salts that are active when given parenterally can be formulated for intramuscular, intrathecal, or intravenous administration.
  • a typical composition for intra-muscular or intrathecal administration will consist of a suspension or solution of active ingredient in an oil, for example arachis oil or sesame oil.
  • a typical composition for intravenous or intrathecal administration will consist of a sterile isotonic aqueous solution containing, for example active ingredient and dextrose or sodium chloride, or a mixture of dextrose and sodium chloride.
  • Other examples are lactated Ringer's injection, lactated Ringer's plus dextrose injection, Normosol-M and dextrose, Isolyte E, acylated Ringer's injection, and the like.
  • a co-solvent for example polyethylene glycol
  • a chelating agent for example ethylenediamine tetracetic acid
  • an anti-oxidant for example, sodium metabisulphite
  • the solution can be freeze dried and then reconstimted with a suitable solvent just prior to administration.
  • the compounds of the invention and their pharmaceutically acceptable salts which are active on rectal administration can be formulated as suppositories.
  • a typical suppository formulation will generally consist of active ingredient with a binding and/or lubricating agent such as a gelatin or cocoa butter or other low melting vegetable or synthetic wax or fat.
  • transdermal compositions or transdermal delivery devices
  • Such compositions include, for example, a backing, active compound reservoir, a control membrane, liner and contact adhesive.
  • transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
  • the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g. , U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference in its entirety.
  • Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • the active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • Suitable doses are in the general range of from 0.01-100 mg/kg/day, preferably 0.1-50 mg/kg/day. For an average 70 kg human, this would amount to 0.7 mg to 7g per day, or preferably 7 mg to 3.5g per day.
  • Formulation Example A This example illustrates the preparation of a representative pharmaceutical composition for oral administration of a compound of this invention:
  • the above ingredients are mixed and introduced into a hard-shell gelatin capsule.
  • Formulation Example B This example illustrates the preparation of another representative pharmaceutical composition for oral administration of a compound of this invention:
  • This example illustrates the preparation of a representative pharmaceutical composition for oral administration of a compound of this invention.
  • An oral suspension is prepared having the following composition.
  • Veegum K (Vanderbilt Co.) 1.0 g
  • This example illustrates the preparation of a representative pharmaceutical composition containing a compound of this invention.
  • An injectable preparation buffered to a pH of 4 is prepared having the following composition:
  • Formulation Example E This example illustrates the preparation of a representative pharmaceutical composition for injection of a compound of this invention.
  • a reconstimted solution is prepared by adding 20 mL of sterile water to 1 g of the compound of this invention. Before use, the solution is then diluted with 200 mL of an intravenous fluid that is compatible with the active compound.
  • Such fluids are chosen from 5% dextrose solution, 0.9% sodium chloride, or a mixmre of 5% dextrose and 0.9% sodium chloride.
  • Other examples are lactated Ringer's injection, lactated Ringer's plus 5% dextrose injection, Normosol-M and 5% dextrose, Isolyte E, and acylated Ringer's injection
  • Formulation Example F This example illustrates the preparation of a representative pharmaceutical composition for topical application of a compound of this invention.
  • Formulation Example G This example illustrates the preparation of a representative pharmaceutical composition containing a compound of this inventon.
  • a suppository totaling 2.5 grams is prepared having the following composition:
  • glycopeptide compounds of this invention are useful in medical treatments and exhibit biological activity, including antibacterial activity, which can be demonstrated in the tests described in the Examples. Such tests are well known to those skilled in the art, and are referenced and described in Lorian “Antibiotics in Laboratory Medicine", Fourth Edition, Williams and Wilkins (1991), which is hereby incorporated by reference.
  • this invention provides methods for treating infectious diseases, especially those caused by Gram-positive microorganisms, in animals.
  • the compounds of this invention are particularly useful in treating infections caused by methicillin-resistant staphylococci.
  • the compounds are useful in treating infection due to enterococci, including vancomycin-resistant enterococci (VRE).
  • VRE vancomycin-resistant enterococci
  • diseases are severe staphylococcal infections, for example, staphylococcal endocarditis and staphylococcal septicemia.
  • the animal may be either susceptible to, or infected with, the microorganism.
  • the method comprises administering to the animal an amount of a compound of this invention which is effective for this purpose.
  • an effective amount of a compound of this invention is a dose between about 0.5 and about 100 mg/kg.
  • a preferred dose is from about 1 to about 60 mg/kg of active compound.
  • a typical daily dose for an adult human is from about 50 mg to about 5 g.
  • the antibiotic can be administered in a single daily dose or in multiple doses per day.
  • the treatment regimen may require administration over extended periods of time, for example, for several days or for from one to six weeks.
  • the amount per administered dose or the total amount administered will depend on such factors as the nature and severity of the infection, the age and general health of the patient, the tolerance of the patient to the antibiotic and the microorganism or microorganisms in the infection.
  • the compounds of this invention have also been found to be more chemically stable compared to N-acyl glycopeptide derivatives. More specifically, it has been observed that acylation of the amino group of the vancosamine moiety of vancomycin increases the rate of hydrolysis of the disaccharide moiety. In contrast, when the compounds of this invention are substimted on the amino group of the vancosamine moiety of vancomycin with a -R a -Y-R b -(Z) X group, no increase in the rate of hydrolysis of the disaccharide moiety is observed.
  • DIBAL-H diisobutylaluminum hydride
  • DIPEA diisopropylethylamine
  • TEMPO 2,2,6,6-tetramethyl-piperidinyloxy, free radical
  • vancomycin hydrochloride semi-hydrate was purchased from Alpharma, Inc. Fort Lee, ⁇ J 07024 (Alpharma AS, Oslo
  • a white suspension of vancomycin aglycon TFA salt (1.0 eq.), CS 2 CO 3 (3.5 eq.) in DMF is stirred at room temperamre for 30 min.
  • An alkyl halide (1.1 eq.) is added.
  • the reaction mixmre is then stirred for 5-24 h before quenching with acetic acid.
  • the resulting brownish solution is dripped into water to give a white precipitate. Filtration affords the crude monoalkylated product which can be purified by reverse-phase HPLC if desired.
  • a solution of a bromoacetal (1 eq), such as dimethyl 2- bromoacetaldehyde, and sodium iodide (1 eq) in DMF is stirred at ambient temperamre for 0.5 h.
  • a substimted thiol (1 eq) such as /z-decyl thiol, followed by potasium carbonate (1 eq).
  • the mixmre is stirred at 25- 80 °C for 4-16 hours.
  • the reaction is then taken up with ethyl acetate, washed twice with water and once with sat. NaCl.
  • a mixmre of a thiol ester (1 eq), such as methyl thioglycolate, sodium iodide (1 eq), an alkyl bromide (1 eq) and potasium carbonate (1 eq) in DMF is stirred at room temperamre for 4-16 hours.
  • the reaction is taken up with ethyl acetate and washed with water and brine.
  • the organic layer is dried over magnesium sulfate and solvent is removed in vacuo. Purification on flash chromatography provides the thio-substituted ester.
  • the thio-substimted ester in dry ether is treated with DIBAL-H (1 M solution in cyclohexane, 1.3 eq) at -78 °C.
  • the reaction is then stirred at -78 °C for 2-4 hours.
  • TLC is used to monitor the reaction progress.
  • ethyl formate 0.5 eq
  • the reaction is then washed with 10% acetic acid, water and brine.
  • the organic layer is dried over magnesium sulfate and the solvent removed to afford the crude thio-substimted aldehyde which is typically used without further purification.
  • a solution of an aminoacetal (1 eq), such as dimethyl 2-aminoacetaldehyde, and diiospropylethylamine (2 eq) in THF is treated with a sulfonyl chloride (1 eq) at 0°C.
  • the reaction is then stirred at room temperamre for 1-4 hours.
  • the reaction is then taken up with ethyl acetate and washed with 0.1 N HCl, water and brine.
  • the solvent is removed in vacuo and the residue purified by flash chromatography gave the sulfonamido-substituted acetal.
  • Fmoc-protected aminoethanol was prepared from aminoethanol by conventional techniques (e.g., as described in Examples B and C below).
  • aqueous layer was extracted with ethyl acetate (2 x 250 mL), the combined organic layers were washed with saturated Na 2 S 2 O 3 , water, and brine, dried over Na 2 SO 4 , filtered and concentrated to about 400 mL. Hexane (1,600 mL) was added to give a white precipitate. After filtration, Fmoc-aminoacetaldehyde (25.2g, 67%) was collected as a white powder.
  • 2-(n-Decylamino)ethanol (2.3 g, 11 mmol, 1.1 eq) and DIPEA (2.0 mL, 11 mmol, 1.1 eq) were dissolved in methylene chloride (15 mL) and cooled in an ice bath.
  • 9-Fluorenylmethyl chloroformate (2.6 g, 10 mmol, 1.0 eq) in methylene chloride (15 mL) was added, the mixmre stirred for 30 minutes then washed with 3N hydrochloric acid (50 mL) twice and saturated sodium bicarbonate (50 mL). The organics were dried over magnesium sulfate, and the solvents removed under reduced pressure.
  • N-Fmoc-2-(decylamino)ethanol (4.6 g, 11 mmol, 108%) was used without further purification.
  • N-Fmoc-2-(n-Decylamino)ethanol (4.6 g, 11 mmol, 1.0 eq) and DIPEA (7.6 mL, 44 mmol, 4.0 eq) were dissolved in methylene chloride (30 mL) and cooled in an ice/acetone bath.
  • a solution of sulfur trioxide pyridine complex (6.9 g, 43 mmol, 4.0 eq) in dimethyl sulfoxide (30 mL) was added, and the solution stirred for 20 minutes. Crushed ice was added and the mixmre partitioned. The organics were washed with 3N hydrochloric acid twice, saturated sodium bicarbonate and saturated sodium chloride, dried over magnesium chloride, and concentrated under vacuum.
  • N-Fmoc-2-(n-Decylamino)acetaldehyde (3.4 g, 8 mmol, 74%) was used without further purification (see example 5).
  • trans -4-Oecenal (7.2 g, 46.6 mmol) was mixed with 40 mL (0.37 moL) of aminoacetaldehyde dimethylacetal in 400 mL of methanol and stirred at room temperamre for 30 minutes.
  • NaCNBH 3 (2.9 g, 46.6 mmol) was added, the reaction was cooled in an ice bath, and 27 mL (0.35 moL) of TFA was added dropwise over 5 minutes. The ice bath was then removed and the reaction was stirred for 70 minutes at room temperamre, concentrated to a third of its volume, and partitioned between ethyl acetate (250 mL) and IN NaOH (200 mL).
  • N-Fmoc-2-(tr ⁇ i'-Dec-4-en-l-ylamino)acetaldehyde dimethyl acetal (5 g, 10.7 mmol) was mixed with 30 mL of TFA and stirred at room temperamre for 30 minutes. The reaction was poured into water (140 mL) and centrifuged to obtain a clear oil. The supernatant was decanted and the oil was mixed with 40 mL of water and centrifuged again.
  • Vancomycin (9.0 g, 5.16 mmol) was added to a solution of N-methyl-D- glucamine (5.03 g, 25.8 mmol) and 37% formaldehyde (0.43 mL, 5.4 mmol) in 50% aqueous acetonitrile (60 mL) under nitrogen and stirred at room temperamre. After 4 hours, the acetonitrile was removed in vacuo, water (30 mL) was added, and the pH was adjusted to ⁇ 4 with 10% trifluoroacetic acid. The solution was purified by reverse-phase HPLC. Fractions containing the desired product were identified by mass spectrometry, pooled, and lyophilized to give the title compound as a white powder. This intermediate may be further derivatized using the procedures described herein.
  • Vancomycin hydrochloride (4.00 g, 2.60 mmol) was suspended in 40 mL of l,3-dimethyl-3,4,5,6-tetrahydro-2-(lH)-pyrimidinone and heated to 70°C for 15 minutes.
  • N-(9-fluorenylmethoxycarbonyl)aminoacetaldehyde (720 mg, 2.6 mmol) was added and the mixmre was heated at 70°C for one hour.
  • Sodium cyanoborohydride 160 mg, 2.5 mmol
  • 2 mL methanol was added and the mixmre was heated at 70 °C for 2 hours, then cooled to room temperamre.
  • the reaction solution was added dropwise to 20 mL of acetonitrile, giving a precipitate that was collected by centrifugation.
  • the precipitate was purified by reverse-phase HPLC on a Ranin C18 Dynamax column (2.5 cm x 25 cm, 8 ⁇ m particle size), at 10 mL/min flow rate using 0.045% TFA in water as buffer A and 0.045 % TFA in acetonitrile as buffer B (HPLC gradient of 10-70% B over 90 minutes), which yielded the title intermediate as its trifluroacetate salt.
  • MS calculated: MH + , 1715; Found, 1715.
  • This compound can be deprotected and further derivatized, for example,via reductive alkylation, as described herein.
  • Vancomycin hydrochloride hydrate (10 g, 6.4 mmol) was dissolved in 100 mL of dimethyl sulfoxide (DMSO) and 3-(dimethylamino)propylamine (3.2 mL, 26 mmol) was added.
  • DMSO dimethyl sulfoxide
  • HOBT 1-hydroxybenzotriazole
  • NN-dimethylformamide DMF
  • the aglycone, as its trifluoroacetate salt (500 mg, 340 umol) was dissolved in 5 mL DMF and potassium carbonate (500 mg, 3.6 mmol) was added.
  • the —I ll- mixture was stirred for 15 minutes at room temperamre then tert-butyl N-(2- bromoethyl)carbamate (77 mg, 340 umol) was added.
  • the mixmre was stirred at room temperamre for 24 hours, then additional tert-butyl N-(2- bromoethyl)carbamate (70 mg, 310 umol) was added.
  • N van -Fmoc-aminoethyl vancomycin was deprotected to give N ⁇ -aminoethyl vancomycin tri-TFA salt using conventional procedures (e.g. as described in Examples 2 and 3)
  • N van -aminoethyl vancomycin tri-TFA salt (15.5 mg, 8.4 micromol) in methanol: DMF: THF (2:1: 1, 1.6mL) was added decanal (92 microL, 59 micromol) and sodium cyanoborohydride (0.1M in methanol, 45 microL, 4.5 micromol). After 45 minutes, the solvents were removed in vacuo, and the residue purified by preperative HPLC. The appropriate fractions were combined and lyophylized to give N van -2-(/z-decylamino)ethyl vancomycin (2.4 mg) as a white powder. Also isolated was N van ,N van -bis-2-(n-decylamino)ethyl vancomycin (2.9mg).
  • Vancomycin hydrochloride (12 g, 7.7 mmol, 1.0 eq), N-Fmoc-2-(n- decylamino)acetaldehyde (3.2 g, 7.6 mmol, 1.0 eq) and DIPEA (2.6 mL, 14.9 mmol, 2.0 eq) were stirred at room temperamre in DMF (120 mL) for 90 minutes.
  • Sodium cyanoborohydride 1.4 g, 22 mmol, 3.0 eq
  • methanol 120 mL
  • trifluoroacetic acid 1.8 mL, 23 mmol, 3.0 eq).
  • the crude product was purified on a reverse-phase flash column, eluting with 10, 20, 30% acetonitrile in water (containing 0.1 % trifluoroacetic acid) to remove polar impurities (such as residual vancomycin) then the product was eluted with 70% acetonitrile in water (containing 0.1 % trifluoroacetic acid) to give 9 g of N van -(N-Fmoc-2-n-decylaminoethyl) vancomycin as its trifluoroacetate salt (4.3 mmol, 56%).
  • N van -(N-Fmoc-2-n-decylaminoethyl) vancomycin 100 mg was dissolved in 1 mL DMF (1 mL) and treated with piperidine (200 uL) for 30 minutes. The mixmre was precipitated into ether, centrifuged and washed with acetonitrile.
  • N van -(N-Fmoc-2-n-decylaminoethyl) vancomycin 100 mg, 48 umol, 1.0 eq
  • glucosamine hydrochloride 31 mg, 144 umol, 3.0 eq
  • DIPEA 60 uL, 344 umol, 7.2 eq
  • R 23 is -CH 2 -N-(N-CH 3 -D-glucamine))
  • the solid was dissolved in DMF (6.0 mL) and piperidine (2.0 mL). After 30 minutes, the product was precipated by the additon of acetonitrile (80 mL). The solid was isolated by centrifugation, then washed with ether (80 mL). The resulting solid was dried in vacuo, and purified by reverse- phase HPLC (10-35 %B) over 40 min at a flow rate of 50 mL/min).
  • Bacterial strains were obtained from either American Type Tissue Culture Collection (ATCC), Stanford University Hospital (SU), Kaiser Permanente Regional Laboratory in Berkeley (KPB), Massachusetts General Hospital (MGH), the Centers for Disease Control (CDC), the San Francisco Veterans' Administration Hospital (SFV A) or the University of California San Francisco
  • Vancomycin resistant enterococci were phenotyped as Van A or Van B based on their sensitivity to teicoplanin. Some vancomycin resistant enterococci that had been genotyped as Van A, Van B, Van Cl or Van C2 were obtained from the Mayo Clinic.
  • MICs Minimal inhibitory concentrations were measured in a microdilution broth procedure under NCCLS guidelines. Routinely, the compounds were serially diluted into Mueller-Hinton broth in 96-well microtiter plates. Overnight culmres of bacterial strains were diluted based on absorbance at 600 nm so that the final concentration in each well was 5 x 10 5 cfu/mL. Plates were remrned to a 35 °C incubator. The following day (or 24 hours in the case of Enterococci strains), MICs were determined by visual inspection of the plates.
  • MSSA methicillin-sensitive Staphylococcus aureus
  • MSSE methicillin-resistant Staphylococcus epidermidis
  • VRE Fm Van A vancomycin resistant Enterococcus faecium sensistive to teicoplanin
  • VRE Fm Van B vancomycin resistant Enterococcus faecalis also resistant to teicoplanin
  • VRE Fs Van A vancomycin resistant Enterococcus faecalis sensitive to teicoplanin
  • VRE Fs Van B enterococcus gallinarium of the Van A genotype
  • VRE Gm Van A enterococcus gallinarium of the Van C-1 genotype
  • VRE Gm Van C-1 enterococcus casseliflavus of the Van C-2 genotype
  • MICs with those strains were determined using either TSA broth supplemented with defibrinated blood or blood agar plates. Compounds which had significant activity against the strains mentioned above were then tested for MIC values in a larger panel of clinical isolates including the species listed above as well as non-speciated coagulase negative Staphylococcus both sensitive and resistant to methicillin (MS-CNS and MR-CNS). In addition, they were tested for MICs against gram negative organisms, such as Escherichia coli and Pseudomonas aeruginosa.
  • the compounds of this invention were active in the above tests in vitro tests and demonstrated a broad spectrum of activity.
  • a compound of this invention was administered either intravenously or subcutaneously and observed for 5-15 minutes. If there were no adverse effects, the dose was increased in a second group of mice. This dose incrementation continued until mortality occurred, or the dose was maximized. Generally, dosing began at 20 mg/kg and increased by 20 mg/kg each time until the maximum tolerated dose (MTD) is achieved.
  • MTD maximum tolerated dose
  • a therapeutic dose in general, approximately 50 mg/kg.
  • S. aureus or E. Faecalis or E. Faecium
  • Neutropenic Thigh Model In this model, antibacterial activity of a compound of this invention was evaluated against an appropriately virulent strain of bacteria (most commonly S. aureus, or E. Faecalis or E. Faecium, sensitive or resistant to vancomycin). Mice were initially rendered neutropenic by administration of cyclophosphamide at 200 mg/kg on day 0 and day 2. On day 4 they were infected in the left anterior thigh by an IM injection of a single dose of bacteria.
  • an appropriately virulent strain of bacteria most commonly S. aureus, or E. Faecalis or E. Faecium, sensitive or resistant to vancomycin.
  • mice were then administered the test compound one hour after the bacteria and at various later times (normally 1, 2.5, 4 and 24 hours) the mice were sacrificed (3 per time point) and the thigh excised, homogenized and the number of CFUs (colony forming units) were determined by plating. Blood was also plated to determine the CFUs in the blood.
  • CFUs colony forming units
  • the rate at which a compound of this invention is removed from the blood can be determined in either rats or mice.
  • rats the test animals were cannulated in the jugular vein.
  • the test compound was administered via tail vein injection, and at various time points (normally 5, 15, 30,60 minutes and 2,4,6 and 24 hours) blood was withdrawn from the cannula
  • mice the test compound was also administered via tail vein injection, and at various time points. Blood was normally obtained by cardiac puncture.
  • the concentration of the remaining test compound was determined by HPLC.
  • the compounds of this invention were active in the above tests in vivo tests and demonstrated a broad spectrum of activity.

Abstract

Disclosed are derivatives of glycopeptide compounds having at least one substituent of the formula: -R?a-Y-Rb-(Z)¿x where Ra, Rb, Y, Z and x are as defined, and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.

Description

GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Serial No. 60/113,728, filed December 23, 1998; U.S. Serial No. 60/129,313, filed April 14, 1999; U.S.
Serial No. 60/164,024, filed November 4, 1999; and U.S. Serial No. 60/169,978, filed December 10, 1999; the disclosures of which are incoφorated herein by reference in their entirety.
BACKGROUND OF THE INVENTION Field of the Invention
This invention relates to novel derivatives of glycopeptide antibiotics. This invention also relates to pharmaceutical compositions containing such glycopeptide derivatives, to methods of using such glycopeptide derivatives as antibacterial agents, and to processes for preparing such glycopeptide derivatives.
Background
Glycopeptides are a well-known class of antibiotics produced by various microorganisms. These complex multi-ring peptide compounds are effective antibacterial agents against a majority of Gram-positive bacteria. The use of glycopeptides as antibiotics, however, has been overshadowed by the semi- synthetic penicillins, cephalosporins and lincomycin due to the higher levels of mammalian toxicity observed with the glycopeptides. In recent years, however, bacteria resistant to the penicillins, cephalosporins and the like have emerged resulting in, for example, multiple-resistant and methicillin-resistant staphylococcal (MRS) infections. Glycopeptides, such as vancomycin, are typically effective against such microorganisms and vancomycin has become the drug of last resort for MRS and other infections. The glycopeptides are believed to be effective against such resistant microorganism because they have a different mode of action than other antibiotics. In this regard, the glycopeptides are believed to selectively inhibit a different step in bacterial cell wall synthesis than the penicillin-type antibiotics.
More specifically, the cell wall of bacteria consists of linear polysaccharide chains cross-linked by short peptides. This arrangement of cross-linked polysaccharides confers mechanical support to the cell wall, thus preventing the bacteria from bursting due to its high internal osmotic pressure. During the synthesis of the bacterial cell wall, cross-linking of the polysaccharides takes place after lipid-linked disaccharide-pentapeptide constructs are incorporated into linear polysaccharide chains by a transglycolase enzyme. The subsequent cross-linking reaction is the last step in the synthesis of the cell wall and is catalyzed by an enzyme known as peptidoglycan transpeptidase.
One method by which antibacterial agents exert their antibacterial activity is by inhibiting the transglycosylase enzyme, thus interfering with the penultimate step in the synthesis of the bacterial cell wall. Although not wishing to be bound by theory, it is believed that glycopeptide antibiotics, such as vancomycin, bind with high affinity and specificity to N-terminal sequences (i.e., L-lysyl-D-alanyl- D-alanine in vancomycin-sensitive organisms) of the peptidoglycan precursors
(known as lipid intermediate II). By binding to and sequestering these precursors, vancomycin prevents their utilization in cell wall biosynthesis. Thus, vancomycin inhibits the bacterial transglycosylase that is responsible for adding lipid intermediate II subunits to growing peptidoglycan chains. This step of bacterial cell wall synthesis preceeds the cross-linking transpeptidation step which is known to be inhibited by beta-lactams antibiotics. It is also believed that vancomycin inhibits transpeptidation which involves the D-alanyl-D-alanine termini. However, since this step occurs subsequent to transglycosylation, inhibition of transpeptidation is not directly observed.
A number of derivatives of vancomycin and other glycopeptides are known in the art. For example, see U.S. Patent Nos. 4,639,433; 4,643,987; 4,497,802; 4,698,327; 5,591,714; 5,840,684; and 5,843,889. Other derivatives are disclosed in EP 0 802 199; EP 0 801 075; EP 0 667 353; WO 97/28812; WO 97/38702; WO 98/52589; WO 98/52592; and in /. Amer. Chem. Soc , 1996, 118, 13107- 13108; J. Amer. Chem. Soc, 1997, 119, 12041-12047; and /. Amer. Chem. Soc , 1994, 116, 4573-4590. The disclosures of these and other documents referred to throughout this application are incorporated herein by reference in their entirety.
A need exists, however, for glycopeptide derivatives having improved activity, selectivity and reduced mammalian toxicity. Moreover, certain microorganisms are beginning to develop resistance to vancomycin, such as vancomycin-resistant enterococci (VRE). Accordingly, it would be highly desirable to provide novel glycopeptide derivatives which are effective against a broad spectrum of bacteria, including resistant strains such as VRE. Moreover, it would be highly advantageous to provide glycopeptide derivatives having improved antibacterial activity and selectivity, and low mammalian toxicity.
SUMMARY OF THE INVENTION The present invention provides novel derivatives of glycopeptide antibiotics having improved properties compared to the unsubstituted glycopeptide, including enhanced activity, selectivity and reduced mammalian toxicity. For example, certain vancomycin derivatives of this invention demonstrate greatly enhanced antibacterial activity compared to vancomycin itself. Such vancomycin derivatives are also highly effective against vancomycin-resistant enterococci strains while exhibiting reduced mammalian toxicity. Accordingly, in one of its composition aspects, this invention provides a glycopeptide compound having at least one substituent of the formula:
-Ra-Y-Rb-(Z)X
wherein each Ra is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene; each Rb is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substimted alkynylene, provided Rb is not a covalent bond when Z is hydrogen; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- , -NRC- , -S(O)- , -SO2- , -NRcC(O)- , -OC(O)- , -NRcSO2- , -OSO2- , -C(O)NRc- , -C(O)O- , -SO2NRc- , -SO2O- , ,-P(O)(ORc)O- , -P(O)(ORc)NRc- , -OP(O)(ORc)O- ,-OP(O)(ORc)NRc- , -OC(O)O- , -NRcC(O)O- , -NRcC(O)NRc- , -OC(O)NRc- and -NRcSO2NRc- ; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; each Rc is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)Rd; each Rd is independently selected from the group consisting of alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic; x is 1 or 2; and pharmaceutically acceptable salts thereof; provided that:
(i) when Y is -NRC- , Rc is alkyl of 1 to 4 carbon atoms, Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms; (ii) when Y is -C(O)NRc- , Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms;
(iii) when Y is sulfur, Z is hydrogen and Rb is alkylene, then Rb contains at least 7 carbon atoms; and
(iv) when Y is oxygen, Z is hydrogen and Rb is alkylene, then Rb contains at least 11 carbon atoms.
Preferably, the glycopeptide compound is substimted with from 1 to 3 substituents of the formula -Ra-Y-Rb-(Z)X.
Each Ra is preferably independently selected from alkylene having from 1 to 10 carbon atoms, more preferably, from 1 to 6 carbon atoms. In a preferred embodiment, Ra is ethylene (-CH2CH2-), propylene (-CH2CH2CH2-) or butylene (-CH2CH2CH2CH2-). Still more preferably, Ra is ethylene or propylene.
When Z is hydrogen, Rb is preferably alkylene of from 8 to 12 carbon atoms. Accordingly, in this embodiment, Rb and Z preferably form an «-octyl, n- nonyl, /i-decyl, tz-undecyl or /z-dodecyl group. When Z is other than hydrogen, Rb is preferably a covalent bond or alkylene of from 1 to 10 carbon atoms. In this embodiment, Rb is preferably, a covalent bond, methylene, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9- or -(CH2)10-.
Each Y is preferably independently selected from the group consisting of oxygen, sulfur, -S-S-, -NRC- , -S(O)- , -SO2- , -NRcC(O)- , -OC(O)- , -NRcSO2- , -C(O)NRc- , -C(O)O- and -SO2NRc- . More preferably, Y is oxygen, sulfur, -NRC- or -NRcSO2- .
Preferably, each Z is independently selected from hydrogen, aryl, cycloalkyl, heteroaryl and heterocyclic. More preferably, Z is hydrogen or aryl. When Z is aryl, preferred Z group include phenyl, substimted phenyl, biphenyl, substimted biphenyl and terphenyl groups. Particularly preferred Z groups are phenyl, 4-isobutylphenyl, 4'-chlorobiphenyl-4-yl, 4'-trifluoromethylbiphenyl-4-yl, 4-(naphth-2-yl)phenyl, 4-(2-phenylethynyl)phenyl, 4-(3,4-dichlorobenzyloxy)- phenyl, and -terphenyl.
Preferably, x is 1.
Particularly preferred -Ra-Y-Rb-(Z)X groups of this invention are selected from the group consisting of:
- CH2CH2- NH- (CH2)9CH3 ;
- CH2CH2CH2- NH- (CH2)8CH3 ; -CH2CH2CH2CH2-NH-(CH2)7CH3;
- CH2CH2- NHSO2- (CH2)9CH3; -CH2CH2-NHSO2-(CH2)nCH3;
Figure imgf000008_0001
- CH2CH2 _ S - (CH2)9CH3 ; -CH2CH2-S-(CH2)10CH3;
- CH2CH2CH2- S ~ (CH2)gCH3 ; ~~ CH2CH2CH2 - S _ (CH2)9CH3 ;
- CH2CH2CH2- S- (CH2)3-CH = CH-(CH2)4CH3 (trans) ;
- CH2CH2CH2CH2- S- (CH2)7CH3 ; -CH2CH2-S(O)-(CH2)9CH3;
-CH2CH2-S-(CH2)6Ph; -CH2CH2-S-(CH2)8Ph; -CH2CH2CH2-S-(CH2)gPh;
- CH2CH2- NH- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2- NH- CH2-4-[4-CH3)2CHCH2-]-Ph; - CH2CH2- NH- CH2-4-(4-CF3-Ph)-Ph;
- CH2CH2- S- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- S- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-S(O)-CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-S-CH2-4-[3,4-di-Cl-PhCH2O-)-Ph;
- CH2CH2- NHSO2- CH2-4-[4-(4-Ph)-Ph]-Ph; -CH2CH2CH2-NHSO2-CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- NHSO2- CH2-4-(Ph-C ≡C-)-Ph; -CH2CH2CH2-NHSO2-4-(4-Cl-Ph)-Ph; and -CH2CH2CH2-NHSO2-4-(naphth-2-yl)-Ph.
Other preferred -Ra-Y-Rb-(Z)X groups are shown in Tables I- VI below.
In another of its composition aspects, this invention provides a compound of formula I:
Figure imgf000010_0001
wherein
R1 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -Ra-Y-Rb-(Z)X; or a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X;
R2 is hydrogen or a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X;
R3 is -ORc, -NRCRC, -O-Ra Y-Rb-(Z)x, -NRC-Ra-Y-Rb-(Z)X, -NRcRe, or -O-Re ;
R4 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -Ra-Y-Rb-(Z)X, -C(O)Rd and a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X; R5 is selected from the group consisting of hydrogen, halo, -CH(RC)-NRCRC, -CH(Rc)-NRcRe and -CH(RC)-NRC-Ra-Y-Rb-(Z)X;
R6 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -Ra-Y-Rb-(Z)X, -C(O)Rd and a saccharide group optionally substimted with -NRC-Ra-Y-Rb-(Z)X, or R5 and R° can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substimted with -NRC-Ra-Y-Rb-(Z)X;
R7 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -Ra-Y-Rb-(Z)X, and -C(O)Rd;
R8 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic; R9 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R10 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic; or R8 and R10 are joined to form -Ar'-O-Ar2- , where Ar1 and Ar2 are independently arylene or heteroarylene;
R11 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R10 and R11 are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring; R12 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic, -C(O)Rd, -C(NH)Rd, -C(O)NRcRc, -C(O)ORd, -C(NH)NRCRC and -Ra- Y-Rb-(Z)X, or R11 and R12 are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;
R13 is selected from the group consisting of hydrogen or -OR14;
R14 is selected from hydrogen, -C(O)Rd and a saccharide group; each Ra is independently selected from the group consisting of alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene; each Rb is independently selected from the group consisting of a covalent bond, alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene, provided Rb is not a covalent bond when Z is hydrogen; each Rc is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)Rd; each Rd is independently selected from the group consisting of alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
Re is a saccharide group; X1, X2 and X3 are independently selected from hydrogen or chloro; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- , -NRC- , -S(O)- , -SO2- , -NRcC(O)- , -OSO2- , -OC(O)- , -NRcSO2- , -C(O)NRc- , -C(O)O- , -SO2NRc- , -SO2O- , -P(O)(ORc)O- , - P(O)(ORc)NRc- , - OP(O)(ORc)O- , - OP(O)(ORc)NRc- , - OC(O)O- , -NRcC(O)O- , -NRcC(O)NRc- , -OC(O)NRc- and -NRcSO2NRc- ; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; n is 0, 1 or 2; x is 1 or 2; and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof; provided that at least one of R1, R2, R3, R4, R5, R6, R7 or R12 has a substimtent of the formula -Ra-Y-Rb-(Z)X; and further provided that:
(i) when Y is -NRC- , Rc is alkyl of 1 to 4 carbon atoms, Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms;
(ii) when Y is -C(O)NRc- , Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms; (iii) when Y is sulfur, Z is hydrogen and Rb is alkylene, then Rb contains at least 7 carbon atoms; and
(iv) when Y is oxygen, Z is hydrogen and Rb is alkylene, then Rb contains at least 11 carbon atoms.
Preferably, R1 is a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X. More preferably, R1 is a saccharide group of the formula:
Figure imgf000013_0001
wherein
R15 is -Ra- Y-Rb-(Z)X, where Ra, R\ Y, Z and x are as defined herein; and
R16 is hydrogen or methyl.
Preferably, R2 is hydrogen.
R3 is preferably -ORc or -NRCRC; more preferably R3 is -OH. Particularly preferred R3 groups are those shown in Tables I-IV as R22.
Preferably, R4, R° and R7 are each independently selected from hydrogen or -C(O)Rd. More preferably, R4, R6 and R7 are each hydrogen.
R5 is preferably hydrogen, -CH2-NHRC, -CH2-NRcRe and -CH2-NH-Ra- Y-Rb-(Z)X, where Ra, Rb, Rc, Re, Y, Z and x are as defined herein. Particularly preferred R5 groups include hydrogen, -CH2-N-(N-CH3-D- glucamine); -CH2-ΝH-CH2CH2-ΝH-(CH2)9CH3; -CH2-NH-CH2CH2-NH- (CH2)πCH3; -CH2-NH-(CH2)5-COOH; and -CH2-N-(2-amino-2-deoxygluconic acid). Other preferred R5 groups are those shown in Table III as R23.
Preferably, R8 is -CH2C(O)ΝH2, -CH2COOH, benzyl, 4-hydroxyphenyl or
3-chloro-4-hydroxyphenyl. More preferably, R8 is -CH2C(O)NH2.
R9 is preferably hydrogen or alkyl. More preferably, R9 is hydrogen.
R10 is preferably alkyl or substimted alkyl. More preferably, R10 is the side-chain of a naturally occurring amino acid. Still more preferably, R10 is isobutyl. Ru is preferably hydrogen or alkyl. More preferably, R11 is hydrogen or methyl.
R12 is preferably hydrogen, alkyl, substimted alkyl or -C(O)Rd. More preferably, R12 is hydrogen or -CH2COOH. Other preferred R12 groups are those shown in Table II as R27.
X1 and X2 are preferably chloro. X3 is preferably hydrogen.
Preferably, n is 0 or 1. More preferably, n is 1.
In still another of its composition aspects, this invention provides a compound of formula II:
Figure imgf000015_0001
wherein R21 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -Ra-Y-Rb-(Z)X; or a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X;
R22 is -ORc, -NRCRC, -O-Ra-Y-Rb-(Z)x or -NRC-Ra-Y-Rb-(Z)X;
R23 is selected from the group consisting of hydrogen, halo, -CH(RC)-NRCRC, -CH(RC)-Re and -CH(RC)-NRC-Ra-Y-Rb-(Z)X;
R24 is selected from the group consisting of hydrogen and lower alkyl; R25 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R26 is selected from the group consisting of hydrogen and lower alkyl; or R25 and R26 are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;
R27 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic, -C(O)Rd, -C(NH)Rd, -C(O)NRcRc, -C(O)ORd, -C(NH)NRCRC and -Ra- Y-Rb-(Z)X, or R26 and R27 are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring; each Ra is independently selected from the group consisting of alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene; each Rb is independently selected from the group consisting of a covalent bond, alkylene, substimted alkylene, alkenylene. substimted alkenylene, alkynylene and substimted alkynylene, provided Rb is not a covalent bond when Z is hydrogen; each Rc is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)Rd; each Rd is independently selected from the group consisting of alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
Re is an aminosaccharide group; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- ,-NRc- , -S(O)- , -SO2- , -NRcC(O)- , -OSO2- , -OC(O)- , - NRcSO2- , - C(O)NRc- , - C(O)O- , - SO2NRc- , - SO2O- , - P(O)(ORc)O- , -P(O)(ORc)NRc- , -OP(O)(ORc)O- ,-OP(O)(ORc)NRc- , -OC(O)O- , -NRcC(O)O- , -NRcC(O)NRc- , -OC(O)NRc- and -NRcSO2NRc- ; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; n is 0, 1 or 2; x is 1 or 2; and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof; provided that at least one of R21, R22, R23 or R27 has a substitutent of the formula -Ra-Y-Rb-(Z)X; and further provided that:
(i) when Y is -NRC- , Rc is alkyl of 1 to 4 carbon atoms, Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms; (ii) when Y is -C(O)NRc- , Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms;
(iii) when Y is sulfur, Z is hydrogen and Rb is alkylene, then Rb contains at least 7 carbon atoms; and (iv) when Y is oxygen, Z is hydrogen and Rb is alkylene, then Rb contains at least 11 carbon atoms.
Preferably, R21 is a saccharide group of the formula:
Figure imgf000018_0001
wherein R15 is -Ra-Y-Rb-(Z)X, where Ra, Rb, Y, Z and x are as defined herein; and
R16 is hydrogen or methyl.
R22 is preferably -ORc or -NRCRC; more preferably R22 is -OH. Particularly preferred R22 groups are those shown in Tables I-IV.
R23 is preferably hydrogen, -CH2-Re, -CH2-NHRC and -CH2-NH-Ra-Y-Rb-(Z)X, where Ra, Rb, Rc, Re, Y, Z and x are as defined herein. Particularly preferred R23 groups include hydrogen, -CH2-N-(N-CH3-D- glucamine); -CH2-ΝH-CH2CH2-ΝH-(CH2)9CH3; -CH2-NH-CH2CH2-NH- (CH2)UCH3; -CH2-NH-(CH2)5-COOH; and -CH2-N-(2-amino-2-deoxygluconic acid). Other preferred R23 groups are shown in Table III.
R24 is preferably hydrogen or alkyl. More preferably, R24 is hydrogen. R25 is preferably alkyl or substimted alkyl. More preferably, R25 is the side-chain of a naturally occurring amino acid. Still more preferably, R25 is isobutyl.
R26 is preferably hydrogen or alkyl. More preferably, R26 is hydrogen or methyl.
R27 is preferably hydrogen, alkyl, substimted alkyl or -C(O)Rd. More preferably, R27 is hydrogen or -CH2COOH. Other preferred R27 groups are those shown in Table II.
In yet another of its composition aspects, this invention provides a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a glycopeptide compound having at least one substituent of the formula:
-Ra-Y-Rb-(Z)X
wherein Ra, Rb, Y, Z and x are as defined herein.
Additionally, this invention provides a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound of formula I or II.
The compounds of this invention are highly effective antibacterial agents. Accordingly, in one of its method aspects, this invention provides a method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a glycopeptide compound having at least one substituent of the formula: -Ra-Y-Rb-(Z)X
wherein Ra, Rb, Y, Z and x are as defined herein.
Additionally, this invention provides a method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula I or II.
This invention also provides processes for preparing glycopeptide derivatives, which processes are described further herein below.
In another of its aspects, this invention is directed to the use of a glycopeptide derivative of formula I or formula II in the manufacture of a formulation or medicament for a medicinal treatment. Preferably, the formulation or medicament is used as an antibacterial agent.
Preferred compounds of this invention are those set forth in the following tables as formulas III, IV, V, VI, VII and VIII, and pharmaceutically-acceptable salts thereof:
19 -
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
t
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000034_0002
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0002
Ph = phenyl
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Ph = phenyl
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000052_0002
- 51
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Ph = phenyl
CTS
Figure imgf000058_0001
Figure imgf000059_0001
Ό e 10
Figure imgf000060_0001
15 Ph = phenyl
Table VI
Figure imgf000061_0001
Figure imgf000061_0002
DETAILED DESCRIPTION OF THE INVENTION
This invention relates to novel derivatives of glycopeptide antibiotics and to pharmaceutical compositions and methods employing such glycopeptide derivatives. When describing the compounds, compositions and methods of this invention, the following terms have the following meanings, unless otherwise indicated.
Definitions
The term "alkyl" refers to a monoradical branched or unbranched saturated hydrocarbon chain preferably having from 1 to 40 carbon atoms, more preferably 1 to 10 carbon atoms, and even more preferably 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, rc-propyl, iso-pτopyl, n-butyl, isobutyl, /z-hexyl, /z-decyl, tetradecyl, and the like.
The term "substimted alkyl" refers to an alkyl group as defined above, having from 1 to 8 substituents, preferably 1 to 5 substitutents, and more preferably 1 to 3 substituents, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO- substimted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl.
The term "alkylene" refers to a diradical of a branched or unbranched saturated hydrocarbon chain, preferably having from 1 to 40 carbon atoms, preferably 1-10 carbon atoms, more preferably 1-6 carbon atoms. This term is exemplified by groups such as methylene (-CH2-), ethylene (-CH2CH2-), the propylene isomers (e.g., -CH2CH2CH2- and -CH(CH3)CH2-) and the like.
The term "substimted alkylene" refers to an alkylene group, as defined above, having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, - SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl. Additionally, such substimted alkylene groups include those where 2 substiments on the alkylene group are fused to form one or more cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heterocyclic or heteroaryl groups fused to the alkylene group. Preferably such fused groups contain from 1 to 3 fused ring strucmres. Additionally, the term substimted alkylene includes alkylene groups in which from 1 to 5 of the alkylene carbon atoms are replaced with oxygen, sulfur or -NR- where R is hydrogen or alkyl. Examples of substituted alkylenes are chloromethylene (-CH(Cl)-), aminoethylene (-CH(NH2)CH2-), 2- carboxypropylene isomers (-CH2CH(CO2H)CH2-), ethoxyethyl (-CH2CH2 O-CH2CH2-) and the like.
The term "alkaryl" refers to the groups -alkylene-aryl and -substimted alkylene-aryl where alkylene, substimted alkylene and aryl are defined herein. Such alkaryl groups are exemplified by benzyl, phenethyl and the like. The term "alkoxy" refers to the groups alkyl-O-, alkenyl-O-, cycloalkyl-O- , cycloalkenyl-O-, and alkynyl-O-, where alkyl, alkenyl, cycloalkyl, cycloalkenyl, and alkynyl are as defined herein. Preferred alkoxy groups are alkyl-O- and include, by way of example, methoxy, ethoxy, /j-propoxy, iso- propoxy, n-butoxy, tert-butoxy, sec-butoxy, /z-pentoxy, n-hexoxy, 1,2- dimethylbutoxy, and the like.
The term "substimted alkoxy" refers to the groups substimted alkyl-O-, substimted alkenyl-O-, substimted cycloalkyl-O-, substimted cycloalkenyl-O-, and substimted alkynyl-O- where substimted alkyl, substimted alkenyl, substimted cycloalkyl, substimted cycloalkenyl and substimted alkynyl are as defined herein.
The term "alkylalkoxy" refers to the groups -alkylene-O-alkyl, alkylene-O-substimted alkyl, substimted alkylene-O-alkyl and substimted alkylene- O-substimted alkyl wherein alkyl, substimted alkyl, alkylene and substimted alkylene are as defined herein. Preferred alkylalkoxy groups are alkylene-O-alkyl and include, by way of example, methylenemethoxy
(-CH2OCH3), ethylenemethoxy (-CH2CH2OCH3), Az-propylene-wσ-propoxy (-CH2CH2CH2OCH(CH3)2), methylene-t-butoxy (-CH2-O-C(CH3)3) and the like.
The term "alkylthioalkoxy" refers to the group -alkylene-S-alkyl, alkylene-S-substimted alkyl, substimted alkylene-S-alkyl and substimted alkylene- S-substimted alkyl wherein alkyl, substimted alkyl, alkylene and substimted alkylene are as defined herein. Preferred alkylthioalkoxy groups are alkylene-S- alkyl and include, by way of example, methylenethiomethoxy (-CH2SCH3), ethylenethiomethoxy (-CH2CH2SCH3), n-propylene-tsø-thiopropoxy (-CH2CH2CH2SCH(CH3)2), methylene-t-thiobutoxy (-CH2SC(CH3)3) and the like. The term "alkenyl" refers to a monoradical of a branched or unbranched unsamrated hydrocarbon group preferably having from 2 to 40 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of vinyl unsaturation. Preferred alkenyl groups include ethenyl (-CH=CH2), /2-propenyl
(-CH2CH=CH2), ώσ-propenyl (-C(CH3) = CH2), and the like.
The term "substimted alkenyl" refers to an alkenyl group as defined above having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl.
The term "alkenylene" refers to a diradical of a branched or unbranched unsamrated hydrocarbon group preferably having from 2 to 40 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of vinyl unsaturation. This term is exemplified by groups such as ethenylene (-CH=CH-), the propenylene isomers (e.g. , -CH2CH=CH- and -C(CH3)=CH-) and the like.
The term "substimted alkenylene" refers to an alkenylene group as defined above having from 1 to 5 substiments, and preferably from 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, - SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl. Additionally, such substimted alkenylene groups include those where 2 substiments on the alkenylene group are fused to form one or more cycloalkyl, substimted cycloalkyl. cycloalkenyl, substimted cycloalkenyl, aryl, heterocyclic or heteroaryl groups fused to the alkenylene group.
The term "alkynyl" refers to a monoradical of an unsamrated hydrocarbon preferably having from 2 to 40 carbon atoms, more preferably 2 to 20 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of acetylene (triple bond) unsamration. Preferred alkynyl groups include ethynyl (-C≡CH), propargyl (-CH2C≡CH) and the like.
The term "substimted alkynyl" refers to an alkynyl group as defined above having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl. The term "alkynylene" refers to a diradical of an unsamrated hydrocarbon preferably having from 2 to 40 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of acetylene (triple bond) unsamration. Preferred alkynylene groups include ethynylene (-C≡C-), propargylene (-CH2C≡C-) and the like.
The term "substimted alkynylene" refers to an alkynylene group as defined above having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, - SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl
The term "acyl" refers to the groups HC(O)-, alkyl-C(O)-, substimted alkyl-C(O)-, cycloalkyl-C(O)-, substimted cycloalkyl-C(O)-, cycloalkenyl-C(O)-, substimted cycloalkenyl-C(O)-, aryl-C(O)-, heteroaryl-C(O)- and heterocyclic- C(O)- where alkyl, substimted alkyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term "acylamino" or "aminocarbonyl" refers to the group -C(O)NRR where each R is independently hydrogen, alkyl, substimted alkyl, aryl, heteroaryl, heterocyclic or where both R groups are joined to form a heterocyclic group (e.g., morpholino) wherein alkyl, substimted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term "aminoacyl" refers to the group -NRC(O)R where each R is independently hydrogen, alkyl, substimted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substimted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term "aminoacyloxy" or " alkoxy carbonylamino" refers to the group -NRC(O)OR where each R is independently hydrogen, alkyl, substimted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substimted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term "acyloxy" refers to the groups alkyl-C(O)O-, substimted alkyl- C(O)O-, cycloalkyl-C(O)O-, substimted cycloalkyl-C(O)O-, aryl-C(O)O-, heteroaryl-C(O)O-, and heterocyclic-C(O)O- wherein alkyl, substimted alkyl, cycloalkyl, substimted cycloalkyl, aryl, heteroaryl, and heterocyclic are as defined herein.
The term "aryl" refers to an unsamrated aromatic carbocyclic group of from 6 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple condensed (fused) rings (e.g., naphthyl or anthryl). Preferred aryls include phenyl, naphthyl and the like.
Unless otherwise constrained by the definition for the aryl substituent, such aryl groups can optionally be substimted with from 1 to 5 substiments, preferably 1 to 3 substiments, selected from the group consisting of acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substimted alkyl, substimted alkoxy, substimted alkenyl, substimted alkynyl, substimted cycloalkyl, substimted cycloalkenyl, amino, substimted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, aminoacyloxy, oxyacylamino, sulfonamide, thioalkoxy, substimted thioalkoxy, thioaryloxy, thioheteroaryloxy, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2- substimted alkyl, -SO2-aryl, -SO2-heteroaryl and trihalomethyl. Preferred aryl substiments include alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy.
The term "aryloxy" refers to the group aryl-O- wherein the aryl group is as defined above including optionally substimted aryl groups as also defined above.
The term "arylene" refers to the diradical derived from aryl (including substimted aryl) as defined above and is exemplified by 1,2-phenylene, 1,3- phenylene, 1,4-phenylene, 1,2-naphthylene and the like.
The term "amino" refers to the group -NH2.
The term "substimted amino" refers to the group -NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, cycloalkyl, substimted cycloalkyl, alkenyl, substimted alkenyl, cycloalkenyl, substimted cycloalkenyl, alkynyl, substimted alkynyl, aryl, heteroaryl and heterocyclic provided that both R's are not hydrogen.
"Amino acid" refers to any of the naturally occurring amino acids, as well as synthetic analogs and derivatives thereof. α-Amino acids comprise a carbon atom to which is bonded an amino group, a carboxy group, a hydrogen atom, and a distinctive group referred to as a "side chain". The side chains of naturally occurring amino acids are well known in the art and include, for example, hydrogen (e.g., as in glycine), alkyl (e.g., as in alanine, valine, leucine, isoleucine, proline), substimted alkyl (e.g., as in threonine, serine, methionine, cysteine, aspartic acid, asparagine, glutamic acid, glutamine, arginine, and lysine), alkaryl (e.g., as in phenylalanine and tryptophan), substimted arylalkyl (e.g., as in tyrosine), and heteroarylalkyl (e.g., as in histidine).
The term "carboxyalkyl" or "alkoxycarbonyl" refers to the groups "-C(O)O-alkyl", "-C(O)O-substituted alkyl", *'-C(O)O-cycloalkyl", "-C(O)O- substimted cycloalkyl", "-C(O)O-alkenyl", "-C(O)O-substituted alkenyl", "-C(O)O-alkynyl" and "-C(O)O-substituted alkynyl" where alkyl, substimted alkyl, cycloalkyl, substimted cycloalkyl, alkenyl, substimted alkenyl, alkynyl and substimted alkynyl alkynyl are as defined herein.
The term "cycloalkyl" refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings. Such cycloalkyl groups include, by way of example, single ring strucmres such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring strucmres such as adamantanyl, and the like.
The term "substimted cycloalkyl" refers to cycloalkyl groups having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl. The term "cycloalkenyl" refers to cyclic alkenyl groups of from 4 to 20 carbon atoms having a single cyclic ring and at least one point of internal unsamration. Examples of suitable cycloalkenyl groups include, for instance, cyclobut-2-enyl, cyclopent-3-enyl, cyclooct-3-enyl and the like.
The term "substimted cycloalkenyl" refers to cycloalkenyl groups having from 1 to 5 substiments, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl.
The term "halo" or "halogen" refers to fluoro, chloro, bromo and iodo.
"Haloalkyl" refers to alkyl as defined herein substituted by 1 -4 halo groups as defined herein, which may be the same or different. Representative haloalkyl groups include, by way of example, trifluoromethyl, 3-fluorododecyl, 12,12,12- trifluorododecyl, 2-bromooctyl, 3-bromo-6-chloroheptyl, and the like.
The term "heteroaryl" refers to an aromatic group of from 1 to 15 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within at least one ring (if there is more than one ring). Unless otherwise constrained by the definition for the heteroaryl substituent, such heteroaryl groups can be optionally substimted with 1 to 5 substiments, preferably 1 to 3 substiments, selected from the group consisting of acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substimted alkyl, substimted alkoxy, substimted alkenyl, substimted alkynyl, substimted cycloalkyl, substimted cycloalkenyl, amino, substimted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substimted thioalkoxy, thioaryloxy, thioheteroaryloxy, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, -SO2-heteroaryl and trihalomethyl. Preferred aryl substiments include alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy. Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl). Preferred heteroaryls include pyridyl, pyrrolyl and furyl.
"Heteroarylalkyl" refers to (heteroaryl)alkyl- where heteroaryl and alkyl are as defined herein. Representative examples include 2-pyridylmethyl and the like.
The term "heteroaryloxy" refers to the group heteroaryl-O-.
The term "heteroarylene" refers to the diradical group derived from heteroaryl (including substimted heteroaryl), as defined above, and is exemplified by the groups 2,6-pyridylene, 2,4-pyridiylene, 1 ,2-quinolinylene, 1,8- quinolinylene, 1,4-benzofuranylene, 2,5-pyridnylene, 2,5-indolenyl and the like.
The term "heterocycle" or "heterocyclic" refers to a monoradical saturated unsamrated group having a single ring or multiple condensed rings, from 1 to 40 carbon atoms and from 1 to 10 hetero atoms, preferably 1 to 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within the ring.
Unless otherwise constrained by the definition for the heterocyclic substiment, such heterocyclic groups can be optionally substimted with 1 to 5, and preferably 1 to 3 substiments, selected from the group consisting of alkoxy, substimted alkoxy, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, acyl, acylamino, acyloxy, amino, substimted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substimted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO- substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, - SO2-aryl and -SO2-heteroaryl. Such heterocyclic groups can have a single ring or multiple condensed rings. Preferred heterocyclics include morpholino, piperidinyl, and the like.
Examples of nitrogen heterocycles and heteroaryls include, but are not limited to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, morpholino, piperidinyl, tetrahydrofuranyl, and the like as well as N-alkoxy-nitrogen containing heterocycles.
Another class of heterocyclics is known as "crown compounds" which refers to a specific class of heterocyclic compounds having one or more repeating units of the formula [-(CH2-)aA-] where a is equal to or greater than 2, and A at each separate occurrence can be O, N, S or P. Examples of crown compounds include, by way of example only, [-(CH2)3-NH-]3, [-((CH2)2-O)4-((CH2)2-NH)2] and the like. Typically such crown compounds can have from 4 to 10 heteroatoms and 8 to 40 carbon atoms.
The term "heterocyclooxy" refers to the group heterocyclic-O-.
The term "thioheterocyclooxy" refers to the group heterocyclic-S-.
The term "heterocyclene" refers to the diradical group formed from a heterocycle, as defined herein, and is exemplified by the groups 2,6-morpholino, 2,5-morpholino and the like.
The term "oxyacylamino" or "aminocarbonyloxy" refers to the group -OC(O)NRR where each R is independently hydrogen, alkyl, substimted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substimted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term "saccharide group" refers to an oxidized, reduced or substimted saccharide monoradical covalently attached to the glycopeptide or other compound via any atom of the saccharide moiety, preferably via the aglycone carbon atom. Respresentative saccharides include, by way of illustration, hexoses such as D- glucose, D-mannose, D-xylose, D-galactose, vancosamine, 3-desmethyl- vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine, N-methyl-D-glucamine, D- glucuronic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, sialyic acid, iduronic acid, L-mcose, and the like; pentoses such as D-ribose or D-arabinose; ketoses such as D-ribulose or D-fructose; disaccharides such as 2-O-( -L- vancosaminyl)-β-D-glucopyranose, 2-O-(3-desmethyl-α-L-vancosaminyl)-β-D- glucopyranose, sucrose, lactose, or maltose; derivatives such as acetals, amines, acylated, sulfated and phosphorylated sugars; oligosaccharides having from 2 to 10 saccharide units. For the purposes of this definition, these saccharides are referenced using conventional three letter nomenclamre and the saccharides can be either in their open or preferably in their pyranose form.
The term "amino-containing saccharide group" refers to a saccharide group having an amino substiment. Representative amino-containing saccharides include L-vancosamine, 3-desmethyl-vancosamine, 3-epi-vancosamine, 4-epi-vancosamine, acosamine, actinosamine, daunosamine, 3-epi-daunosamine, ristosamine, N- methyl-D-glucamine and the like.
The term "spiro-attached cycloalkyl group" refers to a cycloalkyl group attached to another ring via one carbon atom common to both rings.
The term "sulfonamide" refers to a group of the formula -SO2ΝRR, where each R is independently hydrogen, alkyl, substimted alkyl, aryl, heteroaryl, or heterocyclic wherein alkyl, substimted alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
The term "thiol" refers to the group -SH.
The term "thioalkoxy" refers to the group -S-alkyl.
The term "substimted thioalkoxy" refers to the group -S-substituted alkyl.
The term "thioaryloxy" refers to the group aryl-S- wherein the aryl group is as defined above including optionally substimted aryl groups also defined above. The term "thioheteroaryloxy" refers to the group heteroaryl-S- wherein the heteroaryl group is as defined above including optionally substimted aryl groups as also defined above.
As to any of the above groups which contain one or more substiments, it is understood, of course, that such groups do not contain any substitution or substimtion patterns which are sterically impractical and/or synthetically non- feasible. In addition, the compounds of this invention include all stereochemical isomers arising from the substimtion of these compounds.
"Glycopeptide" refers to heptapeptide antibiotics, characterized by a multi- ring peptide core optionally substimted with saccharide groups, such as vancomycin. Examples of glycopeptides included in this definition may be found in "Glycopeptides Classification, Occurrence, and Discovery", by Raymond C. Rao and Louise W. Crandall, ("Drugs and the Pharmaceutical Sciences'Nolume 63, edited by Ramakrishnan Nagarajan, published by Marcal Dekker, Inc.), which is hereby incorporated by reference in its entirety. Representative glycopeptides include those identified as A477, A35512, A40926, A41030, A42867, A47934, A80407, A82846, A83850 ,A84575, AB-65, Actaplanin, Actinoidin, Ardacin, Avoparcin, Azureomycin, Balhimycin, Chloroorientiein, Chloropolysporin, Decaplanin, N-demethylvancomycin, Eremomycin, Galacardin, Helvecardin, Izupeptin, Kibdelin, LL-AM374, Mannopeptin, MM45289, MM47756, MM47761, MM49721, MM47766, MM55260, MM55266, MM55270, MM56597, MM56598, OA-7653, Orenticin, Parvodicin, Ristocetin, Ristomycin, Synmonicin, Teicoplanin, UK-68597, UK-69542, UK-72051, Vancomycin, and the like. The term "glycopeptide" as used herein is also intended to include the general class of peptides disclosed above on which the sugar moiety is absent, i.e. the aglycone series of glycopeptides. For example, removal of the disaccharide moiety appended to the phenol on vancomycin by mild hydrolysis gives vancomycin aglycone. Also within the scope of the invention are glycopeptides that have been further appended with additional saccharide residues, especially aminoglycosides, in a manner similar to vancosamine.
"Vancomycin" refers to a glycopeptide antibiotic having the formula:
Figure imgf000077_0001
When describing vancomycin derivatives, the term "N™"-" indicates that a substiment is covalently attached to the amino group of the vacosamine moiety of vacomycin. Similarly, the term "Nleu-" indicates that a substiment is covalently attached to the amino group of the leucine moiety of vancomycin.
"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substimted" means that a group may or may not be substimted with the described substitutent.
"Transglycosylase enzyme substrate" as used herein denotes the molecular target of the transglycosylase enzyme. The substrate binds to the enzyme and evenmally results in synthesis of the bacterial cell wall. The action of this enzyme is inhibited by a ligand domain that binds to the enzyme substrate. A ligand such as vancomycin binds to this substrate and in effect "sequesters" the substrate to prevent its recognition by the enzyme and subsequent use in the construction of the bacterial cell wall.
"Potency" as used herein refers to the minimum concentration at which a compound or ligand is able to achieve a desirable biological or therapeutic effect. The potency of a compound or ligand is typically proportional to its affinity for its binding site. In some cases, the potency may be non-linearly correlated with its affinity
As used herein, the terms "inert organic solvent" or "inert solvent" or
"inert diluent" mean a solvent or diluent which is essentially inert under the conditions of the reaction in which it is employed as a solvent or diluent. Representative examples of materials which may be used as inert solvents or diluents include, by way of illlustration, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform ("CHC13"), methylene chloride (or dichloromethane or "CH2C12), diethyl ether, ethyl acetate, acetone, methylethyl ketone, methanol, ethanol, propanol, isopropanol, tert- butanol, dioxane, pyridine, and the like. Unless specified to the contrary, the solvents used in the reactions of the present invention are inert solvents. "Pharmaceutically acceptable salt" means those salts which retain the biological effectiveness and properties of the parent compounds and which are not biologically or otherwise harmful as the dosage administered. The compounds of this invention are capable of forming both acid and base salts by virtue of the presence of amino and carboxyl groups respectively.
Pharmaceutically acceptable base addition salts may be prepared from inorganic and organic bases. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substimted amines including naturally-occurring substimted amines, and cyclic amines, including isopropylamine, trimethyl amine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, and N- ethylpiperidine. It should also be understood that other carboxylic acid derivatives would be useful in the practice of this invention, for example carboxylic acid amides, including carboxamides, lower alkyl carboxamides, diøower alkyl) carboxamides, and the like.
Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. The compounds of this invention typically contain one or more chiral centers. Accordingly, this invention is intended to include racemic mixtures, diasteromers, enantiomers and mixture enriched in one or more steroisomer. The scope of the invention as described and claimed encompasses the racemic forms of the compounds as well as the individual enantiomers and non-racemic mixtures thereof.
The term "treatment" as used herein includes any treatment of a condition or disease in an animal, particularly a mammal, more particularly a human, and includes: (i) preventing the disease or condition from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;
(ii) inhibiting the disease or condition, i.e. arresting its development; relieving the disease or condition, i.e. causing regression of the condition; or. relieving the conditions caused by the disease, i.e. symptoms of the disease.
The term "disease state which is alleviated by treatment with a broad spectrum antibacterial" as used herein is intended to cover all disease states which are generally acknowledged in the art to be usefully treated with a broad spectrum antibacterial in general, and those disease states which have been found to be usefully treated by the specific antibacterials of this invention. Such disease states include, but are not limited to, treatment of a mammal afflicted with pathogenic bacteria, in particular staphylococci (methicillin sensitive and resistant), streptococci (penicillin sensitive and resistant), enterococci (vancomycin sensitive and resistant), and Clostridium difficile
The term "therapeutically effective amount" refers to that amount which is sufficient to effect treatment, as defined herein, when administered to a mammal in need of such treatment. The therapeutically effective amount will vary depending on the subject and disease state being treated, the severity of the affliction and the manner of administration, and may be determined routinely by one of ordinary skill in the art. The term "protecting group" or "blocking group" refers to any group which, when bound to one or more hydroxyl, thiol, amino, carboxyl or other groups of the compounds, prevents undesired reactions from occurring at these groups and which protecting group can be removed by conventional chemical or enzymatic steps to reestablish the hydroxyl, thio, amino, carboxyl or other group. The particular removable blocking group employed is not critical and preferred removable hydroxyl blocking groups include conventional substiments such as allyl, benzyl, acetyl, chloroacetyl, thiobenzyl, benzylidine, phenacyl, t-butyl- diphenylsilyl and any other group that can be introduced chemically onto a hydroxyl functionality and later selectively removed either by chemical or enzymatic methods in mild conditions compatible with the nature of the product. Protecting groups are disclosed in more detail in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis" 2nd Ed., 1991, John Wiley and Sons, N.Y.
Preferred removable amino blocking groups include conventional substiments such as t-butyoxycarbonyl (t-BOC), benzyloxycarbonyl (CBZ), fluorenylmethoxycarbonyl (FMOC), allyloxycarbonyl (ALOC) and the like, which can be removed by conventional conditions compatible with the nature of the product.
Preferred carboxyl protecting groups include esters such as methyl, ethyl, propyl, t-butyl etc. which can be removed by mild conditions compatible with the nature of the product.
"Biological effect" as used herein includes, but is not limited to, increased affinity, increased selectivity, increased potency, increased efficacy, increased duration of action, decreased toxicity, and the like. General Synthetic Procedures
The glycopeptide compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and references cited therein.
In the following reaction schemes, the glycopeptide compounds are depicted in a simplified form as a box "G" that shows the carboxy terminus labeled [C], the vancosamine amino terminus labeled [V], the "non-saccharide" amino terminus (leucine amine moiety) labeled [N], and optionally, the resorcinol moiety labeled [R] as follows:
Figure imgf000083_0001
In one preferred embodiment, the glycopeptide compounds of the present invention are prepared by reductive alkylation of a glycopeptide as shown in the following reaction:
Figure imgf000083_0002
where A represents Ra minus one carbon atom and Ra, R\ Y, Z and x are as defined herein. This reaction is typically conducted by first contacting one equivalent of a glycopeptide, such as vancomycin, with an excess, preferably from 1.1 to 1.3 equivalents, of the desired aldehyde in the presence of an excess, preferably about 2.0 equivalents, of a tertiary amine, such as diisopropylethylamine (DIPEA) and the like. This reaction is typically conducted in an inert diluent, such as DMF, at ambient temperature for about 1 to 2 hours until formation of the corresponding imine and/or hemiaminal is substantially complete. The resulting imine and/or hemiaminal is typically not isolated, but is reacted in situ with a metal hydride reducing agent, such as sodium cyanoborohydride and the like, to afford the corresponding amine. This reaction is typically conducted by contacting the imine and/or hemiaminal with about 1 to 1.2 equivalents of the reducing agent at ambient temperature in methanol in the presence of an excess, preferably about 3 equivalents, of trifluoroacetic acid. The resulting alkylated product is readily purified by conventional procedures, such as reverse-phase HPLC. Surprisingly, by forming the imine and/or hemiaminal in the presence of a trialkyl amine, the selectivity for the reductive alkylation reaction is greatly improved, i.e., reductive alkylation at the amino group of the saccharide (e.g. , vancosamine) is favored over reductive alkylation at the N-terminus (e.g., the leucinyl group) by at least 10: 1, more preferably 20:1.
If desired, the glycopeptide compounds of this invention can also be prepared in a step-wise manner in which a precursor to the -Ra-Y-Rb-(Z)X group is first attached the glycopeptide by reductive alkylation, followed by subsequent elaboration of the attached precursor using conventional reagent and procedures to form the -Ra-Y-Rb-(Z)X group as illustrated below. Additionally, ketones may also be employed in the above-described reductive alkylation reactions to afford α- substimted amines.
Any glycopeptide having an amino group may be employed in these reductive alkylation reactions. Such glycopeptides are well-known in the art and are either commercially available or may be isolated using conventional procedures. Suitable glycopeptides are disclosed, by way of example, in U.S.
Patent Nos. 3,067,099; 3,338,786; 3,803,306; 3,928,571; 3,952,095; 4,029,769; 4,051,237; 4,064,233; 4,122,168; 4,239,751; 4,303,646; 4,322,343; 4,378,348; 4,497,802; 4,504,467; 4,542,018; 4,547,488; 4,548,925; 4,548,974; 4,552,701; 4,558,008; 4,639,433; 4,643,987; 4,661,470; 4,694,069; 4,698,327; 4,782,042; 4,914,187; 4,935,238; 4,946,941; 4,994,555; 4,996,148; 5,187,082; 5,192,742; 5,312,738; 5,451,570; 5,591,714; 5,721,208; 5,750,509; 5,840,684; and 5,843,889; the disclosures of which are incorporated herein by reference in their entirety. Preferably, the glycopeptide employed in the above reaction is vancomycin.
The aldehydes and ketones employed in the reactive alkylation reaction are also well-known in the art and are either commercially available or can be prepared by conventional procedures using commercially available starting materials and conventional reagents. Typically, such materials are prepared by conventional coupling of, for example, functionalized acetals having an amino, thiol, hydroxyl, halo or other substimtent, with an suitable intermediate having a complementary functional group to form sulfides, ethers, amines, sulfonamides and the like. Subsequent hydrolysis of the acetal affords the corresponding aldehyde. Such reactions are well-known in the art and are described, for example, in March, Advanced Organic Chemistry, Fourth Edition, John Wiley & Sons, New York (1992), and references cited therein. Representative synthesis of aldehyde compounds are illustrated in Schemes 1-5:
Scheme 1
Figure imgf000085_0001
Scheme 2
Figure imgf000085_0002
Scheme 3
Figure imgf000085_0003
Scheme 4 R80,CI. DiPEA ?Me | °ϊR
Figure imgf000086_0002
Figure imgf000086_0001
Figure imgf000086_0003
D IP EA
where R represents -Rb-(Z)X or -(Rb minus one carbon atom)-(Z). (where Rb, Z and x are as defined herein).
By way of further illustration, the following schemes describe the synthesis of representative starting materials and compounds of this invention. For example, Scheme A illustrates a method for preparing an Fmoc-aminoaldehyde 5 from the corresponding aminoalcohol 3, where A is as defined herein. In this reaction, the aminoalcohol is protected by conventional techniques, for example, by treatment with 9-fluorenylmethyl chloroformate in the presence of base, to yield the Fmoc-protected aminoalcohol 4. Oxidation by known techniques then provides the aldehyde 5.
Scheme A
Figure imgf000086_0004
3 4 5 Scheme B illustrates an alternate route to F-moc- protected aminoaldehyde 5. This route is described in further detail in Sasake, Y., Abe, J. Chem. Pharm. Bull. (1997), 45(1), 13-17.
Scheme B
Figure imgf000087_0001
The Fmoc-protected aminoaldehyde of formula 5 can then be reacted with a glycopeptide, for example vancomycin, as shown in Scheme C.
Scheme C
Figure imgf000087_0002
piperadine
Figure imgf000087_0003
Figure imgf000087_0004
where B represents -(Rb minus one carbon atom)-(Z)x, where Rb, Z and x are as defined herein.
This reaction is conducted under reductive alkylation conditions to yield a glycopeptide intermediate 11. Deprotection of 11 with piperidine yields the corresponding the glycopeptide 12 having a primary amino group. Reaction of 12 with aldehyde 13 under standard reductive alkylation conditions gives glycopeptide derivative 14 and the corresponding bis-adduct 15, which are separated by conventional techniques, such as HPLC.
Scheme D illustrates a method for preparing an Fmoc protected aminoaldehyde 24. In this scheme, reaction of acid chloride 19 with aminoester 20 under conventional amide coupling conditions gives amidoester 21. Reduction of the both the ester and amide moieties using a metal hydride reducing agent, such as lithium aluminum hydride (LAH) gives aminoalcohol 22. Protection and oxidation, as in Scheme A, yields an aldehyde of formula 24.
Scheme D
Figure imgf000088_0001
22 23 24 Alternatively, aldehyde 24 can be prepared as shown in Scheme D' . In this reaction, direct alkylation of amino alcohol 3 under conventional amine alkylation conditions gives amino alcohol 22, which can then be used as described above in Scheme D.
Scheme D'
Figure imgf000089_0001
3 22
Scheme E illustrates an alternative method for preparing aldehyde 24. In this reaction, amino acetal 6 is reductively alkylated to provide 25. Subsequent protection of the amino group and hydrolysis of the acetal under conventional conditions then provides aldehyde 24.
Scheme E
Figure imgf000089_0002
6 25
FmocCI
DIPEA
Figure imgf000089_0003
26 24 Scheme F illustrates another method for reductive alkylation of a glycopeptide. In this scheme, Fmoc-protected aldehyde 24, prepared as descrubed above, is reacted with a glycopeptide 10, such as vancomycin, under reductive alkylation conditions to afford glycopeptide derivative 27. Subsequent deprotection with piperidine provides glycopeptide derivative 14.
Scheme F
Figure imgf000090_0001
piperidine
Figure imgf000090_0002
Scheme G illustrates the conversion of the carboxyl group of a glycopeptide derivative, such as vancomycin, into an amide. In this reaction, amine 28 is reacted with a glycopeptide derivative, such as 27, under standard peptide coupling conditions, for example, PyBOP and HOBT in DMF, to provide amide 29, after deprotection. Scheme G
Figure imgf000091_0001
Scheme H illustrates the introduction of an aminoalkyl sidechain at the resorcinol moiety of a glycopeptide, such as vancomycin, via a Mannich reaction. In this reaction, amine 30 and an aldehyde, such as formalin (a source of formaldehyde), are reacted with the glycopeptide under basic conditions to give the glycopeptide derivative 31.
Scheme H
Figure imgf000091_0002
Similarly, Scheme I illustrates a introduction of a substiment of the formula -Ra- Y-Rb-(Z)X at the resorcinol moiety of a glycopeptide using the Mannich reaction. In these reactions, excess aldehyde, such as formaldehyde, can react to afford the cyclized compounds of formula Vila and/or Vllb. Scheme I
Figure imgf000092_0001
Figure imgf000092_0002
NaCNBH
Figure imgf000092_0003
Scheme J illustrates a synthesis of a glycopeptide derivative using several of the reactions described above. In this scheme, glycopeptide derivative 27 is derivatized at the resorcinol moiety using the Mannich reaction described in Scheme H to provide glycopeptide derivative 40. Deprotection and amide coupling at the carboxyl group, as described in Scheme G, affords glycopeptide derivative 42.
Figure imgf000093_0001
Scheme L illustrates multiple reductive alkylation reaction of a glycopeptide derivative 27 to afford glycopeptide derivative 44a.
Scheme
Figure imgf000093_0003
Figure imgf000093_0002
Additional details and other methods for preparing the compounds of this invention are described in the Examples below.
Pharmaceutical Compositions
This invention also includes pharmaceutical composition containing the novel glycopeptide compounds of this invention. Accordingly, the glycopeptide compound, preferably in the form of a pharmaceutically acceptable salt, can be formulated for oral or parenteral administration for the therapeutic or prophylactic treatment of bacterial infections.
By way of illustration, the glycopeptide compound can be admixed with conventional pharmaceutical carriers and excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers, and the like. Such pharmaceutical compositions will contain from about 0.1 to about 90% by weight of the active compound, and more generally from about 10 to about 30%. The pharmaceutical compositions may contain common carriers and excipients, such as corn starch or gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid. Disintegrators commonly used in the formulations of this invention include croscarmellose, microcrystalline cellulose, corn starch, sodium starch glycolate and alginic acid.
A liquid composition will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example ethanol, glycerine, sorbitol, non-aqueous solvent such as polyethylene glycol, oils or water, with a suspending agent, preservative, surfactant, wetting agent, flavoring or coloring agent. Alternatively, a liquid formulation can be prepared from a reconstitutable powder. For example a powder containing active compound, suspending agent, sucrose and a sweetener can be reconstimted with water to form a suspension; and a syrup can be prepared from a powder containing active ingredient, sucrose and a sweetener.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid compositions. Examples of such carriers include magnesium stearate, starch, lactose, sucrose, microcrystalline cellulose and binders, for example polyvinylpyrrolidone. The tablet can also be provided with a color film coating, or color included as part of the carrier(s). In addition, active compound can be formulated in a controlled release dosage form as a tablet comprising a hydrophilic or hydrophobic matrix.
A composition in the form of a capsule can be prepared using routine encapsulation procedures, for example by incorporation of active compound and excipients into a hard gelatin capsule. Alternatively, a semi-solid matrix of active compound and high molecular weight polyethylene glycol can be prepared and filled into a hard gelatin capsule; or a solution of active compound in polyethylene glycol or a suspension in edible oil, for example liquid paraffin or fractionated coconut oil can be prepared and filled into a soft gelatin capsule.
Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, poly-vinylpyrrolidone (Povidone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose. Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicone fluid, talc, waxes, oils and colloidal silica.
Flavoring agents such as peppermint, oil of wintergreen, cherry flavoring or the like can also be used. Additionally, it may be desirable to add a coloring agent to make the dosage form more attractive in appearance or to help identify the product.
The compounds of the invention and their pharmaceutically acceptable salts that are active when given parenterally can be formulated for intramuscular, intrathecal, or intravenous administration.
A typical composition for intra-muscular or intrathecal administration will consist of a suspension or solution of active ingredient in an oil, for example arachis oil or sesame oil. A typical composition for intravenous or intrathecal administration will consist of a sterile isotonic aqueous solution containing, for example active ingredient and dextrose or sodium chloride, or a mixture of dextrose and sodium chloride. Other examples are lactated Ringer's injection, lactated Ringer's plus dextrose injection, Normosol-M and dextrose, Isolyte E, acylated Ringer's injection, and the like. Optionally, a co-solvent, for example polyethylene glycol, a chelating agent, for example ethylenediamine tetracetic acid, and an anti-oxidant, for example, sodium metabisulphite may be included in the formulation. Alternatively, the solution can be freeze dried and then reconstimted with a suitable solvent just prior to administration.
The compounds of the invention and their pharmaceutically acceptable salts which are active on rectal administration can be formulated as suppositories. A typical suppository formulation will generally consist of active ingredient with a binding and/or lubricating agent such as a gelatin or cocoa butter or other low melting vegetable or synthetic wax or fat.
The compounds of this invention and their pharmaceutically acceptable salts which are active on topical administration can be formulated as transdermal compositions or transdermal delivery devices ("patches"). Such compositions include, for example, a backing, active compound reservoir, a control membrane, liner and contact adhesive. Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g. , U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference in its entirety. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
The active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
Suitable doses are in the general range of from 0.01-100 mg/kg/day, preferably 0.1-50 mg/kg/day. For an average 70 kg human, this would amount to 0.7 mg to 7g per day, or preferably 7 mg to 3.5g per day.
Other suitable formulations for use in the present invention can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985).
The following formulation examples illustrate representative pharmaceutical compositions of the present invention. Formulation Example A This example illustrates the preparation of a representative pharmaceutical composition for oral administration of a compound of this invention:
Ingredients Quantity per tablet, (mg)
Active Compound 200
Lactose, spray-dried 148
Magnesium stearate 2
The above ingredients are mixed and introduced into a hard-shell gelatin capsule.
Formulation Example B This example illustrates the preparation of another representative pharmaceutical composition for oral administration of a compound of this invention:
Ingredients Quantity per tablet, (mg)
Active Compound 400
Cornstarch 50
Lactose 145
Magnesium stearate 5
The above ingredients are mixed intimately and pressed into single scored tablets.
Formulation Example C
This example illustrates the preparation of a representative pharmaceutical composition for oral administration of a compound of this invention. An oral suspension is prepared having the following composition.
Ingredients
Active Compound 1.0 g
Fumaric acid 0.5 g
Sodium chloride 2.0 g
Methyl paraben 0.1 g
Granulated sugar 25.5 g
Sorbitol (70% solution) 12.85 g
Veegum K (Vanderbilt Co.) 1.0 g
Flavoring 0.035 ml
Colorings 0.5 mg
Distilled water q.s. to 100 mL
Formulation Exa imple D
This example illustrates the preparation of a representative pharmaceutical composition containing a compound of this invention.
An injectable preparation buffered to a pH of 4 is prepared having the following composition:
Ingredients
Active Compound 0.2 g
Sodium Acetate Buffer Solution (0.4 M) 2.0 mL HCl (IN) q.s . to pH 4 Water (distilled, sterile) q.s. to 20 mL
Formulation Example E This example illustrates the preparation of a representative pharmaceutical composition for injection of a compound of this invention. A reconstimted solution is prepared by adding 20 mL of sterile water to 1 g of the compound of this invention. Before use, the solution is then diluted with 200 mL of an intravenous fluid that is compatible with the active compound. Such fluids are chosen from 5% dextrose solution, 0.9% sodium chloride, or a mixmre of 5% dextrose and 0.9% sodium chloride. Other examples are lactated Ringer's injection, lactated Ringer's plus 5% dextrose injection, Normosol-M and 5% dextrose, Isolyte E, and acylated Ringer's injection
Formulation Example F This example illustrates the preparation of a representative pharmaceutical composition for topical application of a compound of this invention.
Ingredients grams
Active compound 0.2-10
Span 60 2 Tween 60 2
Mineral oil 5
Petrolatum 10
Methyl paraben 0.15
Propyl paraben 0.05 BHA (butylated hydroxy anisole) 0.01
Water q.s. to 100
All of the above ingredients, except water, are combined and heated to 60°C with stirring. A sufficient quantity of water at 60°C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. 100 g.
Formulation Example G This example illustrates the preparation of a representative pharmaceutical composition containing a compound of this inventon. A suppository totaling 2.5 grams is prepared having the following composition:
Ingredients
Active Compound 500 mg
Witepsol H-15* balance
('triglycerides of saturated vegetable fatty acid; a product of Riches- Nelson, Inc., New York, N.Y.)
Utility
The glycopeptide compounds of this invention, and their pharmaceutically acceptable salts, are useful in medical treatments and exhibit biological activity, including antibacterial activity, which can be demonstrated in the tests described in the Examples. Such tests are well known to those skilled in the art, and are referenced and described in Lorian "Antibiotics in Laboratory Medicine", Fourth Edition, Williams and Wilkins (1991), which is hereby incorporated by reference.
Accordingly, this invention provides methods for treating infectious diseases, especially those caused by Gram-positive microorganisms, in animals. The compounds of this invention are particularly useful in treating infections caused by methicillin-resistant staphylococci. Also, the compounds are useful in treating infection due to enterococci, including vancomycin-resistant enterococci (VRE). Examples of such diseases are severe staphylococcal infections, for example, staphylococcal endocarditis and staphylococcal septicemia. The animal may be either susceptible to, or infected with, the microorganism. The method comprises administering to the animal an amount of a compound of this invention which is effective for this purpose. In general, an effective amount of a compound of this invention is a dose between about 0.5 and about 100 mg/kg. A preferred dose is from about 1 to about 60 mg/kg of active compound. A typical daily dose for an adult human is from about 50 mg to about 5 g.
In practicing this method, the antibiotic can be administered in a single daily dose or in multiple doses per day. The treatment regimen may require administration over extended periods of time, for example, for several days or for from one to six weeks. The amount per administered dose or the total amount administered will depend on such factors as the nature and severity of the infection, the age and general health of the patient, the tolerance of the patient to the antibiotic and the microorganism or microorganisms in the infection.
Among other properties, the compounds of this invention have also been found to be more chemically stable compared to N-acyl glycopeptide derivatives. More specifically, it has been observed that acylation of the amino group of the vancosamine moiety of vancomycin increases the rate of hydrolysis of the disaccharide moiety. In contrast, when the compounds of this invention are substimted on the amino group of the vancosamine moiety of vancomycin with a -Ra-Y-Rb-(Z)X group, no increase in the rate of hydrolysis of the disaccharide moiety is observed.
The following synthetic and biological examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this invention.
EXAMPLES
In the examples below, the following abbreviations have the following meanings. Any abbreviations not defined have their generally accepted meaning. Unless otherwise stated, all temperatures are in degrees Celsius. BOC, Boc = tert-butoxycarbonyl
DIBAL-H = diisobutylaluminum hydride
DIPEA = diisopropylethylamine
DMF = N,N-dimethylformamide
DMSO = dimethyl sulfoxide eq. = equivalent
Et = ethyl
EtOAc = ethyl acetate
Fmoc = 9-fluorenylmethoxycarbonyl
HOBT = 1 -hydroxy benzotriazole hydrate
Me = methyl
PyBOP — benzotriazol-l-yloxytris(pyrrolidino)phosphonium hexafluorophosphate
TEMPO = 2,2,6,6-tetramethyl-piperidinyloxy, free radical
TFA = trifluoroacetic acid
THF r= tetrahydrofuran
TLC, tic = thin layer chromatography
In the following example, vancomycin hydrochloride semi-hydrate was purchased from Alpharma, Inc. Fort Lee, ΝJ 07024 (Alpharma AS, Oslo
Norway). Other reagents and reactants are available from Aldrich Chemical Co., Milwaukee, WI 53201.
General Procedure A Reductive Alkylation of Vancomycin
To a mixmre of vancomycin (1 eq.) and the desired aldehyde (1.3 eq.) in
DMF was added DIPEA (2 eq.). The reaction was stirred at ambient temperature for 1-2 hours and monitored by reverse-phase HPLC. Methanol and NaCNBIL (1 eq.) were added to the solution, followed by TFA (3 eq.). Stirring was continued for an additional hour at ambient temperature. After the reaction was complete, the methanol was removed in vacuo. The residue was precipitated in acetonitrile. Filtration gave the crude product which was then purified by reverse-phase HPLC. If desired, other glycopeptides may be used in this procedure. General Procedure B Aglycon Alkylation Procedure I
A white suspension of vancomycin aglycon TFA salt (1.0 eq.), CS2CO3 (3.5 eq.) in DMF is stirred at room temperamre for 30 min. An alkyl halide (1.1 eq.) is added. The reaction mixmre is then stirred for 5-24 h before quenching with acetic acid. The resulting brownish solution is dripped into water to give a white precipitate. Filtration affords the crude monoalkylated product which can be purified by reverse-phase HPLC if desired.
General Procedure C Aglycon Alkylation Procedure II
Under nitrogen, the trifluoroacetate salt of vancomycin aglycone (1 eq) is dissolved in DMF and stirred vigorously at room temperamre with potassium carbonate (8-10 eq) for an hour. An alkyl halide (1 eq) is added and the mixmre is stirred vigorously overnight. The crude product is collected by precipitation into diethyl ether, washed with acetonitrile and taken up in 10% aqueous acetic acid. The mono-alkylated product is obtained upon reverse-phase HPLC purification.
General Procedure D Preparation of Amino-Substituted Aldehydes
A solution of an aminoacetal (1 eq), such as 2-aminoacetaldehyde dimethyl acetal, an aldehyde (1.05 eq), and NaCNBH3 (1 eq) in CH2C12 is stirred at room temperamre for 1-4 hours. The reaction is monitored by TLC. To the reaction mixmre are added FmocCl(l eq) and DIPEA (2 eq) at 0°C. Stirring is continued for 1-2 hours at room temperamre. The reaction is then washed with 0.1 N HCl, water and brine. The solvent is removed in vacuo and the residue is purified by flash chromatography gave the amino-substituted acetal. To the solution of above amino-substituted acetal in acetone is added 6 N HCl (1.5 eq). The reaction is stirred at room temperamre for 5-16 hours. Solvent is removed in vacuo and the residue is dried under high vacuum to give crude amino-substimted aldehyde which is typically used without further purification.
General Procedure E
Preparation of Thio-Substituted Aldehydes
A solution of a bromoacetal (1 eq), such as dimethyl 2- bromoacetaldehyde, and sodium iodide (1 eq) in DMF is stirred at ambient temperamre for 0.5 h. To the solution is added a substimted thiol (1 eq), such as /z-decyl thiol, followed by potasium carbonate (1 eq). The mixmre is stirred at 25- 80 °C for 4-16 hours. The reaction is then taken up with ethyl acetate, washed twice with water and once with sat. NaCl. The organic layer is dried over MgSO4 and the solvent is removed in vacuo. Purification on flash chromatography (hexan: ethyl acetate = 8: 1) provides the corresponding thio-substituted acetal.
To a solution of the thio-substituted acetal in acetone was added 6 N HCl
(1.5 eq). The reaction is stirred at room temperamre for 5-16 hours. The solvent is removed in vacuo and the residue is dried under high vacuum to give crude thio- substituted aldehyde which is typically used without further purification.
General Procedure F Preparation of Thio-Substituted Aldehydes
A mixmre of a thiol ester (1 eq), such as methyl thioglycolate, sodium iodide (1 eq), an alkyl bromide (1 eq) and potasium carbonate (1 eq) in DMF is stirred at room temperamre for 4-16 hours. The reaction is taken up with ethyl acetate and washed with water and brine. The organic layer is dried over magnesium sulfate and solvent is removed in vacuo. Purification on flash chromatography provides the thio-substituted ester.
The thio-substimted ester in dry ether is treated with DIBAL-H (1 M solution in cyclohexane, 1.3 eq) at -78 °C. The reaction is then stirred at -78 °C for 2-4 hours. TLC is used to monitor the reaction progress. Upon completion, ethyl formate (0.5 eq) is added to quench the reaction. The reaction is then washed with 10% acetic acid, water and brine. The organic layer is dried over magnesium sulfate and the solvent removed to afford the crude thio-substimted aldehyde which is typically used without further purification.
General Procedure G
Preparation of Alkoxy-Substituted Aldehydes
A solution of a hydroxy acetal (1 eq), such as dimethyl 2- hydroxyacetaldehyde, in THF is treated with sodium hydride (1 eq) at 0°C. After hydrogen evolution ceases, an alkyl bromide is added at 0°C. The reaction is then stirred at room temperamre for 1-4 hours. The reaction is taken up with ethyl acetate and washed with water and brine. The solvent is removed in vacuo and the residue typically purified by flash chromatography to afford the alkoxy-substituted acetal.
To a solution of the alkoxy-substituted acetal in acetone is added 6 N HCl (1.5 eq). The reaction is stirred at room temperamre for 5-16 hours. The solvent is removed in vacuo and the residue is dried under high vacuum to give crude alkoxy-substimted aldehyde which is typically used without further purification. General Procedure H Preparation of Sulfonamido-Substituted Aldehydes
A solution of an aminoacetal (1 eq), such as dimethyl 2-aminoacetaldehyde, and diiospropylethylamine (2 eq) in THF is treated with a sulfonyl chloride (1 eq) at 0°C. The reaction is then stirred at room temperamre for 1-4 hours. The reaction is then taken up with ethyl acetate and washed with 0.1 N HCl, water and brine. The solvent is removed in vacuo and the residue purified by flash chromatography gave the sulfonamido-substituted acetal.
To a solution of the sulfonamido-substituented acetal in acetone is added 6 N HCl (1.5 eq). The reaction is stirred at room temperamre for 5-16 hours. The solvent is then removed in vacuo and the residue is dried under high vacuum to give crude sulfonamido-substituted aldehyde which is typically used without further purification.
Example A Preparation of Fmoc-Aminoacetaldehyde
Fmoc-protected aminoethanol was prepared from aminoethanol by conventional techniques (e.g., as described in Examples B and C below).
To a mixmre of Fmoc-aminoethanol (37.64g, 133 mmol, 1.0 equiv), TEMPO (0.008 M in CH2C12, 332.5 mL, 2.66 mmol, 0.02 equiv), KBr (0.5 M in water, 53.2 mL, 26.6 mmol, 0.2 equiv) and ethyl acetate (1,500 mL), at 0 °C, was added NaOCl (0.35 M, buffered to pH 8.6 by NaHCC^, 760 mL, 266 mmol, 2.0 equiv). A mechanical stir was used to ensure efficient stirring, and the reaction was monitored by TLC. After 20 min, the two layers were separated. The aqueous layer was extracted with ethyl acetate (2 x 250 mL), the combined organic layers were washed with saturated Na2S2O3, water, and brine, dried over Na2SO4, filtered and concentrated to about 400 mL. Hexane (1,600 mL) was added to give a white precipitate. After filtration, Fmoc-aminoacetaldehyde (25.2g, 67%) was collected as a white powder.
Example B Preparation of N-Fmoc-2-(n-Decylamino)acetaldehyde
To a solution of n-decanoyl chloride (2.7 mL, 13 mmol, 1.0 eq) in methylene chloride (20 mL) in an ice/acetone bath was added a mixmre of glycine methyl ester hydrochloride (2.0 g, 16 mmol, 1.2 eq) and DIPEA (5.1 mL, 29 mmol, 2.2 eq) in methylene chloride (20 mL) dropwise. The reaction was stirred a further 60 min after complete addition, then washed with 3N hydrochloric acid (50 mL) twice, followed by saturated sodium bicarbonate (50 mL). The organics were dried over magnesium sulfate and the solvents removed under reduced pressure. Methyl 2-Decylamidoacetate (3.0 g, 12 mmol, 95%) was obtained which was used in the next step without further purification.
Under nitrogen, methyl 2-(n-decylamido)acetate (3.0 g, 12 mmol, 1.0 eq) was dissolved in anhydrous tetrahydrofiiran (25 mL) and cooled in an ice bath. A solution of lithium aluminum hydride (1 N, 25 mL, 25 mmol, 2.0 eq) was added carefully. The resulting solution was refluxed under nitrogen overnight, then cooled in an ice bath. Tetrahydrofiiran (50 mL) was added followed by slow addition of sodium sulfate decahydrate until effervescence ceased. The mixmre was allowed to warm to room temperamre, filtered, then concentrated under vacuum. 2-(n-Decylamino)ethanol (2.3 g, 11 mmol, 93%) was obtained which was used without further purification.
2-(n-Decylamino)ethanol (2.3 g, 11 mmol, 1.1 eq) and DIPEA (2.0 mL, 11 mmol, 1.1 eq) were dissolved in methylene chloride (15 mL) and cooled in an ice bath. 9-Fluorenylmethyl chloroformate (2.6 g, 10 mmol, 1.0 eq) in methylene chloride (15 mL) was added, the mixmre stirred for 30 minutes then washed with 3N hydrochloric acid (50 mL) twice and saturated sodium bicarbonate (50 mL). The organics were dried over magnesium sulfate, and the solvents removed under reduced pressure. N-Fmoc-2-(decylamino)ethanol (4.6 g, 11 mmol, 108%) was used without further purification.
N-Fmoc-2-(n-Decylamino)ethanol (4.6 g, 11 mmol, 1.0 eq) and DIPEA (7.6 mL, 44 mmol, 4.0 eq) were dissolved in methylene chloride (30 mL) and cooled in an ice/acetone bath. A solution of sulfur trioxide pyridine complex (6.9 g, 43 mmol, 4.0 eq) in dimethyl sulfoxide (30 mL) was added, and the solution stirred for 20 minutes. Crushed ice was added and the mixmre partitioned. The organics were washed with 3N hydrochloric acid twice, saturated sodium bicarbonate and saturated sodium chloride, dried over magnesium chloride, and concentrated under vacuum. N-Fmoc-2-(n-Decylamino)acetaldehyde (3.4 g, 8 mmol, 74%) was used without further purification (see example 5).
Example C
Preparation of 2-(Decylamino)ethanol
A solution of aminoethanol (30.5 g, 500 mmol, 30.1 mL) and 1- bromodecane (27.65 g, 125 mmol, 26 mL) in ethanol was stirred at 65 °C for 4 hr. The solvent was removed under reduced pressure. The residue was diluted with EtOAc (800 mL) and the organic solution was washed with H2O (2 x 200 mL); saturated aqueous NaHCO3 (200 mL) and saturated brine (200 mL). The organic phase was dried over anhydrous Na2SO4, and concentrated under reduced pressure. The resulting crude product, 2-(decylamino)ethanol, was used without further purification. Example D Preparation of N-Fmoc-2-(trαns-Dec-4-en-l-ylamino)acetaldehyde
trans -4-Oecenal (7.2 g, 46.6 mmol) was mixed with 40 mL (0.37 moL) of aminoacetaldehyde dimethylacetal in 400 mL of methanol and stirred at room temperamre for 30 minutes. NaCNBH3 (2.9 g, 46.6 mmol) was added, the reaction was cooled in an ice bath, and 27 mL (0.35 moL) of TFA was added dropwise over 5 minutes. The ice bath was then removed and the reaction was stirred for 70 minutes at room temperamre, concentrated to a third of its volume, and partitioned between ethyl acetate (250 mL) and IN NaOH (200 mL). The organic layer was washed with water (3 x 75 mL), dried over MgSO4 , filtered and concentrated under reduced pressure to yield 11.1 g (45.6 mmol) of 2-(trαns- dec-4-en-l-ylamino)acetaldehyde dimethyl acetal as a yellow oil that was used directly in the next step.
2-(trα/w-Dec-4-en-l-ylamino)acetaldehyde dimethyl acetal (10.5 g, 43.2 mmol) was mixed with dichloromethane (300 mL) and 7.5 mL (43.2 mmol) diisopropylethyl amine and 11.2 g (43.2 mmol) of FMOC-C1 was added portionwise. The reaction was stirred at room temperamre for 3 hours and then poured into a solution of 10% KHSO4 (200 mL). The organic layer was washed with water (200 mL), dried over MgSO4, and concentrated under reduced pressure. The resulting oil was chromatographed on silica gel in 10%
EtOAc/Hexanes to give 16.1 g (34.6 mmol) of N-Fmoc-2-(trαni,-dec-4-en-l- ylamino)acetaldehyde dimethyl acetal as a clear oil that was used directly in the next step.
N-Fmoc-2-(trαπi'-Dec-4-en-l-ylamino)acetaldehyde dimethyl acetal (5 g, 10.7 mmol) was mixed with 30 mL of TFA and stirred at room temperamre for 30 minutes. The reaction was poured into water (140 mL) and centrifuged to obtain a clear oil. The supernatant was decanted and the oil was mixed with 40 mL of water and centrifuged again. The supernatant was again decanted and the oil was dissolved in dichloromethane (100 mL), dried over MgSO4, filtered, and concentrated under reduced pressure to obtain 5.2 g (12.3 mmol) of N-Fmoc-2- (trαtw-Dec-4-en-l-ylamino)acetaldehyde as a clear oil.
Example E
Preparation of a Compound of Formula V (where R22 is OH and R23 is -CH2-N-(N-CH3-D-glucamine))
Vancomycin (9.0 g, 5.16 mmol) was added to a solution of N-methyl-D- glucamine (5.03 g, 25.8 mmol) and 37% formaldehyde (0.43 mL, 5.4 mmol) in 50% aqueous acetonitrile (60 mL) under nitrogen and stirred at room temperamre. After 4 hours, the acetonitrile was removed in vacuo, water (30 mL) was added, and the pH was adjusted to ~4 with 10% trifluoroacetic acid. The solution was purified by reverse-phase HPLC. Fractions containing the desired product were identified by mass spectrometry, pooled, and lyophilized to give the title compound as a white powder. This intermediate may be further derivatized using the procedures described herein.
Example F
Preparation of a Compound of Formula TV
(where R15 and R16 are H, R22 is OH and R27 is -CH,CH2-NH-Fmoc)
Vancomycin hydrochloride (4.00 g, 2.60 mmol) was suspended in 40 mL of l,3-dimethyl-3,4,5,6-tetrahydro-2-(lH)-pyrimidinone and heated to 70°C for 15 minutes. N-(9-fluorenylmethoxycarbonyl)aminoacetaldehyde (720 mg, 2.6 mmol) was added and the mixmre was heated at 70°C for one hour. Sodium cyanoborohydride (160 mg, 2.5 mmol) in 2 mL methanol was added and the mixmre was heated at 70 °C for 2 hours, then cooled to room temperamre. The reaction solution was added dropwise to 20 mL of acetonitrile, giving a precipitate that was collected by centrifugation. The precipitate was purified by reverse-phase HPLC on a Ranin C18 Dynamax column (2.5 cm x 25 cm, 8μm particle size), at 10 mL/min flow rate using 0.045% TFA in water as buffer A and 0.045 % TFA in acetonitrile as buffer B (HPLC gradient of 10-70% B over 90 minutes), which yielded the title intermediate as its trifluroacetate salt. MS calculated: MH+, 1715; Found, 1715.
This compound can be deprotected and further derivatized, for example,via reductive alkylation, as described herein.
Example G Preparation of an O-Ethyl Aglycone Derivative
Vancomycin hydrochloride hydrate (10 g, 6.4 mmol) was dissolved in 100 mL of dimethyl sulfoxide (DMSO) and 3-(dimethylamino)propylamine (3.2 mL, 26 mmol) was added. PyBOP (3.3 g, 6.4 mmol) and 1-hydroxybenzotriazole (HOBT, 0.9g, 6.4mmol) dissolved in 100 mL NN-dimethylformamide (DMF) was added dropwise at room temperamre. The reaction was stirred for one hour and dripped into acetonitrile to give a white precipitate, which was filtered and washed with acetonitrile, ether and dried under vacuum to give a syrup of crude vancomycin 3-(dimethylamino)propyl amide.
A portion of this syrup was dissolved in 100 mL trifluoroacetic acid (TFA), heated at 323K for 2 hours, cooled to room temperamre and added dropwise to ether, resulting in a green precipitate. The precipitate was collected by filtration, dried under vacuum and purified by reverse-phase HPLC (2-50% acetonitrile in water containing 0.1 % TFA) to give vancomycin 3-(dimethylamino)propyl amide aglycone, as its TFA salt.
The aglycone, as its trifluoroacetate salt (500 mg, 340 umol) was dissolved in 5 mL DMF and potassium carbonate (500 mg, 3.6 mmol) was added. The —I ll- mixture was stirred for 15 minutes at room temperamre then tert-butyl N-(2- bromoethyl)carbamate (77 mg, 340 umol) was added. The mixmre was stirred at room temperamre for 24 hours, then additional tert-butyl N-(2- bromoethyl)carbamate (70 mg, 310 umol) was added. The mixmre was stirred at room temperamre for 7 hours then dripped into ether giving a precipitate that was collected by centrifugation, washed with acetonitrile and dissolved in 5:1:2 water/acetic acid/acetonitrile. This solution was purified by reverse-phase HPLC giving vancomycin 3-(dimethylamino)propyl amide O-2-(N-t-BOC-amino)ethoxy aglycone as the trifluoroacetate salt, which was treated with 1 mL TFA for 30 minutes at room temperamre. Reverse-phase HPLC purification yielded vancomycin 3-(dimethylamino)propyl amide O-(2-aminoethyl) aglycone as the trifluoroacetate salt. This compound can be deprotected and further derivatized, for example, via reductive alkylation, as described above.
Example 1 Synthesis of a Compound of Formula III
(where R15 is -CH2CH2-ΝH-(CH2)9CH3, R17 is H and R22 is OH)
To an oven-dried, 1000 mL round bottomed flask, equipped with magnetic stirring bar, were added vancomycin (34.1 g, 23 mmol, 1 eq), N-Fmoc- aminoacetaldehyde (6.5 g, 23 mmol, leq), DIPEA (8.5 mL, 46 mmol, 2 eq) and DMF (340 mL). The mixmre was stirred at ambient temperamre over 2 hours, and monitored by HPLC. The reaction became homogenous, and - 90% conversion to the imine was observed. Methanol (340 mL) and NaCNBH3 (4.3 g, 69 mmol, 3 eq) were added to the solution, followed by TFA (5.2 mL, 69 mmol, 3eq). Stirring was continued for an additional hour at ambient temperamre. After the reaction was complete, methanol was removed in vacuo. The residue containing the crude product and DMF was slowly poured into a 5 L flask and stirred with acetonitrile (3.5 L). A white precipitate was formed. The suspension was allowed to settle at ambient temperamre and the supernetant was decanted. The white solid was filtered and trimrated with ether (2 L). After filtration, the crude product was dried under high vacuum overnight.
An 8 x 26 cm column was packed with octadecyl bonded silical gel. The column was washed with 800 mL of 90% Solvent B [acetonitrile in water, 0.1 % TFA] and equilibrated with 800 mL of 10% Solvent B. Crude product (10 g) was dissolved in 30% Solvent B (150 mL, containing 2 mL of 3 N HCl) and loaded onto the column. It was then flashed with 10%B (800 mL x 2), 40%B (800 mL x 3) and 90 %B (800 mL). The fractions were checked by analytical HPLC. After lyophilization, Nvan-Fmoc-aminoethyl vancomycin was obtained as its TFA salt.
Nvan-Fmoc-aminoethyl vancomycin was deprotected to give N^-aminoethyl vancomycin tri-TFA salt using conventional procedures (e.g. as described in Examples 2 and 3)
To a solution of Nvan-aminoethyl vancomycin tri-TFA salt (15.5 mg, 8.4 micromol) in methanol: DMF: THF (2:1: 1, 1.6mL) was added decanal (92 microL, 59 micromol) and sodium cyanoborohydride (0.1M in methanol, 45 microL, 4.5 micromol). After 45 minutes, the solvents were removed in vacuo, and the residue purified by preperative HPLC. The appropriate fractions were combined and lyophylized to give Nvan-2-(/z-decylamino)ethyl vancomycin (2.4 mg) as a white powder. Also isolated was Nvan,Nvan-bis-2-(n-decylamino)ethyl vancomycin (2.9mg). Example 2
Synthesis of a Compound of Formula III
(where R1S is -CH2CH2-NH-(CH2)9CH3, R17 is H and R22 is OH)
Vancomycin hydrochloride (12 g, 7.7 mmol, 1.0 eq), N-Fmoc-2-(n- decylamino)acetaldehyde (3.2 g, 7.6 mmol, 1.0 eq) and DIPEA (2.6 mL, 14.9 mmol, 2.0 eq) were stirred at room temperamre in DMF (120 mL) for 90 minutes. Sodium cyanoborohydride (1.4 g, 22 mmol, 3.0 eq) was added, followed by methanol (120 mL) then trifluoroacetic acid (1.8 mL, 23 mmol, 3.0 eq). The mixmre was stirred for 60 minutes at room temperamre, then the methanol removed under reduced pressure. The resulting solution was added to 600 mL diethyl ether giving a precipitate which was filtered, washed with ether, and dried under vacuum. The crude product was purified on a reverse-phase flash column, eluting with 10, 20, 30% acetonitrile in water (containing 0.1 % trifluoroacetic acid) to remove polar impurities (such as residual vancomycin) then the product was eluted with 70% acetonitrile in water (containing 0.1 % trifluoroacetic acid) to give 9 g of Nvan-(N-Fmoc-2-n-decylaminoethyl) vancomycin as its trifluoroacetate salt (4.3 mmol, 56%).
Nvan-(N-Fmoc-2-n-decylaminoethyl) vancomycin (100 mg) was dissolved in 1 mL DMF (1 mL) and treated with piperidine (200 uL) for 30 minutes. The mixmre was precipitated into ether, centrifuged and washed with acetonitrile.
Reverse-phase preparative HPLC (10-70% acetonitrile in water containing 0.1 % trifluoroacetic acid over 120 minutes) gave Nvan-2-(n-decylamino)ethyl vancomycin as its TFA salt. Example 3
Synthesis of a Compound of Formula III
(where R15 is -CH2CH2-NH-(CH2)9CH3, R17 is H and R22 is -N-(D-glucosamine)
Nvan-(N-Fmoc-2-n-decylaminoethyl) vancomycin (100 mg, 48 umol, 1.0 eq) was dissolved in 1 mL DMF and glucosamine hydrochloride was added (31 mg, 144 umol, 3.0 eq). The mixmre was stirred vigorously for 30 minutes (the glucosamine hydrochloride did not fully dissolve), DIPEA (60 uL, 344 umol, 7.2 eq) was added and the mixmre stirred vigorously for a further 30 minutes. A solution of benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP, 50 mg, 96 umol, 2.0 eq) and 1- hydroxybenzotriazole (14 mg, 104 umol, 2.2 eq) in 500 uL DMF was prepared. The PyBOP solution was added in 5 batches of 60 uL at intervals of 5 minutes to the vigorously stirred suspension of the other reaction components. The reaction was stirred an additional 30 minutes then precipitated into acetonitrile. The solid was collected by centrifugation, taken up in lmL NN-dimethylformamide and treated with 200 uL piperidine for 30 minutes. Precipitation into ether was followed by centrifugation and the solid washed with acetonitrile. Reverse-phase preparative HPLC (10-70% acetonitrile in water containing 0.1 % trifluoroacetic acid over 120 minutes) gave a compound of formula III where R15 is -CH2CH2- ΝH-(CH2)9CH3 and R22 is -N-(D-glucosamine as its trifluoroacetate salt.
Example 4
Synthesis of a Compound of Formula III
(where R15 is -CH2CH2-NH-(CH2)9CH3 and R22 is -NH-CH(COOH)CH2COOH)
HOBt (1.47 g, 10.9 mmol), PyBOP (7.57 g, 14.6 mmol), and the bis- fluorenylmethyl ester of L-aspartic acid (TFA, 6.26 g, 10.4 mmol) were added to a well stirred solution of Nvan-(N-Fmoc-2-n-decylaminoethyl) vancomycin (20 g, 10.4 mmol) and DIPEA (5.44 mL, 31.2 mmol) in DMF (440 mL). The reaction was complete after 1 hr by MS. The mixmre was precipitated into CHjCN (4 L) and centrifuged. The supernatant was decanted and the pellet redissolved in DMF (440 mL). Piperidine (44 mL) was added and the reaction monitored by MS. After 1 hr reaction was complete. Precipitate via dropwise addition to E^O (4 L) with continued stirring overnight. The solid was collected via filtration and dried in vacuo. The resulting solid was then triturated with CH3CN and collected via filtration and dried in vacuo giving desired product as an off-white solid which was purified by reverse phase HPLC.
Example 5 Synthesis of a Compound of Formula V (where R15 is H and R23 is -CH2-NH-CH2CH2-NH-(CH2)9CH3)
To 50% aqueous acetonitrile (1.0 mL) was added diaminoethane (30 mg, 0.5 mmol), 37% formalin (7.6 uL, 0.20 mmol) and vancomycin hydrochloride (140 mg, 0.10 mmol). After stirring for 3h, the product was precipitated by the addition of acetonitrile (12 mL). The solid was isolated by centrifugation, then washed with ether (12 mL). The resulting solid was dried in vacuo, and purified by reverse-phase HPLC (5-15 %B over 40min at a flow rate of 50ml/min). Fractions containing the desired product were identified by mass spectrometry, pooled, and lyophilized to give a compound of formula V where R23 is -CH2-NH- CH2CH2NH2 (85 mg) as a white powder. MS calculated (MH+), 1520; found, 1520.
To a solution of the compound from the above step (80 mg, 0.040 mmol) in ethanol (1.0 mL) and DMF (1.0 mL) was added n-decanal (6.3 mg, 0.040 mmol), and the mixmre was stirred for 45 minutes. Sodium cyanoborohydride (0.1M in methanol, 400 uL, 0.040 mmol) was then added and the mixmre stirred for 3 hours. The solvents were removed in vacuo, and the residue purified by preprative HPLC. Fractions containing the desired product were identified by mass spectrometry, pooled, and lyophilized to the title compound as a white powder. MS calculated (MH+), 1661; found, 1661.
Example 6 Synthesis of a Compound of Formula V (where R15 is -CH2-NH-CH2CH2-NH-(CH2)9CH3 R22 is -N-(D-glucosamine) and
R23 is -CH2-N-(N-CH3-D-glucamine))
To 50% aqueous acetonitrile (10 mL) was added sequentially N-methyl-D- glucamine (975 mg, 5.0 mmol), 37% formalin (84 uL, 1.1 mmol), DIPEA (348 uL, 2.0 mmol) and ] an-(N-Fmoc-2-n-decylaminoethyl) vancomycin (2.15 g, 1.030 mmol). After stirring for 16h, the product was precipitated by the addition of acetonitrile (80 mL). The solid was isolated by centrifugation, then washed with acetonitrile (80 mL). The solid was dissolved in DMF (6.0 mL) and piperidine (2.0 mL). After 30 minutes, the product was precipated by the additon of acetonitrile (80 mL). The solid was isolated by centrifugation, then washed with ether (80 mL). The resulting solid was dried in vacuo, and purified by reverse- phase HPLC (10-35 %B) over 40 min at a flow rate of 50 mL/min). Fractions containing the desired product were identified by mass spectrometry, pooled, and lyophilized to give a compound of formula V where R15 is -CH2-NH-CH2CH2-NH- (CH2)9CH3 and R23 is -CH2-N-(N-CH3-D-glucamine (1.34 g) as a white powder. MS calculated (MH+), 1839; found, 1839.
The above compound (tetra TFA salt) (150 mg, 0.065 mmol) was dissolved in DMF. To this solution was added sequentially D-glucosamine hydrochloride (35 mg, 0.16 mmol ), DIPEA (65 uL, 0.32 mmol), and a solution of PyBOP and HOBt in DMF (3.85 mL of a solution 0.02 M in each, 0.077 mmol each). After 30 minutes, the product was precipated by the additon of acetonitrile (40 mL). The solid was isolated by centrifugation, then washed with acetonitrile (40 mL). The resulting solid was dried in vacuo, and purified by reverse-phase HPLC (10- 35 %B over 40min at a flow rate of 50 mL/min). Fractions containing the desired product were identified by mass spectrometry, pooled, and lyophilized to the title compound as a white powder. MS calculated (MH+), 2000; found, 2000.
Example 7 Synthesis of a Compound of Formula IV
(where R15 is -CH2-NH-CH2CH2-NH-(CH2)9CH3 R22 is -OH and R27 is -CH2C(O)OCH2CH3)
A solution of vancomycin monohydrochloride (3.72 g, 2.5 mmol) in DMF(35 mL) was treated with diisopropylethylamine (0.87 mL, 5.0 mmol) followed by N-Fmoc-n-decylaminoacetaldehyde (1.05 g, 2.5 mmol). The resulting reaction mixmre was stirred at room temperamre forl2 hours. Ethyl glyoxylate(2.5 mmol, 50% solution in toluene) was added and the reaction solution was stirred at 50 °C for 6 hours. The reaction mixmre was cooled to room temperamre and was treated with NaCNBH3 (0.376 g, 6.0 mmol) followed by a solution of TFA (0.58 mL, 7.5 mmol) in MeOH (35 mL). After 20 min, MeOH was removed under reduced pressure and the crude was precipitated in acetonitrile (400 mL). The solid was collected by filtration. The crude was purified by preparative HPLC to give title compound. MS(M + H) 1939.2(M + , calculated 1938.7)
Example 8
Synthesis of a Compound of Formula IV
(where R15 is -CH2-C(O)OCH3 R22 is -OH and R27 is -CH2C(O)OCH3)
A solution of vancomycin hydrochloride (7.43 g, 5.0 mmol) in DMSO (100 mL) was treated with diisopropylethylamine (1.74 mL, 10.0 mmol) followed by methyl bromoacetate (0.842 g, 5.5 mmol) at room temperamre. The reaction mixmre was stirred at room temperamre overnight. The crude product was precipitated using acetonitrile (1000 mL). The crude product was collected and purified by preparative HPLC to provide the title product. MS(M + H) 1522.0(M + , calculated 1519.45).
Example 9 Synthesis of a Compound of Formula VIII (where R19 is -CH2-C(O)OC(CH3)3)
Under nitrogen, the trifluoroacetate salt of vancomycin aglycone (385 mg, 310 umol) was dissolved in NN-dimethylformamide (4 mL). Potassium carbonate (400 mg, 2.9 mmol) was added and the mixmre was stirred vigorously at room temperamre with for 55 minutes. tert-Butyl chloroacetate (44 uL, 310 umol) was then added and the mixmre stirred vigorously overnight. The crude reaction mixmre was precipitated into diethyl ether (40 mL) and the solids were collected by centrifugation, washed with acetonitrile (40 mL) and taken up in 10% acqueous acetic acid. The title compound was obtained upon reverse-phase HPLC purification (calculated mass: 1256.4, observed (M+H): 1257.7).
Example 10
Synthesis of a Compound of Formula VIII
(where R19 is -CH2CH2CH2-ΝH-(CH I22))99(CH3)
A white suspension of vancomycin aglycon TFA salt (2.0 g, 1.59 mmol, 1.0 eq) Cs2CO3 (1.81 g, 5.56 mmol, 3.5 eq) and DMF (34.0 mL) was stirred at room temperamre for 30 min. Then t-butyl N-(3-iodopropyl)carbamate (0.54 g, 1.9 mmol, 1.2 eq) was added. The reaction mixmre was stirred for 24 h before quenching with acetic acid. The resulting brownish solution was dripped into water to give a white precipitate. Vacuum filtration gave 1.5 g a white crystalline solid which was used for next step without further purification.
To a mixmre of the above compound (1.05 g, 0.75 mmol, 1.0 eq), DIPEA
(0.65 mL, 3.75 mmol, 5.0 eq) and DMF (10 mL), was added Fmoc-Cl (0.19 g, 0.75 mmol, 1.05 eq) in portions. After stirring at room temperamre for 4 h, TFA (0.6 mL) was added to quench the reaction. Then the reaction mixmre was dripped into 500 mL of water to give a white precipitate. Filtration gave 1.1 g of a white crystalline solid which was used for next step without further purification.
The above compound (1.17 g) was dissolved in 5 mL of TFA, stirred at room temperamre for 2 h. Then the reaction mixmre was dripped into 200 mL of water to give a white precipitate. Filtration gave 0.95 g of a brownish solid which was used for next step without further purification.
To a mixmre of the above compound (100 mg, 0.065 mmol, 1.0 eq), and decanal (26 μL, 0.13 mmol, 2.0 eq) in DMF (1 mL) was added DIPEA (34 μL, 0.20 mmol, 3.0 eq). The reaction was stirred at ambient temperamre for 1 h. Then methanol (1 mL) and NaCNBH3 (9 mg, 0.13 mmol, 2.0 eq) was added to the solution, followed by TFA (20 μL, 0.26 mmol, 4.0 eq). Stirring was continued for 1 h at room temperamre. After the reaction was completed, the reaction mixmre was precipitateed in acetonitrile. Filtration gave a white crystalline solid which was used for next step without further purification.
The above compound was dissolved in 3 mL on DMF, addition of 0.5 mL of piperidine gave a light brownish solution. After stirring at ambient temperamre for 2 h, reaction mixmre was triturated in acetonitrile to give a white solid, a reverse-phase HPLC purification gave the title compound. MS (M+H) calculated: 1342.3; observed: 1342.8.
Using the above procedures and the appropriated starting materials the compounds shown in Tables I- VI were prepared. The mass spectral data for these compounds were as follows: 10
15
20
25
Figure imgf000122_0001
10
15
20
25
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
10
15
20
25
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
10
15
20
25
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Example 11 Determination of Antibacterial Activity
A. In Vitro Determination of Antibacterial Activity 1. Determination of Minimal Inhibitory Concentrations (MICsl
Bacterial strains were obtained from either American Type Tissue Culture Collection (ATCC), Stanford University Hospital (SU), Kaiser Permanente Regional Laboratory in Berkeley (KPB), Massachusetts General Hospital (MGH), the Centers for Disease Control (CDC), the San Francisco Veterans' Administration Hospital (SFV A) or the University of California San Francisco
Hospital (UCSF). Vancomycin resistant enterococci were phenotyped as Van A or Van B based on their sensitivity to teicoplanin. Some vancomycin resistant enterococci that had been genotyped as Van A, Van B, Van Cl or Van C2 were obtained from the Mayo Clinic.
Minimal inhibitory concentrations (MICs) were measured in a microdilution broth procedure under NCCLS guidelines. Routinely, the compounds were serially diluted into Mueller-Hinton broth in 96-well microtiter plates. Overnight culmres of bacterial strains were diluted based on absorbance at 600 nm so that the final concentration in each well was 5 x 105 cfu/mL. Plates were remrned to a 35 °C incubator. The following day (or 24 hours in the case of Enterococci strains), MICs were determined by visual inspection of the plates. Strains routinely tested in the initial screen included methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus, methicillin-sensistive Staphylococcus epidermidis (MSSE), methicillin-resistant
Staphylococcus epidermidis (MRSE), vancomycin sensitive Enterococcus faecium (VSE Fm), vancomycin sensitive Enterococcus faecalis (VSE Fs), vancomycin resistant Enterococcus faecium also resistant to teicoplanin (VRE Fm Van A), vancomycin resistant Enterococcus faecium sensistive to teicoplanin (VRE Fm Van B), vancomycin resistant Enterococcus faecalis also resistant to teicoplanin (VRE Fs Van A), vancomycin resistant Enterococcus faecalis sensitive to teicoplanin (VRE Fs Van B), enterococcus gallinarium of the Van A genotype (VRE Gm Van A), enterococcus gallinarium of the Van C-1 genotype (VRE Gm Van C-1), enterococcus casseliflavus of the Van C-2 genotype (VRE Cs Van C-2), enterococcus flavescens of the Van C-2 genotype (VRE Fv Van C-2), and penicillin-sensitive Streptococcus pneumoniae (PSSP) and penicillin-resistant Streptococcus pneumoniae (PSRP). Because of the inability of PSSP and PSRP to grow well in Mueller-Hinton broth, MICs with those strains were determined using either TSA broth supplemented with defibrinated blood or blood agar plates. Compounds which had significant activity against the strains mentioned above were then tested for MIC values in a larger panel of clinical isolates including the species listed above as well as non-speciated coagulase negative Staphylococcus both sensitive and resistant to methicillin (MS-CNS and MR-CNS). In addition, they were tested for MICs against gram negative organisms, such as Escherichia coli and Pseudomonas aeruginosa.
2. Determination of Kill Time
Experiments to determine the time required to kill the bacteria were conducted as described in Lorian, "Antibiotics in Laboratory Medicine", Fourth Edition, Williams and Wilkins (1991), the disclosure of which is incorporated herein by reference in its entirety. These experiments were conducted normally with both staphylococcus and enterococcus strains.
Briefly, several colonies were selected from an agar plate and grown at 35 °C under constant agitation until it achieved a turbidity of approximately 1.5 and 108 CFU/mL. The sample was then diluted to about 6 x ltf CFU/mL and incubated at 35 °C under constant agitation was continued. At various times aliquots were removed and five ten-fold serial dilutions were performed. The pour plate method was used to determine the number of colony forming units (CFUs).
The compounds of this invention were active in the above tests in vitro tests and demonstrated a broad spectrum of activity.
B. In Vivo Determination of Antibacterial Activity
1. Acute Tolerability Studies in Mice
In these studies, a compound of this invention was administered either intravenously or subcutaneously and observed for 5-15 minutes. If there were no adverse effects, the dose was increased in a second group of mice. This dose incrementation continued until mortality occurred, or the dose was maximized. Generally, dosing began at 20 mg/kg and increased by 20 mg/kg each time until the maximum tolerated dose (MTD) is achieved.
2. Bioavailability Studies in Mice
Mice were administered a compound of this invention either intravenously or subcutaneously at a therapeutic dose (in general, approximately 50 mg/kg). Groups of animals were placed in metabolic cages so that urine and feces could be collected for analysis. Groups of animals (n=3) were sacrificed at various times (10 min, 1 hour and 4 hours). Blood was collected by cardiac puncture and the following organs were harvested— lung, liver, heart, brain, kidney, and spleen. Tissues were weighed and prepared for HPLC analysis. HPLC analysis on the tissue homogenates and fluids was used to determine the concentration of the test compound or Iii present. Metabolic products resulting from changes to the test compound were also determined at this juncture.
3. Mouse Septecemia Model
In this model, an appropriately virulent strain of bacteria (most commonly S. aureus, or E. Faecalis or E. Faecium) was administered to mice (N=5 to 10 mice per group) intraperitoneally. The bacteria was combined with hog gastric mucin to enhance virulence. The dose of bacteria (normally lO O7) was that sufficient to induce mortality in all of the mice over a three day period. One hour after the bacteria was administered, a compound of this invention was administered in a single dose either IV or subcutaneously. Each dose was administered to groups of 5 to 10 mice, at doses that typically ranged from a maximum of about 20 mg/kg to a minimum of less than 1 mg/kg. A positive control (normally vancomycin with vancomycin sensitive strains) was administered in each experiment. The dose at which approximately 50% of the animals are saved was calculated from the results.
4. Neutropenic Thigh Model In this model, antibacterial activity of a compound of this invention was evaluated against an appropriately virulent strain of bacteria (most commonly S. aureus, or E. Faecalis or E. Faecium, sensitive or resistant to vancomycin). Mice were initially rendered neutropenic by administration of cyclophosphamide at 200 mg/kg on day 0 and day 2. On day 4 they were infected in the left anterior thigh by an IM injection of a single dose of bacteria. The mice were then administered the test compound one hour after the bacteria and at various later times (normally 1, 2.5, 4 and 24 hours) the mice were sacrificed (3 per time point) and the thigh excised, homogenized and the number of CFUs (colony forming units) were determined by plating. Blood was also plated to determine the CFUs in the blood.
5. Pharmacokinetic Studies
The rate at which a compound of this invention is removed from the blood can be determined in either rats or mice. In rats, the test animals were cannulated in the jugular vein. The test compound was administered via tail vein injection, and at various time points (normally 5, 15, 30,60 minutes and 2,4,6 and 24 hours) blood was withdrawn from the cannula In mice, the test compound was also administered via tail vein injection, and at various time points. Blood was normally obtained by cardiac puncture. The concentration of the remaining test compound was determined by HPLC.
The compounds of this invention were active in the above tests in vivo tests and demonstrated a broad spectrum of activity.
While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substimted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

Claims

WHAT IS CLAIMED IS:
1. A glycopeptide compound having at least one substiment of the formula:
-Ra-Y-Rb-(Z)X
wherein each Ra is independently selected from the group consisting of alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene; each Rb is independently selected from the group consisting of a covalent bond, alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene, provided Rb is not a covalent bond when Z is hydrogen; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- , -NRC- , -S(O)- , -SO2- , -NReC(O)- , -OC(O)- , -NRcSO2- , -OSO2- , -C(O)NRc- , -C(O)O- , -SO2NRc- , -SO2O- , ,-P(O)(ORc)O- , -P(O)(ORc)NRc- , -OP(O)(ORc)O- ,-OP(O)(ORc)NRc- , -OC(O)O- , -NRcC(O)O- , -NRcC(O)NRc- , -OC(O)NRc- and -NRcSO2NRc-; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; each Rc is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)Rd; each Rd is independently selected from the group consisting of alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic; x is 1 or 2; and pharmaceutically acceptable salts thereof; provided that:
(i) when Y is -NRC- , Rc is alkyl of 1 to 4 carbon atoms, Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms;
(ii) when Y is -C(O)NRc- , Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms; (iii) when Y is sulfur, Z is hydrogen and Rb is alkylene, then Rb contains at least 7 carbon atoms; and
(iv) when Y is oxygen, Z is hydrogen and Rb is alkylene, then Rb contains at least 11 carbon atoms.
2. The compound of Claim 1, wherein the glycopeptide compound is substimted with from 1 to 3 substiments of the formula -Ra-Y-Rb-(Z)X.
3. The compound of Claim 2, wherein each Ra is independently selected from alkylene having from 1 to 10 carbon atoms.
4. The compound of Claim 3, wherein Ra is ethylene or propylene.
5. The compound of Claim 2, wherein Z is hydrogen and Rb is alkylene of from 8 to 12 carbon atoms.
6. The compound of Claim 5, wherein Rb and Z form an /i-octyl, n- nonyl, n-decyl, π-undecyl or rc-dodecyl group.
7. The compound of Claim 2, wherein Z is aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocyclic and Rb is a covalent bond or alkylene of from 1 to 10 carbon atoms.
8. The compound of Claim 7, wherein Z is aryl and Rb is a covalent bond, methylene, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9- or -(CH2)10-.
9. The compound of Claim 2, wherein each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, -NRC- , -S(O)- , -SO2- , -NRcC(O)- , -OC(O)- , -NRcSO2- , -C(O)NRc- , -C(O)O- and -SO2NRc- .
10. The compound of Claim 9, wherein Y is oxygen, sulfur, -NR°- or
-NRcSO2- .
11. The compound of Claim 2, wherein each Z is independently selected from hydrogen, aryl, cycloalkyl, heteroaryl and heterocyclic.
12. The compound of Claim 11 , wherein Z is hydrogen or aryl.
13. The compound of Claim 12, wherein Z is phenyl, substimted phenyl, biphenyl, substimted biphenyl or terphenyl.
14. The compound of Claim 2, wherein the -Ra- Y-Rb-(Z)X group is selected from the group consisting of:
- CH2CH2- NH- (CH2)9CH3; -CH2CH2CH2-NH-(CH2)8CH3;
- CH2CH2CH2CH2- NH- (CH2)7CH3;
- CH2CH2- NHSO2- (CH2)9CH3; -CH2CH2-NHSO2-(CH2)11CH3;
Figure imgf000146_0001
- CH CH2- S- (CH2)9CH3 ; -CH2CH2-S- (CH2)IQCH3; -CH CH2CH2~S-(CH2)jjCH3;
- CH2CH2CH - S - (CH2) CH3 ;
- CH2CH2CH2- S- (CH2)3-CH = CH-(CH2)4CH3 (trans);
- CH2CH2CH2CH2- S- (CH2)7CH3 ;
- CH2CH2- S(O)- (CH2)9CH3; -CH2CH2-S-(CH2)6Ph;
-CH2CH2-S-(CH2)8Ph;
- CH2CH2CH2- S- (CH2)8Ph;
- CH2CH2- NH- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2- NH- CH2-4-[4-CH3)2CHCH2-]-Ph; -CH2CH2-NH-CH2-4-(4-CF3-Ph)-Ph;
- CH2CH2- S- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- S- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph; - CH2CH2CH2- S- CH2-4-[3 ,4-di-Cl-PhCH2O-)-Ph;
-CH2CH2-NHSO2-CH2-4-[4-(4-Ph)-Ph]-Ph;
- CH2CH2CH2- NHSO2- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- NHSO2- CH2-4-(Ph-C ≡ C-)-Ph; -CH2CH2CH2-NHSO2-4-(4-Cl-Ph)-Ph; and -CH2CH2CH2-NHSO2-4-(naphth-2-yl)-Ph.
15. A compound of formula I:
Figure imgf000147_0001
wherein
R1 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -Ra-Y-Rb-(Z)X; or a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X;
R2 is hydrogen or a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X;
R3 is -ORc, -NRCRC, -O-Ra-Y-Rb-(Z)x, -NRC-Ra-Y-Rb-(Z)X, -NRcRe, or -O-Re ;
R4 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -Ra-Y-Rb-(Z)X, -C(O)Rd and a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X; Rs is selected from the group consisting of hydrogen, halo, -CH(RC)-NRCRC, -CH(Rc)-NRcRe and -CH(RC)-NRC-Ra-Y-Rb-(Z)X;
R6 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -Ra-Y-Rb-(Z)X, -C(O)Rd and a saccharide group optionally substimted with -NRC-Ra-Y-Rb-(Z)X, or R5 and R6 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substimted with -NRC-Ra-Y-Rb-(Z)X;
R7 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -Ra-Y-Rb-(Z)X, and -C(O)Rd;
R8 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic; R9 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R10 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic; or R8 and R10 are joined to form - Ar'-O-Ar2- , where Ar1 and Ar2 are independently arylene or heteroarylene;
R11 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R10 and R11 are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring; R12 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic, -C(O)Rd, -C(NH)Rd, -C(O)NRcRc, -C(O)ORd, -C(NH)NRCRC and -Ra- Y-Rb-(Z)X, or R11 and R12 are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;
R13 is selected from the group consisting of hydrogen or -OR14;
R14 is selected from hydrogen, -C(O)Rd and a saccharide group; each Ra is independently selected from the group consisting of alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene; each Rb is independently selected from the group consisting of a covalent bond, alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene, provided Rb is not a covalent bond when Z is hydrogen; each Rc is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)Rd; each Rd is independently selected from the group consisting of alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
Re is a saccharide group; X1, X2 and X3 are independently selected from hydrogen or chloro; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- , -NRC- , -S(O)- , -SO2- , -NRcC(O)- , -OSO2- , -OC(O)- , -NRcSO2- , -C(O)NRc- , -C(O)O- , -SO2NRc- , -SO2O- , -P(O)(ORc)O- , -P(O)(ORc)NRc- , -OP(O)(ORc)O- ,-OP(O)(ORc)NRc- , -OC(O)O- , -NRcC(O)O- , -NRcC(O)NRc- , -OC(O)NRc- and -NRcSO2NRc- ; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; n is 0, 1 or 2; x is 1 or 2; and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof; provided that at least one of R\ R2, R3, R4, R5, R°, R7 or R12 has a substimtent of the formula -Ra-Y-Rb-(Z)X; and further provided that:
(i) when Y is -NRC- , Rc is alkyl of 1 to 4 carbon atoms, Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms;
(ii) when Y is -C(O)NRc- , Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms; (iii) when Y is sulfur, Z is hydrogen and Rb is alkylene, then Rb contains at least 7 carbon atoms; and
(iv) when Y is oxygen, Z is hydrogen and Rb is alkylene, then Rb contains at least 11 carbon atoms.
16. The compound of Claim 15, wherein R1 is a saccharide group optionally substimted with - Ra- Y- Rb- (Z)x .
17. The compound of Claim 16, wherein R1 is a saccharide group of the formula:
Figure imgf000151_0001
wherein
R15 is -Ra-Y-Rb-(Z)X; and
R16 is hydrogen or methyl.
18. The compound of Claim 17, wherein R15 is a -Ra- Y-Rb-(Z)X group selected from the group consisting of:
- CH2CH2- NH- (CH2)9CH3;
- CH2CH2CH2- NH- (CH2)8CH3 ;
- CH2CH2CH2CH2- NH- (CH2)7CH3 ;
- CH2CH2- NHSO2- (CH2)9CH3; -CH2CH2-NHSO2-(CH2)nCH3;
- CH2CH2~ S - (CH2)8CH3 ;
- CH2CH2 - S - (CH ) CH3 ;
- CH2CH2 - S - (CH2) [ CH3 ;
- CH2CH2CH - S - (CH2)8CH3 ; -CH2CH2CH2-S-(CH2)9CH3;
- CH2CH2CH2- S- (CH2)3-CH = CH-(CH2)4CH3 (trans) ;
- CH2CH2CH2CH2- S- (CH2)7CH3;
- CH2CH2- S(O)- (CH2)9CH3; -CH2CH2-S-(CH2)6Ph; -CH2CH2-S-(CH2)8Ph;
- CH2CH2CH2- S - (CH2)8Ph;
- CH2CH2- NH- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2-NH-CH2-4-[4-CH3)2CHCH2-]-Ph; - CH2CH2- NH- CH2-4-(4-CF3-Ph)-Ph;
- CH2CH2- S- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-S-CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-S-CH2-4-[3,4-di-Cl-PhCH2O-)-Ph;
- CH2CH2- NHSO2- CH2-4-[4-(4-Ph)-Ph]-Ph;
- CH2CH2CH2- NHSO2- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-NHSO2-CH2-4-(Ph-C≡C-)-Ph;
- CH2CH2CH2- NHSO2- 4-(4-Cl-Ph)-Ph; and -CH2CH2CH2-NHSO2-4-(naphth-2-yl)-Ph.
19. The compound of Claim 15, wherein R3 is -OH or -NRCRC.
20. The compound of Claim 15, wherein R5 is hydrogen, -CH2-N-(N- CH3-D-glucamine) ; -CH2-ΝH-CH2CH2-ΝH-(CH2)9CH3 ; -CH2-NH-CH2CH2-NH- (CH2)nCH3; -CH2-NH-(CH2)5-COOH; and -CH2-N-(2-amino-2-deoxygluconic acid).
21. The compound of Claim 15, wherein R8 is -CH2C(O)ΝH2, -CH2COOH, benzyl, 4-hydroxyphenyl or 3-chloro-4-hydroxyphenyl.
22. The compound of Claim 15, wherein R9 is hydrogen and R11 is hydrogen or methyl.
23. The compound of Claim 22, wherein R10 is alkyl or substimted alkyl.
24. The compound of Claim 23, wherein R12 is hydrogen, alkyl, substimted alkyl or -C(O)Rd.
25. The compound of Claim 24, wherein n is 1.
26. A compound of formula II:
Figure imgf000153_0001
wherein
R21 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -Ra-Y-Rb-(Z)X; or a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X; R22 is -ORc, -NRCRC. -O-Ra-Y-Rb-(Z)x or -NRC-Ra-Y-R -(Z)X;
R23 is selected from the group consisting of hydrogen, halo, -CH(RC)-NRCRC, -CH(RC)-Re and -CH(RC)-NRC-Ra-Y-Rb-(Z)X;
R24 is selected from the group consisting of hydrogen and lower alkyl; R25 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R26 is selected from the group consisting of hydrogen and lower alkyl; or R25 and R26 are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;
R27 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic, -C(O)Rd, -C(NH)Rd, -C(O)NRcRc, -C(O)ORd, -C(NH)NRCRC and -Ra- Y-Rb-(Z)X, or R26 and R27 are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring; each Ra is independently selected from the group consisting of alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene; each Rb is independently selected from the group consisting of a covalent bond, alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene, provided Rb is not a covalent bond when Z is hydrogen; each Rc is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)Rd; each Rd is independently selected from the group consisting of alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic; Re is an aminosaccharide group; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- ,-NRc- , -S(O)- , -SO2- , -NRcC(O)- , -OSO2- , -OC(O)- , -NRcSO2- , -C(O)NRc- , -C(O)O- , -SO2NRc- , -SO2O- , -P(O)(ORc)O- , -P(O)(ORc)NRc- , -OP(O)(ORc)O- ,-OP(O)(ORc)NRc- , -OC(O)O- , - NRcC(O)O- , - NRcC(O)NRc- , - OC(O)NRc- and - NRcSO2NRc- ; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; n is 0, 1 or 2; : is 1 or 2; and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof; provided that at least one of R21, R22, R23 or R27 has a substimtent of the formula -Ra-Y-Rb-(Z)X; and further provided that:
(i) when Y is -NRC- , Rc is alkyl of 1 to 4 carbon atoms, Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms;
(ii) when Y is -C(O)NRc- , Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms;
(iii) when Y is sulfur, Z is hydrogen and Rb is alkylene, then Rb contains at least 7 carbon atoms; and (iv) when Y is oxygen, Z is hydrogen and Rb is alkylene, then Rb contains at least 11 carbon atoms.
27. The compound of Claim 26, wherein R21 is a saccharide group of the formula:
Figure imgf000156_0001
wherein
R15 is -Ra-Y-Rb-(Z)X, and
R16 is hydrogen or methyl.
28. The compound of Claim 27, wherein R15 is a -Ra- Y-Rb-(Z)X group selected from the group consisting of:
- CH2CH2- NH- (CH2)9CH3;
- CH2CH2CH2- NH- (CH2)8CH3 ;
- CH2CH2CH2CH2- NH- (CH2)7CH3 ; -CH2CH2-NHSO2-(CH2)9CH3; -CH2CH2-NHSO2-(CH2)nCH3;
-CH2CH2 _S- (CH2)8CH3; -CH2CH2-S-(CH2)9CH3;
- CH2CH2 - S - (CH2) 10CH3 ;
- CH2CH2CH2- S - (CH2)8CH3 ; -CH2CH2CH2-S-(CH2)9CH3;
- CH2CH2CH2- S- (CH2)3-CH = CH-(CH2)4CH3 (trans) ;
- CH2CH2CH2CH2- S- (CH2)7CH3 ;
- CH2CH2- S(O)- (CH2)9CH3; -CH2CH2-S-(CH2)6Ph; -CH2CH2-S-(CH2)8Ph; - CH2CH2CH2- S- (CH2)8Ph;
- CH2CH2- NH- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2-NH-CH2-4-[4-CH3)2CHCH2-]-Ph; -CH2CH2-NH-CH2-4-(4-CF3-Ph)-Ph; -CH2CH2-S-CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- S- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-S(O)-CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-S-CH2-4-[3,4-di-Cl-PhCH2O-)-Ph; - CH2CH2- NHSO2- CH2-4-[4-(4-Ph)-Ph]-Ph;
- CH2CH2CH2- NHSO2- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- NHSO2- CH2-4-(Ph-C = C-)-Ph; -CH2CH2CH2-NHSO2-4-(4-Cl-Ph)-Ph; and -CH2CH2CH2-NHSO2-4-(naphth-2-yl)-Ph.
29. The compound of Claim 26, wherein R22 is - OH or - NRCRC.
30. The compound of Claim 26, wherein R23 is hydrogen, -CH2-N-(N- CH3-D-glucamine); -CH2-ΝH-CH2CH2-ΝH-(CH2)9CH3; -CH2-ΝH-CH2CH2-ΝH- (CH2)UCH3; -CH2-NH-(CH2)5-COOH; or -CH2-N-(2-amino-2-deoxygluconic acid).
31. The compound of Claim 26, wherein R24 is hydrogen and R26 is hydrogen or methyl.
32. The compound of Claim 31, wherein R25 is alkyl or substimted alkyl.
33. The compound of Claim 32, wherein R25 is isobutyl.
34. The compound of Claim 33, wherein R27 is hydrogen, alkyl, substimted alkyl or -C(O)Rd.
35. A compound shown in any of Tables I, II, III, IV, V or VI, or a pharmaceutically-acceptable salt thereof.
36. A pharmaceutical composition comprising a pharmaceutically- acceptable carrier and a therapeutically effective amount of a glycopeptide compound having at least one substiment of the formula:
-Ra-Y-Rb-(Z)X
wherein each Ra is independently selected from the group consisting of alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene; each Rb is independently selected from the group consisting of a covalent bond, alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene, provided Rb is not a covalent bond when Z is hydrogen; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- , -NRC- , -S(O)- , -SO2- , -NRcC(O)- , -OC(O)- , -NRcSO2- , -OSO2- , -C(O)NRc- , -C(O)O- , -SO2NRc- , -SO2O- , ,-P(O)(ORc)O- , - P(O)(ORc)NRc- , - OP(O)(ORc)O- , - OP(O)(ORc)NRc- , - OC(O)O- , -NRcC(O)O- , -NRcC(O)NRc- , -OC(O)NRc- and -NRcSO2NRc- ; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; each Rc is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)Rd; each Rd is independently selected from the group consisting of alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic; x is 1 or 2; and pharmaceutically acceptable salts thereof; provided that: (i) when Y is -NRC- , Rc is alkyl of 1 to 4 carbon atoms, Z is hydrogen and Rb is alkylene, then R° contains at least 5 carbon atoms;
(ii) when Y is -C(O)NRc- , Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms;
(iii) when Y is sulfur, Z is hydrogen and Rb is alkylene, then Rb contains at least 7 carbon atoms; and
(iv) when Y is oxygen, Z is hydrogen and Rb is alkylene, then Rb contains at least 11 carbon atoms.
37. The pharmaceutical composition of Claim 36, wherein the glycopeptide compound is substimted with from 1 to 3 substiments of the formula -Ra-Y-Rb-(Z)X.
38. The pharmaceutical composition of Claim 37, wherein each Ra is independently selected from alkylene having from 1 to 10 carbon atoms.
39. The pharmaceutical composition of Claim 38, wherein Ra is ethylene or propylene.
40. The pharmaceutical composition of Claim 37, wherein Z is hydrogen and Rb is alkylene of from 8 to 12 carbon atoms.
41. The pharmaceutical composition of Claim 40, wherein Rb and Z form an n-octyl, ϊ-nonyl, n-decyl, rt-undecyl or «-dodecyl group.
42. The pharmaceutical composition of Claim 37, wherein Z is aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocyclic and Rb is a covalent bond or alkylene of from 1 to 10 carbon atoms.
43. The pharmaceutical composition of Claim 42, wherein Z is aryl and Rb is a covalent bond, methylene, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9- or -(CH2)10-.
44. The pharmaceutical composition of Claim 37, wherein each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, -NR- , -S(O)- , -SO2- , -NRcC(O)- , -OC(O)- , -NRcSO2- , -C(O)NRc- , -C(O)O- and -SO2NRc- .
45. The pharmaceutical composition of Claim 44, wherein Y is oxygen, sulfur, -NRC- or -NRcSO2- .
46. The pharmaceutical composition of Claim 37, wherein each Z is independently selected from hydrogen, aryl, cycloalkyl, heteroaryl and heterocyclic.
47. The pharmaceutical composition of Claim 46, wherein Z is hydrogen or aryl.
48. The pharmaceutical composition of Claim 47, wherein Z is phenyl, substimted phenyl, biphenyl, substimted biphenyl or terphenyl.
49. The pharmaceutical composition of Claim 37, wherein the -Ra-Y-Rb-(Z)X group is selected from the group consisting of: -CH2CH2-NH-(CH2)9CH3;
- CH2CH2CH2- NH- (CH2)8CH3 ;
- CH2CH2CH2CH2- NH- (CH2)7CH3 ;
- CH2CH2- NHSO2- (CH2)9CH3;
- CH2CH2- NHSO2- (CH2)UCH3 ; -CH2CH2-S-(CH2)8CH3;
- CH2CH2 - S - (CH2) CH3 ;
- CH2CH2- S- (CH2)10CH3;
- CH2CH2CH2 - S - (CH )8CH3 ;
- CH2CH2CH2- S- (CH2)9CH3 ; - CH2CH2CH2- S- (CH2)3-CH = CH-(CH2)4CH3 (trans);
- CH2CH2CH2CH2 - S - (CH2)7CH3 ;
- CH2CH2- S(O)- (CH2)9CH3 ; -CH2CH2-S-(CH2)6Ph; -CH2CH2-S-(CH2)8Ph; -CH2CH2CH2-S-(CH2)8Ph;
- CH2CH2- NH- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2- NH- CH2-4-[4-CH3)2CHCH2-]-Ph;
- CH2CH2- NH- CH2-4-(4-CF3-Ph)-Ph;
- CH2CH2- S- CH2-4-(4-Cl-Ph)-Ph; - CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph;
-CH2CH2CH2-S-CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-S-CH2-4-[3,4-di-Cl-PhCH2O-)-Ph; - CH2CH2- NHSO2- CH2-4-[4-(4-Ph)-Ph]-Ph; -CH2CH2CH2-NHSO2-CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- NHSO2- CH2-4-(Ph-C ≡ C-)-Ph; -CH2CH2CH2- NHSO2-4-(4-Cl-Ph)-Ph; and -CH2CH2CH2-NHSO2-4-(naphth-2-yl)-Ph.
50. A pharmaceutical composition comprising a pharmaceutically- acceptable carrier and a therapeutically effective amount of a compound of formula I:
Figure imgf000162_0001
wherein
R1 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -Ra-Y-Rb-(Z)X; or a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X; R2 is hydrogen or a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X;
R3 is -ORc, -NRCRC, -O-Ra-Y-Rb-(Z)x, -NRC-Ra-Y-Rb-(Z)X, -NRcRe, or -O-Re ; R4 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -Ra-Y-Rb-(Z)X, -C(O)Rd and a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X;
R5 is selected from the group consisting of hydrogen, halo, -CH(RC)-NRCRC, -CH(Rc)-NRcRe and -CH(RC)-NRC-Ra-Y-Rb-(Z)X; R6 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -Ra-Y-Rb-(Z)X, -C(O)Rd and a saccharide group optionally substimted with -NRC-Ra-Y-Rb-(Z)X, or R5 and R6 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substimted with -NRC-Ra-Y-Rb-(Z)X; R7 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, -Ra-Y-Rb-(Z)X, and -C(O)Rd;
R8 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R9 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R10 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic; or R8 and R10 are joined to form - Ar'-O- Ar2- , where Ar1 and Ar2 are independently arylene or heteroarylene;
Ru is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R10 and R" are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;
R12 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic, -C(O)Rd, -C(NH)Rd, -C(O)NRcRc, -C(O)ORd, -C(NH)NRCRC and -Ra- Y-Rb-(Z)X, or R11 and R12 are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;
R13 is selected from the group consisting of hydrogen or -OR14; R14 is selected from hydrogen, -C(O)Rd and a saccharide group; each Ra is independently selected from the group consisting of alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene; each Rb is independently selected from the group consisting of a covalent bond, alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene, provided Rb is not a covalent bond when Z is hydrogen; each Rc is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)Rd; each Rd is independently selected from the group consisting of alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl. substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
Re is a saccharide group;
X1, X2 and X3 are independently selected from hydrogen or chloro; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- , -NRC- , -S(O)- , -SO2- , -NRcC(O)- , -OSO2- , -OC(O)- , -NRcSO2- , -C(O)NRc- , -C(O)O- , -SO2NRc- , -SO2O- , -P(O)(ORc)O- , -P(O)(ORc)NRc- , -OP(O)(ORc)O- ,-OP(O)(ORc)NRc- , -OC(O)O- , -NRcC(O)O- , -NRcC(O)NRc- , -OC(O)NRc- and -NRcSO2NRc- ; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; Z is 0, 1 or 2; x is 1 or 2; and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof; provided that at least one of R1, R2, R3, R4, R5, R°, R7 or R12 has a substimtent of the formula -Ra-Y-Rb-(Z)X; and further provided that:
(i) when Y is -NRC- , Rc is alkyl of 1 to 4 carbon atoms, Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms; (ii) when Y is -C(O)NRc- , Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms;
(iii) when Y is sulfur, Z is hydrogen and Rb is alkylene, then Rb contains at least 7 carbon atoms; and
(iv) when Y is oxygen, Z is hydrogen and Rb is alkylene, then Rb contains at least 11 carbon atoms.
51. The pharmaceutical composition of Claim 50, wherein R1 is a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X.
52. The pharmaceutical composition of Claim 51, wherein R1 is a saccharide group of the formula:
Figure imgf000166_0001
wherein
R15 is -Ra-Y-Rb-(Z)X; and
R16 is hydrogen or methyl.
53. The pharmaceutical composition of Claim 52, wherein R15 is a -Ra-Y-Rb-(Z)X group selected from the group consisting of:
- CH2CH2- NH- (CH2)9CH3 ;
- CH2CH2CH2- NH- (CH2)8CH3; - CH2CH2CH2CH2- NH- (CH2)7CH3 ;
- CH2CH2- NHSO2- (CH2)9CH3 ;
- CH2CH2- NHSO2- (CH2)UCH3 ;
- CH2CH2- S- (CH2)8CH3 ;
- CH2CH2- S- (CH2)9CH3 ; -CH2CH2-S-(CH2)10CH3;
- CH CH2CH2- S- (CH2)8CH3 ;
- CH2CH2CH2- S- (CH2)9CH3;
- CH2CH2CH2- S - (CH2)3-CH = CH-(CH2)4CH3 (trans) ;
- CH2CH CH2CH2- S- (CH )7CH3 ; - CH2CH2- S(O)- (CH2)9CH3 ; -CH2CH2-S-(CH2)6Ph; -CH2CH2-S-(CH2)8Ph;
- CH2CH2CH2- S- (CH2)8Ph; -CH2CH2-NH-CH2-4-(4-Cl-Ph)-Ph;
-CH2CH2-NH-CH2-4-[4-CH3)2CHCH2-]-Ph;
- CH2CH2- NH- CH2-4-(4-CF3-Ph)-Ph;
- CH2CH2- S- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-S-CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-S-CH2-4-[3,4-di-Cl-PhCH2O-)-Ph;
- CH2CH2- NHSO2- CH2-4-[4-(4-Ph)-Ph]-Ph;
- CH2CH2CH2- NHSO2- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2CH2-NHSO2-CH2-4-(Ph-C≡C-)-Ph;
-CH2CH2CH2-NHSO2-4-(4-Cl-Ph)-Ph; and
- CH2CH2CH2- NHSO2- 4-(naphth-2-yl)-Ph.
54. The pharmaceutical composition of Claim 50, wherein R3 is -OH or -NRCRC.
55. The pharmaceutical composition of Claim 50, wherein R5 is hydrogen, -CH2-N-(N-CH3-D-glucamine); -CH2-ΝH-CH2CH2-ΝH-(CH2)9CH3; - CH2-NH-CH2CH2-NH-(CH2)nCH3; -CH2-NH-(CH2)5-COOH; and -CH2-N-(2- amino-2-deoxy gluconic acid).
56. The pharmaceutical composition of Claim 50, wherein R8 is -CH2C(O)ΝH2, -CH2COOH, benzyl, 4-hydroxyphenyl or 3-chloro-4- hydroxyphenyl.
57. The pharmaceutical composition of Claim 50, wherein R9 is hydrogen and R11 is hydrogen or methyl.
58. The pharmaceutical composition of Claim 57, wherein R10 is alkyl or substimted alkyl.
59. The pharmaceutical composition of Claim 58, wherein R12 is hydrogen, alkyl, substimted alkyl or -C(O)Rd.
60. The pharmaceutical composition of Claim 50, wherein n is 1.
61. A pharmaceutical composition comprising a pharmaceutically- acceptable carrier and a therapeutically effective amount of a compound of formula II:
Figure imgf000168_0001
wherein R21 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -R -Y-Rb-(Z)X; or a saccharide group optionally substimted with -Ra-Y-Rb-(Z)X;
R22 is -ORc, -NRCRC, -O-Ra- Y-Rb-(Z)X or -NRC-Ra-Y-Rb-(Z)X;
R23 is selected from the group consisting of hydrogen, halo, -CH(RC)-NRCRC, -CH(RC)-Re and -CH(RC)-NRC-Ra-Y-Rb-(Z)X;
R24 is selected from the group consisting of hydrogen and lower alkyl; R25 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R26 is selected from the group consisting of hydrogen and lower alkyl; or R25 and R26 are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;
R27 is selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic, -C(O)Rd, -C(NH)Rd, -C(O)NRcRc, -C(O)ORd, -C(NH)NRCRC and -Ra-Y-Rb-(Z)X, or R26 and R27 are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring; each Ra is independently selected from the group consisting of alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene; each Rb is independently selected from the group consisting of a covalent bond, alkylene, substimted alkylene, alkenylene, substimted alkenylene, alkynylene and substimted alkynylene, provided Rb is not a covalent bond when Z is hydrogen; each Rc is independently selected from the group consisting of hydrogen, alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)Rd; each Rd is independently selected from the group consisting of alkyl, substimted alkyl, alkenyl, substimted alkenyl, alkynyl, substimted alkynyl, cycloalkyl, substimted cycloalkyl, cycloalkenyl, substimted cycloalkenyl, aryl, heteroaryl and heterocyclic;
Re is an aminosaccharide group; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S- ,-NRc- , -S(O)- , -SO2- , -NRcC(O)- , -OSO2- , -OC(O)- , -NRcSO2- , -C(O)NRc- , -C(O)O- , -SO2NRc- , -SO2O- , -P(O)(ORc)O- , - P(O)(ORc)NRc- , - OP(O)(ORc)O- , - OP(O)(ORc)NRc- , - OC(O)O- , -NRcC(O)O- , -NRcC(O)NRc- , -OC(O)NRc- and -NRcSO2NRc- ; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; n is 0, 1 or 2; x is 1 or 2; and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof; provided that at least one of R21, R22, R23 or R27 has a substimtent of the formula -Ra-Y-Rb-(Z)X; and further provided that:
(i) when Y is -NRC- , Rc is alkyl of 1 to 4 carbon atoms, Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms; (ii) when Y is -C(O)NRc- , Z is hydrogen and Rb is alkylene, then Rb contains at least 5 carbon atoms;
(iii) when Y is sulfur, Z is hydrogen and Rb is alkylene, then Rb contains at least 7 carbon atoms; and (iv) when Y is oxygen, Z is hydrogen and Rb is alkylene, then Rb contains at least 11 carbon atoms.
62. The pharmaceutical composition of Claim 61, wherein R21 is a saccharide group of the formula:
Figure imgf000171_0001
wherein
R15 is -Ra-Y-Rb-(Z)X, and
R16 is hydrogen or methyl.
63. The pharmaceutical composition of Claim 62, wherein R15 is a -Ra-Y-Rb-(Z)X group selected from the group consisting of: -CH2CH2-NH-(CH2)9CH3;
- CH2CH2CH2- NH- (CH2)8CH3;
- CH2CH2CH2CH2- NH- (CH2)7CH3 ;
- CH2CH2- NHSO2- (CH2)9CH3 ; -CH2CH2-NHSO2-(CH2)nCH3; -CH2CH2-S-(CH2)8CH3;
-CH2CH2-S-(CH2)9CH3;
- CH2CH2- S- (CH2)ιoCH3;
- CH2CH2CH2- S - (CH2)8CH3 ; - CH2CH2CH2- S_ (CH2) CH ;
- CH2CH2CH2- S- (CH2)3-CH = CH-(CH2)4CH3 (trans) ;
- CH2CH2CH2CH2- S- (CH2)7CH3; -CH2CH2-S(O)-(CH2)9CH3; -CH2CH2-S-(CH2)6Ph;
-CH2CH2-S-(CH2)8Ph;
- CH2CH2CH2- S- (CH2)8Ph;
- CH2CH2- NH- CH2-4-(4-Cl-Ph)-Ph; -CH2CH2-NH-CH2-4-[4-CH3)2CHCH2-]-Ph; -CH2CH2-NH-CH2-4-(4-CF3-Ph)-Ph;
- CH2CH2- S- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- S- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- S(O)- CH2-4-(4-Cl-Ph)-Ph; - CH2CH2CH2- S- CH2-4-[3 ,4-di-Cl-PhCH2O-)-Ph;
- CH2CH2- NHSO2- CH2-4-[4-(4-Ph)-Ph]-Ph;
- CH2CH2CH2- NHSO2- CH2-4-(4-Cl-Ph)-Ph;
- CH2CH2CH2- NHSO2- CH2-4-(Ph-C ≡ C-)-Ph; -CH2CH2CH2-NHSO2-4-(4-Cl-Ph)-Ph; and - CH2CH2CH2- NHSO2-4-(naphth-2-yl)-Ph.
64. The pharmaceutical composition of Claim 61, wherein R22 is -OH or -NRCRC.
65. The pharmaceutical composition of Claim 61, wherein R23 is hydrogen, -CH2-N-(N-CH3-D-glucamine); -CH2-ΝH-CH2CH2-ΝH-(CH2)9CH3; - CH2-NH-CH2CH2-NH-(CH2)UCH3; -CH2-NH-(CH2)5-COOH; or -CH2-N-(2- amino-2-deoxygluconic acid).
66. The pharmaceutical composition of Claim 61, wherein R24 is hydrogen and R26 is hydrogen or methyl.
67. The pharmaceutical composition of Claim 66, wherein R25 is alkyl or substimted alkyl.
68. The pharmaceutical composition of Claim 67, wherein R25 is isobutyl.
69. The pharmaceutical composition of Claim 68, wherein R27 is hydrogen, alkyl, substimted alkyl or -C(O)Rd.
70. A pharmaceutical composition comprising a pharmaceutically- acceptable carrier and a therapeutically effective amount of a compound shown in any of Tables I, II, III, IV, V or VI, or a pharmaceutically-acceptable salt thereof.
71. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition of Claim 36, 50 or 61.
PCT/US1999/030543 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical compositions containing the same WO2000039156A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
JP2000591067A JP4362017B2 (en) 1998-12-23 1999-12-22 Glycopeptide derivative and pharmaceutical composition containing the same
AT99965331T ATE242783T1 (en) 1998-12-23 1999-12-22 GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IL14009399A IL140093A0 (en) 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical compositions containing the same
PL348451A PL198311B1 (en) 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical compositions containing the same
EP99965331A EP1140993B1 (en) 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical compositions containing the same
AU31273/00A AU768204B2 (en) 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical compositions containing the same
NZ508594A NZ508594A (en) 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical compositions containing the same
CA2336445A CA2336445C (en) 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical compositions containing the same
BRPI9914221A BRPI9914221B8 (en) 1998-12-23 1999-12-22 glycopeptide derivatives and pharmaceutical compositions containing them
DK99965331T DK1140993T3 (en) 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical preparations containing them
SI9930389T SI1140993T1 (en) 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical compositions containing the same
DE69908819T DE69908819T2 (en) 1998-12-23 1999-12-22 GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE
HU0400887A HU230190B1 (en) 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical compositions containing the same
US09/674,456 US6455669B1 (en) 1998-12-23 2000-11-01 Glycopeptide derivatives and pharmaceutical compositions containing the same
IL140093A IL140093A (en) 1998-12-23 2000-12-05 Glycopeptide derivatives and pharmaceutical compositions containing the same
ZA200007222A ZA200007222B (en) 1998-12-23 2000-12-06 Glycopeptide derivatives and pharmaceutical compositions containing the same.
NO20006323A NO326066B1 (en) 1998-12-23 2000-12-12 Glycopeptide derivatives, pharmaceutical compositions and uses thereof.
HK02102171.5A HK1040721B (en) 1998-12-23 2002-03-21 Glycopeptide derivatives and pharmaceutical compositions containing the same

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US11372898P 1998-12-23 1998-12-23
US60/113,728 1998-12-23
US12931399P 1999-04-14 1999-04-14
US60/129,313 1999-04-14
US16402499P 1999-11-04 1999-11-04
US60/164,024 1999-11-04
US16997899P 1999-12-10 1999-12-10
US60/169,978 1999-12-10

Publications (1)

Publication Number Publication Date
WO2000039156A1 true WO2000039156A1 (en) 2000-07-06

Family

ID=27493926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030543 WO2000039156A1 (en) 1998-12-23 1999-12-22 Glycopeptide derivatives and pharmaceutical compositions containing the same

Country Status (23)

Country Link
US (9) US6392012B1 (en)
EP (1) EP1140993B1 (en)
JP (1) JP4362017B2 (en)
KR (1) KR100665204B1 (en)
CN (1) CN1249081C (en)
AT (1) ATE242783T1 (en)
AU (1) AU768204B2 (en)
BR (1) BRPI9914221B8 (en)
CA (1) CA2336445C (en)
CZ (1) CZ301184B6 (en)
DE (1) DE69908819T2 (en)
DK (1) DK1140993T3 (en)
ES (1) ES2201825T3 (en)
HK (1) HK1040721B (en)
HU (1) HU230190B1 (en)
IL (2) IL140093A0 (en)
NO (1) NO326066B1 (en)
NZ (1) NZ508594A (en)
PL (1) PL198311B1 (en)
PT (1) PT1140993E (en)
SI (1) SI1140993T1 (en)
WO (1) WO2000039156A1 (en)
ZA (1) ZA200007222B (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057071A2 (en) * 2000-02-04 2001-08-09 Advanced Medicine, Inc. Glycopeptide derivatives having antibiotic activity
WO2001081372A2 (en) * 2000-04-25 2001-11-01 The Trustees Of Princeton University Vancomycin analogs
WO2001083520A2 (en) * 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
WO2001098328A2 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide phosphonate derivatives
WO2001098327A2 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
WO2001098329A1 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
EP1173193A1 (en) * 1999-04-02 2002-01-23 The Trustees of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
WO2001082971A3 (en) * 2000-05-02 2002-05-23 Advanced Medicine Inc Cyclodextrin containing glycopeptide antibiotic compositions
WO2003029270A2 (en) * 2001-08-24 2003-04-10 Theravance, Inc. Process for preparing glycopeptide phosphonate derivatives
WO2003031449A2 (en) * 2001-10-12 2003-04-17 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2003099858A1 (en) 2002-05-24 2003-12-04 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US6831150B2 (en) 2000-05-02 2004-12-14 Theravance, Inc. Reductive alkylation process
WO2005005436A2 (en) * 2003-07-11 2005-01-20 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
JP2005526129A (en) * 2002-05-17 2005-09-02 デパートメント オブ ヘルス アンド ヒューマン サービシーズ Antituberculosis drugs, compositions and methods
US6951963B2 (en) 2002-06-17 2005-10-04 Theravance, Inc. Process for preparing N-protected β-amino aldehyde compounds
US7015305B2 (en) 2001-08-24 2006-03-21 Theravance, Inc. Process for preparing glycopeptide derivatives
WO2006053643A1 (en) * 2004-11-18 2006-05-26 Bayer Cropscience Ag N-heterocyclyl phthalic acid diamides as insecticides
WO2006057303A1 (en) 2004-11-29 2006-06-01 National University Corporation Nagoya University Glycopeptide antibiotic monomer derivatives
US7067481B2 (en) 2003-05-23 2006-06-27 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2007035938A2 (en) 2005-09-22 2007-03-29 Medivas, Llc BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2007138999A1 (en) 2006-05-26 2007-12-06 Shionogi & Co., Ltd. Glycopeptide antibiotic derivative
WO2009081958A1 (en) 2007-12-26 2009-07-02 Shionogi & Co., Ltd. Glycosylated glycopeptide antibiotic derivative
WO2009123713A1 (en) 2008-04-01 2009-10-08 Cornell University Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof
US8198303B2 (en) 2002-05-17 2012-06-12 Sequella, Inc. Methods of use and compositions for the diagnosis and treatment of infectious diseases
WO2015040467A1 (en) * 2013-09-23 2015-03-26 Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) Vancomycin-sugar conjugates and uses thereof
WO2016103284A1 (en) * 2014-12-25 2016-06-30 Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) Glycopeptides and uses thereof
EP3450450A4 (en) * 2016-04-29 2019-04-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Vancomycin derivative, preparation method, pharmaceutical composition and use thereof
WO2019170046A1 (en) 2018-03-06 2019-09-12 上海来益生物药物研究开发中心有限责任公司 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method therefor and application thereof
WO2021060980A1 (en) * 2019-09-24 2021-04-01 Universiteit Leiden Antibiotic compounds
AU2018273887B2 (en) * 2017-05-22 2022-09-08 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140993B1 (en) * 1998-12-23 2003-06-11 Theravance, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
ATE322975T1 (en) 2001-09-19 2006-04-15 Procter & Gamble COLOR PRINTED MULTI-LAYER STRUCTURE, AN ABSORBENT ARTICLE MADE THEREFROM AND METHOD FOR PRODUCING THE SAME
WO2004004712A1 (en) * 2002-07-09 2004-01-15 Fasgen, Llc Methods of treating microbial infections in humans and animals
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US6900175B2 (en) * 2002-11-18 2005-05-31 Vicuron Pharmaceuticals Inc. Methods of administering dalbavancin for treatment of bacterial infections
US8304597B2 (en) 2004-12-15 2012-11-06 The Procter And Gamble Company Method of using an absorbent article having a functional enhancement indicator
US7632918B2 (en) * 2005-02-28 2009-12-15 Novartis Vaccines And Diagnostics, Inc. Semi-synthetic glycopeptides with antibiotic activity
US20070185015A1 (en) * 2005-02-28 2007-08-09 Chiron Corporation and North China Pharmaceutical Corporation Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity
US7368422B2 (en) * 2005-02-28 2008-05-06 Novartis Vaccines And Diagnostics Inc. Semi-synthetic rearranged vancomycin/desmethyl-vancomycin-based glycopeptides with antibiotic activity
US20070173438A1 (en) * 2006-01-13 2007-07-26 The Scripps Research Institute [PSI[CH2NH]PG4] glycopeptide antibiotic analogs
CA2710602A1 (en) * 2007-12-26 2009-07-09 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
CN101928330B (en) * 2009-06-26 2013-10-16 上海来益生物药物研究开发中心有限责任公司 New compound and application thereof
WO2012129493A1 (en) * 2011-03-24 2012-09-27 Seachaid Pharmaceuticals, Inc. Vancomycin derivatives
US20190203240A1 (en) * 2016-01-15 2019-07-04 Universitaet Hamburg Methods for the production of rhamnosylated flavonoids
US10696698B2 (en) * 2016-01-28 2020-06-30 ACatechol, Inc. Surface primer compositions and methods of use
CN107987131B (en) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 Compound with anti-drug-resistance bacterial activity, preparation method and application thereof
CN111620931B (en) * 2020-06-12 2021-12-17 苏州博源医疗科技有限公司 Vancomycin derivative and preparation method and application thereof
CN114213284B (en) * 2022-01-04 2023-08-01 丽珠集团福州福兴医药有限公司 (9H-fluoren-9-yl) -decyl (2-oxo-ethyl) carbamic acid methyl ester and synthesis method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0182157A2 (en) * 1984-11-13 1986-05-28 GRUPPO LEPETIT S.p.A. Ester derivatives of antibiotic L 17046
WO1988006600A1 (en) * 1987-03-02 1988-09-07 Gruppo Lepetit S.P.A. Substituted alkylamides of teicoplanin compounds
EP0351597A2 (en) * 1988-07-21 1990-01-24 GRUPPO LEPETIT S.p.A. "N15-alkyl and N15,N15-di-alkyl derivatives of teicoplanin antibiotics carrying functional groups on the alkyl side chain
EP0376041A2 (en) * 1988-12-27 1990-07-04 GRUPPO LEPETIT S.p.A. C63-Amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanins
WO1990011300A1 (en) * 1989-03-29 1990-10-04 Gruppo Lepetit S.P.A. New substituted alkylamide derivatives of teicoplanin
EP0525499A1 (en) * 1991-07-29 1993-02-03 GRUPPO LEPETIT S.p.A. Amide derivatives of antibiotic A 40926

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497802A (en) 1983-10-21 1985-02-05 Eli Lilly And Company N-Acyl glycopeptide derivatives
US4914187A (en) 1984-11-13 1990-04-03 Gruppo Lepetit S.P.A Ester derivatives of antibiotic L 17046
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
FR2632185B1 (en) * 1988-06-01 1992-05-22 Rhone Poulenc Chimie SILICA FOR TOOTHPASTE COMPOSITIONS COMPATIBLE IN PARTICULAR WITH ZINC
US5534420A (en) 1988-07-28 1996-07-09 Eli Lilly And Company Biotransformation of glycopeptide antibiotics
CA2031803C (en) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
AU647122B2 (en) 1990-05-28 1994-03-17 Gruppo Lepetit S.P.A. C63-amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy- teicoplanin and their use as medicaments against bacteria resistant to glycopeptide antibiotics
WO1992017456A1 (en) 1991-03-26 1992-10-15 Fujisawa Pharmaceutical Co., Ltd. Amino acid derivative and salt thereof
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
MY128335A (en) 1994-01-28 2007-01-31 Lilly Co Eli Glycopeptide antibiotic derivatives
IT1282586B1 (en) 1996-02-08 1998-03-31 Chemical And Biolog Ind PHARMACEUTICAL COMPOSITIONS FOR THE BIOLOGICAL TREATMENT OF INFECTIONS DUE TO STRAINS OF ENTEROCOCCUS FAECIUM RESISTANT TO
AU2341197A (en) 1996-03-21 1997-10-10 Intercardia, Inc. Solid phase lipoglycopeptide library, compositions and methods
AU2441697A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Covalently-linked glycopeptide dimers
AU2609297A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Glycopeptide compounds
AU719947B2 (en) 1996-04-23 2000-05-18 Vicuron Pharmaceuticals Inc. Improved chemical process for preparing amide derivatives of antibiotic A 40926
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
US5952466A (en) 1997-11-12 1999-09-14 Eli Lilly And Company Reductive alkylation of glycopeptide antibiotics
US5939382A (en) 1996-11-21 1999-08-17 Eli Lilly And Company Reducing agent for reductive alkylation of glycopeptide antibiotics
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US5919771A (en) 1997-05-20 1999-07-06 Eli Lilly And Company Urea and thiourea derivatives of glycopeptides
US5952310A (en) 1997-05-20 1999-09-14 Eli Lilly And Company Glycopeptide hexapeptides
US5977063A (en) 1997-05-20 1999-11-02 Eli Lilly And Company Alkylated hexapeptides
US6518242B1 (en) * 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents
AU3307399A (en) 1998-02-20 1999-09-06 Advanced Medicine, Inc. Novel antibacterial agents
CA2330619A1 (en) 1998-05-01 1999-11-11 Eli Lilly And Company N1-modified glycopeptides
WO2000004044A1 (en) 1998-07-14 2000-01-27 Princeton University Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
EP1140993B1 (en) * 1998-12-23 2003-06-11 Theravance, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
UA75083C2 (en) * 2000-06-22 2006-03-15 Тераванс, Інк. Derivatives of glycopeptidephosphonates
ATE556088T1 (en) * 2002-05-24 2012-05-15 Theravance Inc CONJUGATE CONTAINING CEPHALOSPORIN AND GLYCOPEPTIDE ANTIBIOTIC
DE602004012269T2 (en) * 2003-07-11 2009-04-30 Theravance, Inc., South San Francisco CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0182157A2 (en) * 1984-11-13 1986-05-28 GRUPPO LEPETIT S.p.A. Ester derivatives of antibiotic L 17046
WO1988006600A1 (en) * 1987-03-02 1988-09-07 Gruppo Lepetit S.P.A. Substituted alkylamides of teicoplanin compounds
EP0351597A2 (en) * 1988-07-21 1990-01-24 GRUPPO LEPETIT S.p.A. "N15-alkyl and N15,N15-di-alkyl derivatives of teicoplanin antibiotics carrying functional groups on the alkyl side chain
EP0376041A2 (en) * 1988-12-27 1990-07-04 GRUPPO LEPETIT S.p.A. C63-Amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanins
WO1990011300A1 (en) * 1989-03-29 1990-10-04 Gruppo Lepetit S.P.A. New substituted alkylamide derivatives of teicoplanin
EP0525499A1 (en) * 1991-07-29 1993-02-03 GRUPPO LEPETIT S.p.A. Amide derivatives of antibiotic A 40926

Cited By (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699836B2 (en) 1999-04-02 2004-03-02 The Trustees Of Princeton University Vancomycin analogs
EP1173193A4 (en) * 1999-04-02 2003-01-29 Univ Princeton Desleucyl glycopeptide antibiotics and methods of making same
EP1173193A1 (en) * 1999-04-02 2002-01-23 The Trustees of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
WO2001057071A2 (en) * 2000-02-04 2001-08-09 Advanced Medicine, Inc. Glycopeptide derivatives having antibiotic activity
WO2001057071A3 (en) * 2000-02-04 2003-10-30 Advanced Medicine Inc Glycopeptide derivatives having antibiotic activity
WO2001081372A3 (en) * 2000-04-25 2002-05-16 Univ Princeton Vancomycin analogs
WO2001081372A2 (en) * 2000-04-25 2001-11-01 The Trustees Of Princeton University Vancomycin analogs
US7244705B2 (en) 2000-05-02 2007-07-17 Theravance, Inc. Polyacid glycopeptide derivatives
US7067483B2 (en) 2000-05-02 2006-06-27 Theravance, Inc. Pharmaceutical compositions containing a gycopeptide antibiotic and a cyclodextrin
US7074760B2 (en) 2000-05-02 2006-07-11 Theravance, Inc. Polyacid glycopeptide derivatives
WO2001082971A3 (en) * 2000-05-02 2002-05-23 Advanced Medicine Inc Cyclodextrin containing glycopeptide antibiotic compositions
WO2001083520A3 (en) * 2000-05-02 2002-05-30 Advanced Medicine Inc Polyacid glycopeptide derivatives
US8158580B2 (en) 2000-05-02 2012-04-17 Theravance, Inc. Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
US7026288B2 (en) 2000-05-02 2006-04-11 Theravance, Inc. Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
US6906031B2 (en) 2000-05-02 2005-06-14 Theravance, Inc. Polyacid glycopeptide derivatives
US6858584B2 (en) 2000-05-02 2005-02-22 Theravance, Inc. Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
US6831150B2 (en) 2000-05-02 2004-12-14 Theravance, Inc. Reductive alkylation process
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
WO2001083520A2 (en) * 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
US8101575B2 (en) 2000-06-22 2012-01-24 Theravance, Inc. Glycopeptide phosphonate derivatives
WO2001098327A3 (en) * 2000-06-22 2002-04-04 Advanced Medicine Inc Glycopeptide carboxy-saccharide derivatives
US6635618B2 (en) 2000-06-22 2003-10-21 Theravance, Inc. Glycopeptide phosphonate derivatives
US6620781B2 (en) 2000-06-22 2003-09-16 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
US6828299B2 (en) 2000-06-22 2004-12-07 Theravance, Inc. Polyhydroxy glycopeptide derivatives
US7157554B2 (en) 2000-06-22 2007-01-02 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
US8859506B2 (en) 2000-06-22 2014-10-14 Theravance Biopharma Antibiotics Ip, Llc Glycopeptide phosphonate derivatives
AU2001261107B2 (en) * 2000-06-22 2006-07-20 Cumberland Pharmaceuticals Inc. Glycopeptide phosphonate derivatives
US7700550B2 (en) 2000-06-22 2010-04-20 Theravance, Inc. Glycopeptide phosphonate derivatives
US6872701B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide phosphonate derivatives
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
US8541375B2 (en) 2000-06-22 2013-09-24 Theravance, Inc. Glycopeptide phosphonate derivatives
US6887976B2 (en) 2000-06-22 2005-05-03 Theravance, Inc. Glycopeptide phosphonate derivatives
US6903070B2 (en) 2000-06-22 2005-06-07 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
US7351691B2 (en) 2000-06-22 2008-04-01 Theravance, Inc. Glycopeptide phosphonate derivatives
WO2001098329A1 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
WO2001098328A3 (en) * 2000-06-22 2002-04-11 Advanced Medicine Inc Glycopeptide phosphonate derivatives
WO2001098328A2 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide phosphonate derivatives
US7208471B2 (en) 2000-06-22 2007-04-24 Theravance, Inc. Glycopeptide phosphonate derivatives
US7265086B2 (en) 2000-06-22 2007-09-04 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
US7008923B2 (en) 2000-06-22 2006-03-07 Theravance, Inc. Glycopeptide phosphonate derivatives
WO2001098327A2 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
US8093354B2 (en) 2001-08-24 2012-01-10 Theravance, Inc. Process for preparing glycopeptide phosphonate derivatives
WO2003029270A2 (en) * 2001-08-24 2003-04-10 Theravance, Inc. Process for preparing glycopeptide phosphonate derivatives
US7015305B2 (en) 2001-08-24 2006-03-21 Theravance, Inc. Process for preparing glycopeptide derivatives
US6979723B2 (en) 2001-08-24 2005-12-27 Theravance, Inc. Process for preparing glycopeptide phosphonate derivatives
US7301004B2 (en) 2001-08-24 2007-11-27 Theravance, Inc. Process for preparing glycopeptide phosphonate derivatives
US7160984B2 (en) 2001-08-24 2007-01-09 Theravance, Inc. Process for preparing glycopeptide derivatives
KR100909438B1 (en) * 2001-08-24 2009-07-28 세라밴스 인코포레이티드 Process for preparing glycopeptide phosphonate derivative
US7074890B2 (en) 2001-08-24 2006-07-11 Theravance, Inc. Process for preparing glycopeptide phosphonate derivatives
US7728104B2 (en) 2001-08-24 2010-06-01 Theravance, Inc. Process for preparing glycopeptide phosphonate derivatives
WO2003029270A3 (en) * 2001-08-24 2003-09-04 Theravance Inc Process for preparing glycopeptide phosphonate derivatives
US7341993B2 (en) 2001-10-12 2008-03-11 Theravance, Inc. Cross-linked glycopeptide—cephalosporin antibiotics
US7649080B2 (en) 2001-10-12 2010-01-19 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2003031449A3 (en) * 2001-10-12 2003-08-28 Theravance Inc Cross-linked glycopeptide-cephalosporin antibiotics
US8044195B2 (en) 2001-10-12 2011-10-25 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US7713931B2 (en) 2001-10-12 2010-05-11 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US8557978B2 (en) 2001-10-12 2013-10-15 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US6974797B2 (en) 2001-10-12 2005-12-13 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US7655621B2 (en) 2001-10-12 2010-02-02 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US7553962B2 (en) 2001-10-12 2009-06-30 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US7601690B2 (en) 2001-10-12 2009-10-13 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US7612037B2 (en) 2001-10-12 2009-11-03 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2003031449A2 (en) * 2001-10-12 2003-04-17 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
AU2002332111B2 (en) * 2001-10-12 2008-04-17 Theravance Biopharma Antibiotics Ip, Llc Cross-linked glycopeptide-cephalosporin antibiotics
HRP20040243B1 (en) * 2001-10-12 2008-07-31 Theravance Cross-linked glycopeptide-cephalosporin antibiotics
US8198303B2 (en) 2002-05-17 2012-06-12 Sequella, Inc. Methods of use and compositions for the diagnosis and treatment of infectious diseases
JP4667862B2 (en) * 2002-05-17 2011-04-13 デパートメント オブ ヘルス アンド ヒューマン サービシーズ Antituberculosis drugs, compositions and methods
JP2005526129A (en) * 2002-05-17 2005-09-02 デパートメント オブ ヘルス アンド ヒューマン サービシーズ Antituberculosis drugs, compositions and methods
US8268894B2 (en) 2002-05-17 2012-09-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of infectious diseases
US7405199B2 (en) 2002-05-24 2008-07-29 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US6878686B2 (en) 2002-05-24 2005-04-12 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US8084417B2 (en) 2002-05-24 2011-12-27 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2003099858A1 (en) 2002-05-24 2003-12-04 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US6995138B2 (en) 2002-05-24 2006-02-07 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US6951963B2 (en) 2002-06-17 2005-10-04 Theravance, Inc. Process for preparing N-protected β-amino aldehyde compounds
US7332471B2 (en) 2003-05-23 2008-02-19 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US8314217B2 (en) 2003-05-23 2012-11-20 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US7067481B2 (en) 2003-05-23 2006-06-27 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
JP2010254697A (en) * 2003-07-11 2010-11-11 Theravance Inc Crosslinked glycopeptide-cephalosporin antibiotic
JP2013047267A (en) * 2003-07-11 2013-03-07 Theravance Inc Cross-linked glycopeptide-cephalosporin antibiotics
WO2005005436A2 (en) * 2003-07-11 2005-01-20 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2005005436A3 (en) * 2003-07-11 2005-03-10 Theravance Inc Cross-linked glycopeptide-cephalosporin antibiotics
US7279458B2 (en) 2003-07-11 2007-10-09 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US7067482B2 (en) 2003-07-11 2006-06-27 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2006053643A1 (en) * 2004-11-18 2006-05-26 Bayer Cropscience Ag N-heterocyclyl phthalic acid diamides as insecticides
US7884242B2 (en) 2004-11-18 2011-02-08 Bayer Cropscience Ag N-heterocyclylphthaldiamides as insecticides
EP2314599A1 (en) 2004-11-29 2011-04-27 National University Corporation Nagoya University Glycopeptide antibiotic monomer derivatives
US8778874B2 (en) 2004-11-29 2014-07-15 National University Corporation Nagoya University Glycopeptide antibiotic monomer derivatives
WO2006057303A1 (en) 2004-11-29 2006-06-01 National University Corporation Nagoya University Glycopeptide antibiotic monomer derivatives
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2007035938A2 (en) 2005-09-22 2007-03-29 Medivas, Llc BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE
EP2030982A4 (en) * 2006-05-26 2012-01-25 Shionogi & Co Glycopeptide antibiotic derivative
WO2007138999A1 (en) 2006-05-26 2007-12-06 Shionogi & Co., Ltd. Glycopeptide antibiotic derivative
EP2030982A1 (en) * 2006-05-26 2009-03-04 SHIONOGI & CO., LTD. Glycopeptide antibiotic derivative
US8933012B2 (en) 2006-05-26 2015-01-13 Shionogi & Co., Ltd. Glycopeptide antibiotic derivative
US8481696B2 (en) 2007-12-26 2013-07-09 Shionogi & Co., Ltd. Glycosylated glycopeptide antibiotic derivatives
WO2009081958A1 (en) 2007-12-26 2009-07-02 Shionogi & Co., Ltd. Glycosylated glycopeptide antibiotic derivative
WO2009123713A1 (en) 2008-04-01 2009-10-08 Cornell University Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof
WO2015040467A1 (en) * 2013-09-23 2015-03-26 Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) Vancomycin-sugar conjugates and uses thereof
WO2016103284A1 (en) * 2014-12-25 2016-06-30 Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) Glycopeptides and uses thereof
EP3450450A4 (en) * 2016-04-29 2019-04-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Vancomycin derivative, preparation method, pharmaceutical composition and use thereof
US10961278B2 (en) * 2016-04-29 2021-03-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Vancomycin derivative, preparation method, pharmaceutical composition and use thereof
AU2018273887B2 (en) * 2017-05-22 2022-09-08 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof
US11857597B2 (en) 2017-05-22 2024-01-02 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof
WO2019170046A1 (en) 2018-03-06 2019-09-12 上海来益生物药物研究开发中心有限责任公司 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method therefor and application thereof
WO2021060980A1 (en) * 2019-09-24 2021-04-01 Universiteit Leiden Antibiotic compounds
NL2023883B1 (en) * 2019-09-24 2021-04-26 Univ Leiden Antibiotic compounds

Also Published As

Publication number Publication date
US6392012B1 (en) 2002-05-21
CN1315961A (en) 2001-10-03
SI1140993T1 (en) 2003-12-31
BRPI9914221B8 (en) 2021-05-25
HK1040721B (en) 2003-10-17
US6455669B1 (en) 2002-09-24
US20060241024A1 (en) 2006-10-26
JP2002533472A (en) 2002-10-08
NO326066B1 (en) 2008-09-08
BR9914221A (en) 2001-06-26
IL140093A (en) 2006-06-11
KR100665204B1 (en) 2007-01-04
KR20010085857A (en) 2001-09-07
DK1140993T3 (en) 2003-10-06
US6444786B1 (en) 2002-09-03
NZ508594A (en) 2003-05-30
US8030445B2 (en) 2011-10-04
US6962970B2 (en) 2005-11-08
HU230190B1 (en) 2015-09-28
US20040204346A1 (en) 2004-10-14
NO20006323L (en) 2001-02-12
HK1040721A1 (en) 2002-06-21
CZ301184B6 (en) 2009-12-02
EP1140993B1 (en) 2003-06-11
US6949681B2 (en) 2005-09-27
ES2201825T3 (en) 2004-03-16
AU3127300A (en) 2000-07-31
CA2336445A1 (en) 2000-07-06
CA2336445C (en) 2011-07-19
ATE242783T1 (en) 2003-06-15
CZ200122A3 (en) 2001-06-13
US20080103292A1 (en) 2008-05-01
AU768204B2 (en) 2003-12-04
PL198311B1 (en) 2008-06-30
US7723470B2 (en) 2010-05-25
NO20006323D0 (en) 2000-12-12
US7351791B2 (en) 2008-04-01
US20030060598A1 (en) 2003-03-27
JP4362017B2 (en) 2009-11-11
DE69908819T2 (en) 2004-05-06
BR9914221B1 (en) 2013-12-31
EP1140993A1 (en) 2001-10-10
CN1249081C (en) 2006-04-05
US20090215982A1 (en) 2009-08-27
PT1140993E (en) 2003-10-31
DE69908819D1 (en) 2003-07-17
US7101964B2 (en) 2006-09-05
ZA200007222B (en) 2002-03-06
HUP0400887A3 (en) 2012-09-28
PL348451A1 (en) 2002-05-20
HUP0400887A2 (en) 2004-08-30
US20050239690A1 (en) 2005-10-27
IL140093A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
EP1140993B1 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
US7265086B2 (en) Glycopeptide carboxy-saccharide derivatives
PL207101B1 (en) Glycopeptide phosphonate derivatives
US6828299B2 (en) Polyhydroxy glycopeptide derivatives
WO2001083520A2 (en) Polyacid glycopeptide derivatives
US20030008812A1 (en) Glycopeptide derivatives
WO2001057071A2 (en) Glycopeptide derivatives having antibiotic activity
WO2001098326A2 (en) Glycopeptide disulfide and thioester derivatives
US20030078371A1 (en) Glycopeptide disulfide and thioester derivatives
MXPA01001861A (en) Glycopeptide derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809434.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09674456

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 508594

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 140093

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2000/07222

Country of ref document: ZA

Ref document number: 200007222

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 31273/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2336445

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2001-22

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/138/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001861

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017003918

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 591067

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: PV2001-22

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/869/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1999965331

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999965331

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999965331

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 31273/00

Country of ref document: AU